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General introduction and outline of this thesis
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Approximately 15% of clinically recognized pregnancies fail to result in a live birth 
(1). A miscarriage can be defined as a pregnancy that ends spontaneously before the 
fetus has reached a viable gestational age. Most miscarriages occur before 12 weeks, 
frequently caused by sporadic fetal chromosome abnormalities. It has been estimated 
that only 2–3% of pregnancies end spontaneously in the second trimester(2). Recurrent 
miscarriage is commonly defined as three or more consecutive pregnancy losses before 
22 weeks of gestation(3). It is a problem affecting 0.5-3% of all fertile couples(4). 
Recurrent miscarriage is a highly heterogeneous condition. Whenever the diagnosis 
‘recurrent miscarriage’ is established, an underlying cause is identified in only 25-50% 
of cases(5, 6). Possible etiologic factors include genetic disorders, uterine anomalies, 
endocrine factors, maternal autoimmune disorders, metabolic disorders, maternal 
thrombophilia, obesity and toxic factors such as smoking and alcohol consumption. 
Cardiovascular disease is the leading cause of death in women in the Western world(7). 
Clinical manifestation of cardiovascular disease in women is different compared to 
men(8, 9). Historically, cardiovascular risk factors in women have been insufficiently 
recognized, diagnosed and treated(10). Most data used to develop prevention guidelines 
came from trials that enrolled few or no women. In 2004, the American Heart association 
published evidence-based guidelines for cardiovascular prevention in women(11). In 
the most recent guideline, pregnancy complications as a history of pregnancy induced 
hypertension or preeclampsia, and gestational diabetes are mentioned as important 
risk factors for cardiovascular disease(12). Recurrent miscarriage is not mentioned in 
current guidelines as a risk factor for cardiovascular disease. A woman is classified as ‘at 
risk for cardiovascular disease’ when she is having one or more risk factor(s). Other risk 
factors are, for example; cigarette smoking, high blood pressure and a family history of 
premature cardiovascular disease in a first-degree relative. The guidelines further call 
for new research to identify events during ‘periods of potential vulnerability’ such as 
pregnancy, across a woman’s lifespan that might influence her cardiovascular disease 
risk(12).
Pregnancy provides a unique opportunity to estimate a woman’s risk because of its 
exceptional cardiovascular and metabolic stress. Cardiac output increases enormously, 
there is a decrease in maternal systemic vascular resistance; the renin-angiotensin-
aldosterone system is significantly activated; and the heart and vasculature undergo 
remodeling. These changes are already significant in the first weeks of gestation(13). 
Pregnancy can be considered as a vascular “stress test” (14) and can unmask early or 
preexisting endothelial dysfunction and vascular or metabolic disease. This suggests that 
women at high risk of future cardiovascular disease are identifiable during pregnancy. 
(Figure 1) 
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Figure 1. Pregnancy as a vascular ‘stress test’.
Women at high risk of future cardiovascular disease, indicated by the red line in fi gure 1, 
are crossing the threshold for clinical vascular disease during pregnancy. Women at low 
risk of future cardiovascular disease (blue line) will pass this test with an uncomplicated 
pregnancy. 
Since the cardiovascular and metabolic changes are already signifi cantly present in the 
fi rst trimester, recurrent miscarriage might be a fi rst sign of subsequent cardiovascular 
disease in women. As earlier stated recurrent miscarriage is a highly heterogenous 
condition. Several hypotheses are possible for an association between recurrent mis-
carriage and cardiovascular disease; shared common risk factors such as obesity and 
smoking(15), thrombophilia, and a genetic predisposition is assumed(16). 
Epidemiologic studies are showing an association between both conditions; a recently 
published meta-analysis found an association between recurrent miscarriage and 
coronary heart disease: pooled odds ratio 1.99, 95%CI (1.13-3.50)(17). Though, clinical 
heterogeneity between studies was evident. An assessment of the association between 
recurrent miscarriage and cerebrovascular disease was not possible due to the small 
number of studies available.  
In this thesis, we further want to examine the association between recurrent miscarriage 
and cardiovascular disease, since current research is sparse. Therefore, in chapter 2 
we report a large retrospective cohort study with a long follow-up which assessed 
whether consecutive miscarriage is (independently) associated with an increased risk of 
cardiovascular disease later in life, including ischemic heart disease and cerebrovascular 
disease. 
PSM 20180328 Proefschrift Wagner.indd   11 14-05-18   10:18
CHAPTER  1
12
Worldwide multivariable risk assessment tools are developed to detect apparently 
healthy individuals at high risk for cardiovascular disease and to effectively implement 
prevention strategies(18). At present the most common externally validated risk model 
is the Framingham risk score(19). We hypothesize that women with a history of recurrent 
miscarriage have a more unfavorable cardiovascular risk profile already at a young 
age compared to women with no miscarriage. If so, women with recurrent miscarriage 
represent an ideal target population for preventive strategies. In chapter 3 we conducted 
a follow-up study to determine cardiovascular risk factors and predict the long term 
cardiovascular disease risk using Framingham risk scores in women with a history of 
recurrent miscarriage compared to women with no miscarriage.
In addition to classic cardiovascular risk factors, there is a wide variety of novel 
cardiovascular biomarkers associated with future cardiovascular disease. Biomarkers 
regarding inflammation, thrombosis, lipid metabolism, renal function and myocardial 
damage.  For example; high-sensitivity C-reactive protein (HsCRP), an inflammatory 
biomarker,  lipoprotein(a) (Lp(a)), a lipid related biomarker and homocysteine, a throm-
bosis biomarker, which alters the process of hemostasis. Hyperhomocysteinemia is 
associated with recurrent miscarriage and with cardiovascular disease(20, 21). These 
novel cardiovascular biomarkers might contribute in linking recurrent miscarriage 
to cardiovascular disease and therefore can lead to a better understanding of the 
association. In chapter 4 we conducted a follow-up study to determine novel cardio-
vascular biomarkers in women with a history of recurrent miscarriage compared to 
women with no miscarriage. 
We hypothesize that the association between miscarriages and cardiovascular disease 
indicates shared common acquired risk factors, such as smoking and antiphospholipid 
syndrome, and shared heritable (genetic) risk factors. A Scottish retrospective cohort 
study found an increased incidence of ischemic heart disease in the parents of women 
who experienced multiple miscarriages before their first birth, which supports the 
hypothesis of shared genetic factors(22). A family history of (premature) cardiovascular 
disease is an independent predictor of myocardial infarction and cardiovascular 
disease(23). We conducted a matched case-control study to investigate whether a 
family history of premature cardiovascular disease was more common in women who 
experienced recurrent miscarriage compared to women with no miscarriage, which is 
described in chapter 5.
As earlier stated, research suggests a multifactorial etiology in recurrent miscarriage 
with a role for genetics. A familial predisposition is described in literature. An increase 
in the risk of spontaneous miscarriage was seen in family of women with recurrent 
miscarriage compared to control women(23-26). In addition, a case-control study 
showed that women with two or more unexplained recurrent miscarriage more often 
had a family history of recurrent miscarriage compared to healthy control subjects, 
RR 3.2 (95%CI 1.3-8.1)(27). However, it is still unclear what specific genes are involved 




and what individual variants contribute to the development of recurrent miscarriage. 
Polymorphisms have been investigated in almost 90 different genes(28). We hypothesize 
that there are shared genetic polymorphisms which are associated with recurrent 
miscarriage and cardiovascular disease. Therefore, a systematic overview of the genetic 
variants associated with recurrent miscarriage was described in chapter 6. A meta-
analysis was performed to assess the pooled effect of the genetic variants that are 
repeatedly investigated and that are significantly associated with recurrent miscarriage 
in at least two of the performed studies (and find possible genetic links between recurrent 
miscarriage and cardiovascular disease).
Other pregnancy complications, for instance, pregnancy induced hypertension, 
preeclampsia, intrauterine growth restriction and pre-term delivery may increase the 
risk of cardiovascular disease later in life(29, 30). It is unclear whether these pregnancy 
complications are on the causal pathway between miscarriage and cardiovascular 
disease(31, 32), they are possibly a confounding factor. Women with recurrent miscarriage 
might have more complicated pregnancies prior and after their recurrent miscarriage. 
Not all women with recurrent miscarriage will have an ongoing pregnancy, so will not 
have the chance to develop pregnancy complications. Approximately 40% of the women 
with recurrent miscarriage have a previous ongoing pregnancy and are diagnosed with 
secondary recurrent miscarriage(4). Women who did not have an ongoing pregnancy 
prior to their recurrent miscarriage are diagnosed with primary miscarriage. The chance 
of a live birth in the subsequent pregnancy after recurrent miscarriage is reported to 
be 60-90%(33-35). A review identified an increased risk for placenta previa, premature 
preterm rupture of membranes, preterm delivery, intrauterine growth restriction, 
low birth weight and congenital abnormalities in the pregnancy subsequent to the 
recurrent miscarriage(36). Little is known about pregnancy outcome prior to recurrent 
miscarriage(5, 37, 38). Endothelial dysfunction has been hypothesized as the underlying 
link between recurrent miscarriage, preeclampsia, intrauterine growth restriction and 
future cardiovascular events(16). Other pathophysiological links could be inherited 
and acquired thrombophilia such as antiphospholipid syndrome. As knowledge of 
obstetric details regarding the pregnancy prior to miscarriage may contribute to our 
understanding of the development of recurrent miscarriage, or cardiovascular disease 
and their possible link, in chapter 7 a retrospective cohort study was performed to assess 
if women with secondary recurrent miscarriage have a more complicated first pregnancy 
compared to control women.
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Objective To assess if miscarriage, whether consecutive or not, is associated with an 
increased risk of subsequent cardiovascular disease.
Methods A cohort study was performed using women with at least one miscarriage or 
live birth recorded from 1950 - 2010 in the Aberdeen Maternity and Neonatal Databank. 
The exposed groups consisted of women with non-consecutive, two consecutive or 
≥ three consecutive miscarriages; the unexposed group consisted of all women with 
at least one live birth and no miscarriages. Women were linked to Scottish Morbidity 
Records for hospital admissions for cardiovascular conditions, cardiac surgery and death 
registrations. Main outcome measures were ischemic heart disease, cerebrovascular 
disease and a composite outcome of any disease of circulatory system. A sensitivity 
analysis was performed dividing the women into those who had one, two or ≥ three 
miscarriages irrespective of these were consecutive or not.
Results After excluding women with pre-existing hypertension, type one diabetes 
mellitus, kidney disease and ‘disease of circulatory system’, 60105 women were analysed; 
9419 with non-, 940 with two, 167 with ≥ three consecutive miscarriages and 49579 with 
no miscarriage. In the multivariate analyses a significant association was found between 
ischemic heart disease and women with two {Hazard Ratios (HR) 1.75 (95% confidence 
interval (CI) 1.22-2.52-1.72)} or ≥ three {HR 3.18 (95%CI 1.49-6.80-4.51)} consecutive 
miscarriages. Similar patterns of risk were observed in the sensitivity analysis. 
Conclusions Women with a history of two or more miscarriages, irrespective of whether 
consecutive or not, appear to have an increased risk of ischemic heart disease.
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Globally, cardiovascular disease(CVD) is a major cause of premature mortality in 
women[1]. There is increasing evidence that women with adverse pregnancy outcomes 
are at increased risk of CVD[2]. A history of preeclampsia, gestational diabetes or 
pregnancy-induced hypertension is mentioned as a major risk factor for cardiovascular 
disease in women in the American Heart Association guideline[3]. The association 
between recurrent miscarriage and CVD is less clear[4 5].
Approximately 15% of clinically recognized pregnancies fail to result in a live birth[6]. 
Recurrent miscarriage is commonly defined as three or more consecutive pregnancy 
losses before 22 weeks’ gestation[7] and affects 0.5 to 3% of fertile couples[8]. Recurrent 
miscarriage is a highly heterogeneous condition. Possible etiologic factors include genetic 
disorders, uterine anomalies, endocrine factors, maternal autoimmune disorders, 
metabolic disorders, maternal thrombophilia and lifestyle factors[9]. An underlying 
cause may be identified in 25-50% of cases.
CVD and recurrent miscarriage share risk factors such as smoking and obesity[10]. 
Further endothelial dysfunction has been hypothesized as the underlying link between 
recurrent miscarriage, preeclampsia, IUGR and future cardiovascular events[11]. It is 
possible therefore that recurrent miscarriage is a first sign of subsequent CVD in women. 
Early identification of women at increased risk of CVD from their reproductive history 
may enable them to benefit from screening and preventive interventions[12].
A recently published meta-analysis found an association between recurrent miscarriage 
and coronary heart disease: pooled odds ratio 1.99 (1.13 to 3.50)[4]. However clinical 
heterogeneity between studies was evident. The effect of recurrent miscarriage on 
cerebrovascular disease could not be pooled due to the small number of primary studies. 
A large cohort study, not included in the meta-analysis, reported an association[5].
We report here a retrospective cohort study with a long follow-up which assessed if 
miscarriage (consecutive or not) is associated with an increased risk of subsequent CVD.
METHODS 
Data sources and record linkage: The Aberdeen Maternity and Neonatal Databank (AMND) 
has recorded and stored information on all pregnancy-related events occurring in a geo-
graphically defined population living in Aberdeen Scotland from 1950 to the present date. 
Data were extracted for all women with at least one singleton live birth or miscarriage from 
1950 until 2010. These women were linked using probabilistic record linkage to Scottish 
Morbidity Record (SMR 01) to identify any hospital admissions (SMR data available since 
1968) for cardiovascular conditions and to the National Register of Scotland (NRS) for 
death registrations (up to 2013). After linkage the dataset was anonymised. 
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To ensure confidentiality, the linked dataset was managed by the Grampian Data Safe 
Haven, a facility providing a secure environment for the safe linkage, analysis, manage-
ment and storage of datasets containing non-consented clinical data.
Study design: In this retrospective cohort study, the women were grouped according 
to their reproductive history into four mutually exclusive groups: no miscarriage, non-
consecutive miscarriage, two consecutive miscarriages and three or more consecutive 
miscarriages. Women with miscarriages could have had one or more live births prior to, 
or after, their consecutive or non-consecutive miscarriages. The non-consecutive mis-
carriage group consisted of women with one miscarriage or more than one miscarriage 
that were not consecutive. Women experiencing miscarriage(s) formed the exposed 
cohorts while those without a history of miscarriage and at least one live birth comprised 
the unexposed cohort (reference group). 
The AMND uses the International Classification of Disease-version 9 (ICD-9) to code 
events. Miscarriage in this study refers to spontaneous loss of pregnancy before 24 weeks 
of gestation. 
Outcome: The primary outcomes of interest were arterial CVD identified by admission 
to hospital or death from ischemic heart disease (ICD-9 411, 413-414, ICD-10 I20-I25), 
cerebrovascular disease (ICD-9 430-438, ICD-10 I60-I69, G45), or a composite outcome of 
any disease of the circulatory system, defined as admission to hospital or death due to 
diseases of the circulatory system ((ICD-9 390-459 ICD-10 I00-I99, G45) or cardiac surgery 
(OPCS4 Classification of Surgical Operations and Procedures: K40 saphenous vein graft 
replacement of coronary artery, K51 diagnostic transluminal operations on coronary 
artery, K65 catheterisation of heart, K75 percutaneous transluminal balloon angioplasty 
and insertion of stent into coronary artery).
In a separate sensitivity analysis we divided the women into those who had one, two 
or three or more miscarriages irrespective of whether these events were consecutive or 
not. Subgroup analyses were performed dividing the women into those with consecutive 
and non-consecutive miscarriages (2 or more) and primary and secondary consecutive 
miscarriages. Primary miscarriages were defined as miscarriages without a prior live 
birth. Secondary miscarriages as miscarriages after a prior live birth. For all analyses 
women with pre-existing cardiovascular related disease were excluded. Pre-existing 
disease was defined as disease before entry time in the cohort (see statistical analysis 
below); divided into pre-existing hypertension, pre-existing type one diabetes, kidney 
disease and any disease of the circulatory system.
Definition of covariates: 
Baseline characteristics and covariates were obtained from AMND. Gravidity, parity and 
primary versus secondary miscarriages were retrieved. Birth dates were collected, as 
well as dates of pregnancy events and dates of the cardiovascular outcome. Maternal age 
was defined as age at the time of last pregnancy event or age at first, second consecutive 
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or third consecutive miscarriage, depending on the reproductive history. Self-reported 
smoking habits are coded in AMND at the time of the first antenatal clinic visit. As a 
covariate ‘ever’ or ‘never’ smoked were used. Socio economic deprivation is coded in 
the AMND using the husband/ partner’s social class according to the Registrar General’s 
occupation based social class[13]. The social class was divided into two categories: class 
1-3a- ‘non manual’, class 3b to 5- ‘manual’. Body mass index (BMI) was measured at first 
antenatal visit. For each woman a mean BMI (using information from all pregnancies) was 
calculated.
Statistical analyses
All data were extracted, linked and entered into SPSS (Statistical Package for Social 
Science; SPSS Inc., Chicago, IL) version 21.0. Statistical comparisons of baseline 
characteristics between the exposed and unexposed groups were done using 
independent samples t-test, the χ2 test or Fisher’s exact test, as appropriate. P-values 
of 0.05 or less were used to indicate statistical significance. Kaplan-Meier’s curves of 
survival from cardiovascular events of interest were constructed for each of the exposure 
groups, including log rank tests. To calculate the event-free survival, univariate and 
multivariate analyses were done by Cox regression analysis. Hazard ratios (HR) were 
calculated with 95% confidence intervals (CIs). Time since exposure in years was used 
as underlying time variable. Entry time was defined as the year of the last pregnancy 
event for women in the unexposed cohort. Depending on their reproductive history, 
the entry time for women in the exposed cohort was year of first miscarriage, second 
consecutive miscarriage or third consecutive miscarriage. End time was defined as 
the date of the cardiovascular event, or in case no event occurred January 2013. The 
following covariates were included in the adjusted analyses: maternal age at entry time 
and BMI (as continuous variables), social class and smoking (as categorical variables). 
All of the covariates used for adjustment were significantly associated with CVD. 
A complete case analysis was performed, as well as a Cox regression using multiple 
imputation for the missing values (creating five different ‘complete’ datasets using 
maternal age, BMI, social class, smoking). 
Power calculation
A power calculation was performed a priori in nQuery advisor using the smallest exposed 
cohort. The prevalence of CVD in women aged 55-64 in Scotland is 15.3%[14]. Assuming 
the same prevalence in the unexposed cohort, using a 2 sided test with 90% power at 
5% significance level, to detect a clinically relevant HR of 2.0 we would need 177 in the 
smallest exposed cohort and 705 in the unexposed group.




We identified 65227 women who had a pregnancy ending in miscarriage and/or live 
birth between 1950 and 2010 (Figure 1). A total of 5122 women had some pre-existing 
cardiovascular related disease. 
Figure 1 Flow chart selection of cohort
Table 1 Pre-existing morbidity in 65227 women; divided in women experiencing consecutive 
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p- values refer to comparisons between miscarriage group and no miscarriage group.
aComparison between 2 and ≥3 consecutive miscarriages
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The prevalence of pre-existing hypertension was higher in women with miscarriages 
compared to women with no miscarriages, the prevalence of pre-existing diseases of 
the circulatory system was higher in women with consecutive miscarriages compared to 
women with no miscarriages (Table 1). Women with pre-existing disease were excluded 
from all analyses, leaving 60105 women; 9419 women with none, 940 women with two 
and 167 women with three or more consecutive miscarriages, and 49579 women with at 
least one live birth and no miscarriages.
The exposed and unexposed groups differed at baseline on maternal age; women in the 
non-consecutive miscarriage group being younger and women in the two and ≥ three 
miscarriage groups older than the no miscarriage group (Table 2). 
Table 2 Comparison of characteristics between women experiencing consecutive miscarriages 
















































Gravidity mean(SD) 1.78 (0.92) 2.60(1.46) (p<0.01) 3.96(1.56) (p<0.01) 4.90(1.52) (p<0.01)
Parity mean(SD) 1.59 (0.72) 1.27(1.15) (p<0.01) 1.50(1.13) (p=0.03) 1.29(1.05) (p<0.01)
Primary miscarriages (%) ------- 6552 (69.6) 609 (64.8) 117 (70.1)
At least one continuing  
pregnancy (%)
49579 (100) 6219 (66.0) (p<0.01) 725 (77.1) (p<0.01) 123 (73.7) (p<0.01)
p- values refer to comparisons between miscarriage group and no miscarriage group.
amaternal age at last pregnancy or miscarriage, depending on exposure
b percentage without missing
BMI= body mass index; RGSC= Registrar General Social Class
Mean BMI was higher in the exposed groups, although only significantly so in the non- 
consecutive miscarriage group. Women in the miscarriage groups were more likely to be 
‘ever smokers’ than those with no miscarriages, significantly so for the non- consecutive 
and two consecutive miscarriage groups. Significantly more women in the two 
consecutive miscarriage group were of ‘non-manual’ socio-economic status than those 
in the no miscarriage group, although this variable was missing for a large proportion of 
women in each group. 
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Median follow-up time was 17 years (range 0-62 years). An association was found on 
univariate analysis between two or three consecutive miscarriages and most cardio-
vascular endpoints examined (tables 3-5).












Events N (%) 1440 (2.9) 272 (2.9) 30 (3.2) 7 (4.2)
Person-yearsa 1006 192 15 3
Univariate HR (95% CI) 1.0 0.92 (0.81-1.05) 2.24 (1.56-3.22) 4.00 (1.90-8.42)








Multivariateb,e HR (95% CI) 1.0 0.99 (0.87-1.13) 1.75 (1.22-2.52) 3.18 (1.49-6.80)
aPerson-years in thousands
bAdjusted for maternal age, body mass index, social class, smoking
cComplete case analysis
dPercentage of cases with missing covariates; exposed and unexposed group together
eMultiple imputation model, model includes maternal age, body mass index, social class, smoking
HR: Hazard ratio; CI: confidence interval












Events N (%) 826 (1.7) 139 (1.5) 14 (1.5) 3 (1.8)
Person-yearsa 1010 193 15 3
Univariate HR (95% CI) 1.0 0.82 (0.68-0.98) 1.71 (1.01-2.90) 2.53 (0.81-7.86)








Multivariateb,e HR (95% CI) 1.0 0.88 (0.73-1.05) 1.30 (0.77-2.22) --
aPerson-years in thousands
bAdjusted for maternal age, body mass index, social class, smoking
cComplete case analysis
dPercentage of cases with missing covariates; exposed and unexposed group together
eMultiple imputation model, model includes maternal age, body mass index, social class, smoking
HR: Hazard ratio; CI: confidence interval
Figure 2 shows the event free survival for ischemic heart disease for the unexposed 
and exposed groups. In the multivariate Cox regression analysis between consecutive 
miscarriages and ischemic heart disease (Table 3), the HR in the ≥three miscarriage group 
was 3.18 (95%CI 1.49-6.80) (multiple imputation model). Results from the Cox regression 
analysis between consecutive miscarriages and cerebrovascular disease can be found 
in Table 4. We were unable to perform multivariate analyses for women experiencing 
≥  three consecutive miscarriages because of small numbers. 
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Events N (%) 6841 (13.8) 1207 (12.8) 126 (13.4) 23 (13.8)
Person-yearsa 957 184 14 2
Univariate HR (95% CI) 1.0 0.88 (0.83-0.94) 1.53 (1.28-1.82) 1.70 (1.13-2.56)








Multivariateb,e HR (95% CI) 1.0 0.97 (0.91-1.03) 1.34 (1.12-1.60) 1.38 (0.91-2.09)
aPerson-years in thousands
bAdjusted for maternal age, body mass index, social class, smoking
cComplete case analysis
dPercentage of cases with missing covariates; exposed and unexposed group together
eMultiple imputation model, model includes maternal age, body mass index, social class, smoking
HR: Hazard ratio; CI: confidence interval









Events N (%) 1440 (2.9) 262 (2.9) 36 (2.9) 11 (3.9)
Person-yearsa 1006 184 19 4
Univariate HR (95% CI) 1.0 0.90(0.79-1.03) 2.38(1.71-3.32) 4.35(2.40-7.89)








Multivariateb,e HR (95% CI) 1.0 0.97 (0.85-1.11) 1.82 (1.30-2.54) 3.18 (1.76-5.78)
aPerson-years in thousands
bAdjusted for maternal age, body mass index, social class, smoking
cComplete case analysis
dPercentage of cases with missing covariates; exposed and unexposed group together
eMultiple imputation model, model includes maternal age, body mass index, social class, smoking
HR: Hazard ratio; CI: confidence interval
In the model looking at diseases of the circulatory system, HRs remained significantly 
elevated after multivariate analyses in the two consecutive miscarriage group; whereas 
statistical significance was lost in the ≥ three consecutive miscarriage group (Table 5). 
Sensitivity analysis: A sensitivity analysis was performed using data whereby women 
were allocated to groups according to the total number of miscarriages, irrespective of 
whether these were consecutive or not (Table 6, supplementary data). In this analysis 
there were 9022 women in the one miscarriage group, 1222 in the two miscarriages 
group and 282 in the ≥three miscarriages group. The results were consistent with those 
described above; univariate analyses found increasing HR’s by number of miscarriages, 
for each cardiovascular endpoint examined. This association remained significant in the 
multivariate analysis for ischemic heart disease (Table 6) and diseases of the circulatory 










.0 20.0 40.0 60.0
Time in Years








Number of consecutive miscarriages
no miscarriage 
non-consecutive miscarriage 
2 consecutive miscarriages 
≥ 3 consecutive miscarriages 
Log rank no vs non-consecutive miscarriage  p = 0.202
Log rank no vs 2 consecutive miscarriages p < 0.001
Log rank no vs ≥ 3 consecutive miscarriages  p < 0.001
Life Tables for Ischemic Heart Disease
TIME 0 YEARS 10 YEARS 20 YEARS 30 YEARS 40 YEARS 50 YEARS 60 YEARS
no miscarriage 49579 34927 21458 12116 6544 4047 492
non-consecutive
miscarriage
9419 6831 3397 2110 1394 813 196
2 consecutive 
miscarriages
940 605 239 130 64 24 1
≥ 3 consecutive
miscarriages
167 115 42 17 9 2 -
Consecutive miscarriages
Figure 2 Kaplan-Meier estimate: event-free survival for ischaemic heart disease
Subgroup analyses (supplementary data): Hazard ratios of ischemic heart disease and 
diseases of the circulatory system were lower in the women with consecutive miscarriages 
compared to the women with 2 or more non-consecutive miscarriage in the multivariate 
(multiple imputation) model. No significant difference was found in the subgroup 
analysis comparing women with primary and secondary consecutive miscarriages, for 
each cardiovascular endpoint examined. 
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Our data suggest that women with a history of two or more miscarriages, irrespective of 
whether consecutive or not, have an increased risk of ischemic heart disease. 
Strengths and limitations
To our knowledge, this study has the longest follow-up compared to other studies on 
this topic [5 15 16], giving time for CVD to develop. Another strength was the ability to 
exclude women with relevant pre-existing morbidity (type one diabetes, hypertension 
and kidney disease) from the analysis. Unfortunately information about type 2 diabetes 
was not available. Data about exposure was recorded prospectively, and information 
about outcome was collected from two national datasets, thereby eliminating recall 
bias. The quality of data collected from hospital admissions is periodically assessed, the 
accuracy of SMR 01 data was 88% for Main Condition [17]. Inaccuracy of outcome and 
wrong linkage (possibility of 3%) [18], is unlikely to introduce bias as collection of these 
data and linkage was done blind to the exposure status of the women. We are confident 
that complete reproductive histories of the women were captured in the AMND thereby 
minimising the possibility of misclassification according to the number of miscarriages. 
Previous studies have found that data from the AMND is more than 90% accurate 
regarding the studied exposure variables of miscarriage assessed by case note review[19]
( www.abdn.ac.uk/amnd). The covariates like BMI were collected at time of exposure, by 
health care personnel who were blind to any outcome at that time, adding validity to the 
measurement. 
Since the patient population is exclusively from Scotland our findings may not be 
applicable to other populations, for example as a result of genetic differences. Mis-
classification of exposure could have occurred if miscarriages were underreported (more 
likely to occur during the earlier years of the Databank before the widespread use of 
ultrasound or improved pregnancy tests). If this is the case, women who experienced 
miscarriages could have been placed in the no miscarriage group, and our risk estimation 
could have been underestimated. Bias could have been introduced due to missing data 
about smoking habits and social class. Women who have had an ongoing pregnancy were 
less likely to have missing data, because variables were better recorded at their antenatal 
visits. To reduce the risk of bias due to missing data we performed both complete case 
analysis and multiple imputation. 
Each of the univariate HRs for different endpoints in the non-consecutive miscarriage 
group was less than one. This is likely to have been because these women were younger 
at exposure (first miscarriage) than women in the unexposed group (last pregnancy). 
When age was adjusted for the direction of effect changed. We defined maternal age in 
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the unexposed group as age at last pregnancy because from this point women could not 
become part of the exposed groups; they were no longer at risk for miscarriage.
Some women experience a complication during pregnancy, such as preeclampsia, 
placental abruption, IUGR or pre-term delivery, events which may increase their risk of 
CVD later in life[2 20]. A substantial proportion of the women in the miscarriage groups had 
no ongoing pregnancy, so did not have the chance to develop pregnancy complications. 
We did not adjust for history of complications of pregnancy since it is unclear whether 
these events are on the causal pathway between miscarriage and CVD[19 21]. If they are 
not, and if there are important differences in the prevalence of these complications, the 
effect of not making an adjustment will be to bias the effect towards null and therefore 
any effect seen in our analysis is likely to be an underestimate.
Interpretation
Our findings concur with the meta-analysis by Oliver-Williams et al[4], which included 10 
studies investigating the association between miscarriage and coronary heart disease 
However, comparability between case-control studies in the meta-analysis was moderate 
and 6 of the included studies had no or minimal adjustment for confounding factors[4]. 
Due to the small number of studies available, the meta-analysis was unable to examine 
the association between recurrent miscarriage and cerebrovascular disease[4]. Our data 
suggest (on univariate analysis) an increased risk of cerebrovascular disease for women 
with two and ≥ three consecutive miscarriages. An association between miscarriage and 
cerebral infarction was seen in a large cohort study[5]. Although our estimates are based 
on relatively small numbers they can contribute to future meta-analyses. 
Any higher risk of CVD later in life in women with consecutive miscarriages is probably 
multifactorial in aetiology. It is noteworthy that we observed an association  between 
consecutive miscarriages and pre-existing cardiovascular related disease such as; 
 hypertension, and diseases of circulatory system (including cardiac surgery). This 
suggests that miscarriage and CVD share either common risk factors or mechanism(s) 
of  effect or both. One of the mechanisms involved may be related to the metabolic 
syndrome, as research suggests an association between miscarriage and insulin resis-
tance and obesity[22]. Antiphospholipid syndrome is known to be a risk factor for women 
experiencing miscarriage, as well as CVD[23]. Another contribution to aetiology could 
be genetic; several papers describe a higher risk of miscarriage in women with a family 
history of miscarriage[24 25] and Smith et al 2011[26] found an increased risk of CVD in 
parents of women who had recurrent miscarriage. 
Most of previous studies has focused on whether total number of miscarriages, rather 
than the consecutive nature of the events, is associated with future risk of cardiovascular 
disease. 
We focused on the consecutive nature, as in the clinic recurrent miscarriage is mostly 
defined as three or more consecutive miscarriages. Also from a pathophysiological point 
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of view consecutive miscarriages are interesting, since it is more likely that a maternal 
factor plays a role[9]. Ranthe described an increased risk of cerebral infarction and 
renovascular hypertension in women with consecutive compared to non-consecutive 
miscarriages[5]. In our paper similar patterns of risk were observed when the data were 
examined by number of consecutive miscarriages or total number of miscarriages, 
irrespective of whether consecutive or not. In subgroup analyses, risks for ischemic heart 
disease and diseases of the circulatory system were lower in women with consecutive 
miscarriages compared to women with 2 or more non-consecutive miscarriages. 
This suggests that the number of miscarriage (2 or more) is more important than the 
consecutive nature of events. Although, it is important to recognise that these subgroup 
analyses had more limited statistical power than our main analysis. The American Heart 
Association advises monitoring and control of risk factors postpartum in women with 
a history of hypertensive complications of pregnancy[3]. As the HR for ischemic heart 
disease in women with two or more miscarriages is comparable with the HR for CVD 
in women with hypertensive disorders of pregnancy[20] we think that a comparable 
approach for women with two or more miscarriages is justified.
Conclusion
Women who have experienced miscarriages appear to have an increased risk of ischemic 
heart disease, suggesting its importance as an independent risk indicator. Miscarriage 
may also be an important risk indicator for other cardiovascular outcomes. We suggest 
that women who have experienced two or more miscarriages, irrespective of whether 
consecutive or not, should be made aware of an increased cardiovascular risk and advised 
appropriate risk factor modifications. Work is needed to determine whether women with 
such a history will benefit from these screening and preventative interventions. 
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Supplementary data  
Sensitivity analyses; groups divided by total number of miscarriages:










Events N (%) 826 (1.7) 138 (1.5) 13 (1.1) 5 (1.8)
Person-yearsa 1010 185 19 4
Univariate HR (95% CI) 1.0 0.83(0.69-0.99) 1.38(0.80-2.39) 2.90(1.20-6.98)








Multivariateb,e HR (95% CI) 1.0 0.89 (0.74-1.06) 1.03 (0.59-1.77) 2.07 (0.86-5.01)
aPerson-years in thousands
bAdjusted for maternal age, body mass index, social class, smoking
cComplete case analysis
dPercentage of cases with missing covariates; exposed and unexposed group together
eMultiple imputation model, model includes maternal age, body mass index, social class, smoking
HR: Hazard ratio; CI: confidence interval.
Table 8 Survival analysis Diseases of the Circulatory System (including cardiac surgery) – groups 









Events N (%) 6841 (13.8) 1155 (12.8) 152 (12.5) 45 (16)
Person-yearsa 957 177 18 4
Univariate HR (95% CI) 1.0 0.87 (0.82-0.93) 1.53 (1.30-1.79) 2.23 (1.66-2.99)








Multivariateb,e HR (95% CI) 1.0 0.95 (0.89-1.01) 1.32 (1.12-1.55) 1.72 (1.28-2.31)
aPerson-years in thousands
bAdjusted for maternal age, body mass index, social class, smoking
cComplete case analysis
dPercentage of cases with missing covariates; exposed and unexposed group together
eMultiple imputation model, model includes maternal age, body mass index, social class, smoking
HR: Hazard ratio; CI: confidence interval
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Ischemic Heart Disease Events N (%) 10 (2.5) 12 (3.3)
Univariate HR (95% CI) 1.0 0.74 (0.37-1.50)




Multivariateb,d HR (95% CI) 1.0 0.45 (0.21-0.97)
Cerebrovascular Disease Events N (%) 1 (0.3) 17 (1.5)
Univariate HR (95% CI) 1.0 3.70 (0.49-28.00)




Multivariateb,d HR (95% CI) 1.0 2.71 (0.34-21.48)
Diseases of the Circulatory System 
(including cardiac surgery)
Events N (%) 48 (12.2) 149 (13.5)
Univariate HR (95% CI) 1.0 0.79 (0.57-1.09)




Multivariateb,d HR (95% CI) 1.0 0.63 (0.44-0.89)
aAdjusted for maternal age, body mass index, social class, smoking
bComplete case analysis
cPercentage of cases with missing covariates; groups together
dMultiple imputation model, model includes maternal age, body mass index, social class, smoking
HR: Hazard ratio; CI: confidence interval
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Ischemic Heart Disease Events N (%) 25 (3.4) 12 (3.1) 
Univariate HR (95% CI) 1.0 1.18 (0.59-2.38) 




Multivariateb,d HR (95% CI) 1.0 1.25 (0.61-2.56)
Cerebrovascular Disease Events N (%) 14 (1.9) 3 (0.8)
Univariate HR (95% CI) 1.0 0.61 (0.17-2.19)




Multivariateb,d HR (95% CI) 1.0 0.61 (0.17-2.19)
Diseases of the Circulatory 
System (including cardiac surgery)
Events N (%) 95 (13.1) 54 (14.2)
Univariate HR (95% CI) 1.0 1.30 (0.93-1.82)
Multivariatea,b HR (95% CI)
Missingc (%)
1.0 1.21 (0.75-1.94)
Multivariateb,d HR (95% CI) 1.0 1.24 (0.88-1.74)
aAdjusted for maternal age, body mass index, social class, smoking
bComplete case analysis
cPercentage of cases with missing covariates; groups together
dMultiple imputation model, model includes maternal age, body mass index, social class, smoking
HR: Hazard ratio; CI: confi dence interval
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Background  Cardiovascular disease is the leading cause of death in women. Obser-
vational studies suggest that women with a history of recurrent miscarriage have an 
increased risk of cardiovascular disease.
Methods Women who visited the recurrent miscarriage clinic at Leiden University Medical 
Centre (between 2000-2010) and had their third consecutive miscarriage < 31 years, were 
invited to participate in this follow-up study (between 2012-2014). The reference group 
consisted of women with at least one uncomplicated pregnancy and no miscarriage, 
matched on zip code, age, and date of pregnancy. All women were invited for risk factor 
screening, including physical examination and blood collection. Main outcome measures 
were the (extrapolated) 10- and 30-year cardiovascular risk scores using the Framingham 
risk score. A sub analysis was performed for women with idiopathic recurrent miscarriage.
Results 36 women were included in both groups. Mean follow-up was 7.5 years. Women 
with recurrent miscarriage had a significantly higher extrapolated 10-year cardiovascular 
risk score (mean 6.24%, SD 5.44) compared to women with no miscarriage (mean 3.56%, 
SD 1.82, p=0.007) and a significantly higher 30-year cardiovascular risk score (mean 
9.86%, SD 9.10) compared to women with no miscarriage (mean 6.39%, SD 4.20, p=0.04). 
Similar results were found in women with idiopathic recurrent miscarriage (n=28). 
Conclusions Women with a history of recurrent miscarriage differ in cardiovascular risk 
profile at young age compared to women with no miscarriage. The findings support an 
opportunity to identify women at risk of cardiovascular disease later in life and a possible 
moment for intervention.
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Cardiovascular disease(CVD) is the leading cause of death in women in the western 
world[1]. Women have a unique risk profile for CVD compared to men[2]. There is 
increasing evidence that women with adverse pregnancy outcomes are at increased risk 
of premature CVD. Pregnancy can be considered as a “stress test” unmasking underlying 
cardiovascular defects[3]. A history of gestational diabetes, preeclampsia or pregnancy 
induced hypertension is mentioned as a major risk factor in women for developing CVD 
in the American Heart Association Guidelines[2]. Miscarriages are not considered in this 
guideline. 
Recurrent miscarriage is commonly defined as three or more consecutive pregnancy 
losses before 22 weeks of gestation[4] and affects 0.5-3% of all fertile couples[5]. 
Recurrent miscarriage is a highly heterogeneous condition. Possible etiologic factors 
include genetic disorders, uterine anomalies, endocrine factors, maternal autoimmune 
disorders, metabolic disorders, maternal thrombophilia and lifestyle factors[6]. An 
underlying cause may be identified in 25-50% of cases. Observational studies suggest 
that also women with a history of recurrent miscarriage have an increased risk of CVD[7-
10]. Several hypotheses are possible for the association between both diseases; shared 
common risk factors such as obesity and smoking[11], endothelial dysfunction[12], and a 
genetic predisposition is assumed[13].  
Determining cardiovascular risk factors in women with recurrent miscarriage could be 
an opportunity to identify women at high risk for future CVD at a young age. Worldwide 
multivariable risk assessment tools are developed to detect apparently healthy individuals 
at high risk for CVD and to effectively implement prevention strategies[14]. At present the 
most common externally validated risk model is the Framingham risk score[15]. 
We conducted a follow-up study to determine cardiovascular risk factors and predict the 






Women who visited the recurrent miscarriage clinic at Leiden University Medical Centre 
between 2000 and 2010 and had their third consecutive miscarriage below the age of 
31 years were invited to participate in this follow-up study. Recurrent miscarriage was 
defined as ≥ 3 consecutive miscarriages before 22 weeks of gestation. All women had 
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a routine recurrent miscarriage work-up to identify possible causes for the recurrent 
miscarriage: a standardised history of the couple was performed, karyotyping of the 
couple (this was offered routinely before 2005 to all couples, after 2005 this was only 
offered in presence of low maternal age and/or positive family history for recurrent 
miscarriage)[16], presence of uterus anomalies by ultrasound or hysteroscopy and 
presence of acquired and heritable thrombophilia was assessed. Acquired thrombophilia: 
antiphospholipid syndrome was defined as the presence of anticardiolipin antibodies or 
lupus anticoagulant in repeated samples taken 3 months apart and at least 10 weeks 
after delivery[17], after revision of the classification criteria the presence of anti-β2 
glycoprotein-I was added to the work-up[18]. Hyperhomocysteinemia was evaluated. 
Heritable thrombophilia was defined by the presence of a factor V Leiden mutation, factor 
II (prothrombin) gene mutation, protein C or S deficiency or antithrombin deficiency. 
Women with primary miscarriage (no live birth before miscarriage) and secondary 
miscarriage (live birth(s) before miscarriage) were included. The time interval between 
the diagnosis recurrent miscarriage and the time of follow-up had to be at least 2 years. 
Unexposed
Women with one or more uncomplicated pregnancy(ies) and no miscarriages were 
enrolled (reference group). In the Netherlands, it is common practice that independent 
community midwives are taking care of low-risk women (with no medical or obstetrical 
history) during pregnancy and child birth. The zip code of each woman with recurrent 
miscarriage was used to contact the nearest midwifery practice to take the impact 
of socio-economic status into account. Women with the same zip code, the same age 
(difference in birthdate maximal 1 year) and of which the time of first delivery was close 
to the time of the third miscarriage of the matched exposed woman (maximum 6 months 
before or 6 months after) were asked to participate. Women with recurrent miscarriage 
were included in the study before the matched controls were invited to participate, 
a small difference in follow-time was therefore expected. In both groups, pregnant 
and lactating women (within the last 3 months) were excluded. Enrolment took place 
between 2012 and 2014.
Procedures and definitions
After enrolment, all women were asked to fill out a web based questionnaire and were 
invited for risk factor screening. The questionnaire included general information, medical 
history, family history of CVD, use of medication, intoxications and obstetric history. 
Information about medical history, use of medication, intoxications and pregnancy 
outcome was cross checked in obstetrical records to overcome recall bias. Gestational 
diabetes was defined as a glucose intolerance resulting in hyperglycaemia with onset 
during pregnancy[19]. Preeclampsia was defined as systolic blood pressure above 
140 mmHg and/or diastolic pressure above 90 mmHg combined with proteinuria[20], 
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pregnancy induced hypertension as systolic blood pressure above 140 mmHg and/or 
diastolic pressure above 90 mmHg or higher measured on two occasions(after 20 weeks’ 
gestation)[21], preterm birth as a delivery between 24 and 37 weeks gestation, intra-
uterine growth restriction as birth weight below the 10th percentile for gestational age 
and sex according to the Netherlands Perinatal Registry birth weight percentiles[22]. 
Assessment of classic cardiovascular risk factors was performed by trained research 
nurses or doctors at the Leiden University Medical Centre or at the participants’ 
home. Blood pressure was measured manually with a validated sphygmomanometer 
in sitting position at the left upper arm with the appropriate cuff size, the mean of two 
measurements was taken. Length and weight was measured wearing light clothes and 
without shoes; length was measured to the nearest 1 cm and weight to the nearest 1 kg. 
Body mass index(BMI) was calculated as weight/ length2, Venous blood samples were 
collected after an overnight fast and assayed for classical risk factors of CVD (glucose, 
insulin, HbA1c, total cholesterol, HDL cholesterol, triglycerides), Insulin resistance was 
assessed by the homeostasis model assessment (HOMA)[23]. The blood samples were 
centrifuged, separated and frozen at -80°C within 2 hours. Routine chemistry analyses 
were performed on a Roche Modular P800 chemistry analyser using reagents of Roche 
Diagnostics (Mannheim, Germany). Analytical variation of all analytes was well below 5%. 
Insulin was analysed on an Immulite 2000 Xpi immunoanalyser of Siemens Healthcare 
Diagnostics (Tarry town, NY, USA). Analytical variation varied between 5% and 8%. 
HbA1c was analysed using a Boronate affinity chromatographic system (Primus Ultra2, 
Trinity Biotech, Bray Ireland). Analytical variation was well below 2%. All analyses were 
performed by technicians blinded for obstetrical history. Family history of premature 
myocardial infarction (MI) and/or stroke was defined as having at least one parent with 
MI and/or stroke before the age of 60.
10- and 30-Year CVD risk by the Framingham score[24, 25] was calculated using information 
on age, systolic blood pressure, antihypertensive treatment, smoking, diabetes and lipid 
spectrum (total cholesterol and HDL cholesterol) or BMI (a simpler model of the risk score). 
Both models, using lipids and using BMI, were applied. CVD was defined as coronary 
death, MI, coronary insufficiency, angina pectoris, ischemic stroke, haemorrhagic stroke, 
transient ischemic attack, peripheral artery disease and heart failure. The 10-Year CVD risk 
score was calculated twice; using current age and subsequently estimating the risk as if 
the woman was 60 years of age (due to the young age of our participants, the estimated 
absolute 10-year CVD risk was likely to be low). This approach has been recommended 
in the cardiovascular risk factor management guidelines for young women with elevated 
risk factor levels [26]. During our study period a new guideline was published[27], which 
revised the approach to CVD in the young in using ‘cardiovascular risk age’. This method 
was not applicable to our young cohort (age < 40 years) and we decided to follow the afore-
mentioned approach. The risk estimation was repeated in a subgroup analysis including 
women with idiopathic recurrent miscarriage. Recurrent miscarriage was defined as 
idiopathic when the work-up for causes of recurrent miscarriage showed no abnor malities. 




The calculation was based on results of the Hyras study: the (extrapolated) 10-year CVD 
risk was 4,4% (SD 1.9) in women with uncomplicated pregnancies[28]. We planned to 
include women in 1:1 ratio, i.e. a woman who had recurrent miscarriage matched to 1 
control subject. A relative risk of 1,5 or higher was considered to be clinically relevant. A 
sample size of 68 women (34 exposed, 34 non-exposed) was sufficient, with a 10% drop-
out rate (two sided alpha .05. power 90%).
Statistics
Data were analysed using SPSS software version 22.0 (Statistical Package for Social 
Science; SPSS, Chicago, Illinois, USA). Comparisons of normal distributed data were 
performed using paired T- test. Comparisons of continuous data were performed using 
the McNemar’s test. For all tests, a p-value < 0.05 is indicated statistical significant.
Ethics
Approval from the medical ethics committee of Leiden University Medical Centre (P04-
020; October 3, 2012) was obtained and all participants gave informed consent. The 
study was registered with the Dutch trial registry NTR3408. This study is part of the REMI 
(REcurrent MIscarriages) studies, studies which investigate consequences and causes of 
recurrent miscarriages.
Results
A flowchart of the inclusion of the participants is shown in Figure 1. Of the 76 included 
women, 4 women were excluded from analysis, because they did not meet the inclusion 
criteria for this study as described in Figure 1. Leaving 36 matched pairs. 
Women with recurrent miscarriage had a significantly higher gravidity and lower parity 
than those in the no miscarriage group (Table 1). Women with recurrent miscarriage 
were more often smokers during pregnancy (p=0.05). On all other variables groups were 
comparable. 
78% of the women with recurrent miscarriage (n=28) were diagnosed with idiopathic 
recurrent miscarriage. Parental chromosomal abnormality was found in one case, 
antiphospholipid syndrome in one case, hyperhomocysteinemia in three cases and 
heritable thrombophilia was found in three cases.
Mean follow-up time was 6.8 years (SD 3.0) in women with recurrent miscarriage and 
8.1 years in women with no miscarriage (SD 2.9), (p<0.001). Classical cardiovascular risk 
factors are described in Table 2. Women with recurrent miscarriage were slightly younger 
at time of follow-up than women with no miscarriage (p<0.001). Values of classical 
cardiovascular risk factors were higher in women with recurrent miscarriage compared 
to no miscarriage, although only significant for systolic blood pressure.
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Maternal age at index pregnancya 26.36 (2.65) 26.47 (2.69) 0.70
Caucasian (%) 32 (88.9) 30 (83.3) 0.63
University level education (%) 16 (44.4) 8 (22.2) 0.08
Gravidity 2.28 (0.62) 7.11 (2.07) <0.001
Parity 2.25 (0.60) 1.64 (0.83) 0.001
Primary miscarriages (%) -- 27 (75.0) --
At least one continuing pregnancyb (%) 36 (100) 35 (97.2) 0.31
Smoking during pregnancyc (%) 5 (13.9) 14 (38.9) 0.05
Gestational diabetesc (%) 0 (0) 0 (0) --
Preeclampsia/Gestational hypertensionb,c (%) 0 (0) 3 (8.3) 0.08
Preterm birthc (%) 1 (2.8) 4 (11.1) 0.38
Intra uterine growth restrictionc (%) 4 (11.1) 4 (11.1) 1.00
Data are presented as mean (SD)
aAge at first pregnancy for unexposed women, age at third consecutive miscarriage for exposed women
b Chi-squared test. Mc Nemars test not possible (at least one variable in each 2-way table is a constant)
c In at least one continuing pregnancy




Matched to women without miscarriage
Invited n= 148
Excluded from analysis 
• Recurrent miscarriage: n=2 (1 lactating, 1 non consecutive miscarriage)
• No miscarriage: n=2 (1 history of miscarriage, 1 matched to excluded woman) 






Declined to participate due to emotional reasons 
n= 17
Did not meet inclusion criteria 








Did not meet inclusion criteria (pregnant/lactating 
during study period) 
n= 10
Figure 1.  Flow chart Selection of participants
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Maternal age at follow-up 34.50 (3.59) 33.28 (3.51) <0.001 
Smoking at follow-up (%) 5 (13.9) 10 (27.8) 0.23
BMI at follow-up 23.78 (3.49) 25.89 (7.08) 0.09
Systolic blood pressure mmHg 101.11 (10.72) 111.11 (13.06) <0.001
Diastolic blood pressure mmHg 67.22 (7.62) 70.64 (9.54) 0.08
Antihypertensive medication usea (%) 0 (0) 3 (8.33) 0.08
HOMA score 2.28 (1.95) 3.40 (6.20) 0.31
HbA1c mmol/mol Hb 29.89 (2.45) 32.25 (8.36) 0.13
Total cholesterol mmol/L 4.89 (0.76) 4.76 (0.68) 0.46
HDL cholesterol mmol/L 1.71 (0.39) 1.59 (0.49) 0.25
Triglycerides mmol/L 0.98 (0.29) 1.12 (0.61) 0.24
Family history of premature MI and/or stroke (%)         
Missing=1
9 (25.7) 8 (22.9) 1.00
Data are presented as mean (SD)
aChi-squared test. Mc Nemars test not possible (at least one variable in each 2-way table is a constant)
BMI body mass index, HOMA homeostasis model assessment, HbA1C haemoglobin A1c, HDL high-density lipoproteins, 
MI myocardial infarction
Women with recurrent miscarriage had significantly higher mean CVD risk scores 
compared to women with no miscarriage (Table 3), independent of using the lipids or 
the BMI model. In the subgroup analysis including women with idiopathic recurrent 
miscarriage comparable results to the total group were found (Table 3). 
Discussion
Main findings
In this follow-up study an increased (extrapolated) 10 and 30-year CVD risk was found in 
women with a history of recurrent miscarriage compared to women with no miscarriages, 
calculated by Framingham risk scores (lipids and BMI model). Women with recurrent 
miscarriage had an increased systolic blood pressure compared to women with no 
miscarriage at time of follow-up. 
Interpretation
The Framingham risk score is the most externally validated risk score and is widely used 
in North American countries[15]. It is the only model which can estimate the 10 and 30-
year CVD risk (mortality and morbidity) and is therefore useful to estimate risks for a 
young population. European guidelines advise the use of SCORE, which assesses only 
mortality risk and therefore is less useful in our young population[29]. Overestimation 
of the risk of CVD is possible using the Framingham score in a European cohort[15]. If so, 
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an overestimation of the risk occurred in both groups and therefore is not changing the 
direction of effect. Due to the young age of our participants we calculated the 10-year 
risk scores as if the women were 60 years of age according guidelines for young women 
with elevated risk factor levels[26]. The new method of ‘cardiovascular risk age’[27] 
was not applicable to our young cohort (age < 40 years). A disadvantage of this method, 
extrapolating to an age of 60 years, is that the real risk could be underestimated assuming 
that levels of cardiovascular risk factors will increase without prevention or intervention. 
Perhaps this is the reason why we found a quite large difference between the 10-Year CVD 
risk after extrapolating the age to 60 years and the 30-Year CVD scores, in women with 
recurrent miscarriage mean risk 6.24% and 9.86%, respectively.
Only few studies have been performed regarding cardiovascular risk factors in women 
with recurrent miscarriage. Our findings are inconsistent with the results of the study 
from Mahendru et al[30], which found no difference in cardiovascular function and risk 
factors between women with unexplained recurrent miscarriage (n=26) and women with 
uncomplicated pregnancy before a subsequent pregnancy. Explanations for this may 
be a lack of power, short follow-up time (median 8 months in study from Mahendru et 
al) or the difference in selection of the women with recurrent miscarriage; we used an 
age criterion; recurrent miscarriage ≤ 30 years versus unexplained recurrent miscarriage 
irrespective of age in the other study. Our findings are in line with the report by Germain 
et al[12] who found that women with recurrent pregnancy loss (n= 29), defined as ≥ 2 
consecutive miscarriages, have an altered cardiovascular risk profile compared to women 
with uncomplicated pregnancy (significant for total cholesterol). Their methods differed 
from ours as they excluded all women with: overweight, chronic hypertension, diabetes, 
renal and CVD at index pregnancy, smokers and women with thrombophilia except 
for antiphospholipid syndrome (APS), introducing a high level of selection bias. The 
explanation for this is that they investigated the hypothesis that endothelial dysfunction 
could be the link between miscarriage and CVD (and these factors alter markers of 
endothelial function). We performed a subgroup analysis including only women with 
idiopathic recurrent miscarriage (n=28) (Table 3), which showed comparable results to 
the results of the total group. Therefore, in this study the increased risk of CVD in women 
with recurrent miscarriage cannot be explained by the presence of known acquired and 
heritable thrombophilia. 
In Table 2 we described the individual classical risk factors. Only systolic blood pressure 
was significantly higher in women recurrent miscarriage compared to no miscarriage. 
Since we did not perform a sample size analysis based on individual risk factors, a lack 
of power is likely when investigating the individual risk factors. It would be interesting 
to investigate these risk factors in a larger study group to answer the question which 
risk factor is contributing the most to the elevated CVD risk in women with recurrent 
miscarriage. As we were only able to look at cardiovascular risk factors in women after 
they experienced recurrent miscarriage we are not answering the question about cause 
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and effect. Although pre-existing CVD risk factors are associated with an increased risk 
of developing miscarriages, it is not known whether miscarriages merely unmask risk 
or contributes directly to future CVD. Miscarriages could trigger a pathophysiological 
mechanism or cascade that in turn leads to CVD, potentially via interactions with classical 
risk factors.
Strengths/limitations
To our knowledge this is the first study which investigated and calculated CVD risk 
scores in women with a history of recurrent miscarriage. A strength of our research is 
the unique, well defined cohort. Recurrent miscarriage is a highly heterogenic condition, 
to strive to more homogeneity, in present study we included only women who had their 
third consecutive miscarriage below the age of 31. A younger age at diagnosis makes 
a maternal cause of recurrent miscarriage more plausible and reduces the change of 
miscarriages due to foetal abnormalities[31]. Another strength is the availability of 
a wide range of covariates in both groups (Table 1). We decided not to adjust for any 
covariates in our CVD risk estimation as both groups were comparable at baseline, 
except for gravidity and parity what is a direct consequence of the exposure (recurrent 
miscarriage). Besides, some covariates have an effect at our outcome of interest. For 
example, it wouldn’t make sense to adjust for BMI or smoking as both are included as 
variables in the risk estimation[32]. Some women experienced a complication during 
pregnancy, such as gestational diabetes and preeclampsia which may increase their risk 
of CVD later in life[2, 33]. We did not adjust for history of complications of pregnancy since 
these events are possibly on the causal pathway between miscarriage and CVD[34]. If we 
assume that they are not on this pathway and that these events are confounding factors 
we should have adjusted for these pregnancy complications. Therefore, we repeated the 
risk calculations for women who did not have a pregnancy complicated by gestational 
diabetes, preeclampsia, pregnancy induced hypertension and/or preterm birth (online 
supplementary data). Women with recurrent miscarriage (N=30) had still a significantly 
higher extrapolated 10-year cardiovascular risk score (using lipids: mean 5.31%, SD 3.96) 
compared to women with no miscarriage (mean 3.59%, SD 1.94, p=0.03). Comparable 
results were found in women with idiopathic recurrent miscarriage (N=24) (online 
supplementary data). Therefore, we can conclude that the elevated risk scores in women 
with recurrent miscarriage cannot be explained solely by other pregnancy complications 
known to be a risk factor in women for developing CVD.
Limitations of our study should be acknowledged. The risk for CVD in women with recurrent 
miscarriage could be underestimated due to the following reasons: At first selection bias 
may have been introduced. Women declined to participate due to  emotional reasons or 
did not respond on the invitation for this follow-up study. It is imaginable that the ‘worst’ 
cases, women without a live birth, were more likely to decline or not respond (only one 
woman in our study group had no live birth). Secondly, women received  lifestyle advice 
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during their consultations at the recurrent miscarriage clinic. Individual risk factors may 
have been changed which could decrease the risk profile. And finally, bias could have 
been introduced since women with recurrent miscarriage were included in the study 
before the matched controls were invited to participate resulting in a small difference 
in age (1.2 years) at follow-up. In case this small difference will influence the results, the 
increased risk in women with recurrent miscarriage would be an underestimate because 
risk factors are likely to increase with age. On the other hand, since the unexposed group 
consisted of women who had at least one uncomplicated pregnancy, this may have 
resulted in a healthier cohort compared to a population based cohort. Selection bias 
is also possible in the unexposed group; probably women with a higher education are 
more likely to participate (although no significant difference was found for university 
level education between both groups). Another limitation is the relatively small sample 
size. A preliminary calculation was performed based on the 10-year risk score with 
age extrapolated to 60 years, which showed that 34 women in both groups would be 
sufficient. Though it is possible that, especially for the subgroup analyses, our study may 
partly be underpowered and we should be cautious drawing conclusions. 
Perspectives
In present study, we show that women with a history of recurrent miscarriage, irrespective 
whether idiopathic or not, differ in cardiovascular risk profile at a young age compared to 
women with no miscarriage. Our study provides intriguing data which support the need 
for more research to find out if women with a history of recurrent miscarriage should be 
offered screening and counselling for cardiovascular risk factors. 
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Objectives A history of recurrent miscarriage is associated with future cardiovascular 
disease. The aim of this study was to determine novel cardiovascular biomarkers in 
women with a history of recurrent miscarriage as this might lead to a better understanding 
of the association.
Study design Women who visited the recurrent miscarriage clinic at Leiden University 
Medical Centre (between 2000 – 2010), and had three consecutive miscarriages ≤ 30 years 
were invited to participate in this follow-up study (between 2012-2014). The reference 
group consisted of women with at least one uncomplicated pregnancy and a history of 
no miscarriage, matched on zip code, age, and date of pregnancy.
Main outcome measures Cardiovascular biomarkers were determined, classified into; 
inflammation (HsCRP, lipoprotein-associated phospholipase A2), thrombosis (homo-
cysteine, folate, anti-cardiolipin antibodies and anti-ß-2-glycoprotein antibodies), lipid 
metabolism (lipoprotein(a)), renal function (creatinine, microalbuminuria), myocardial 
damage (N-terminal pro-brain natriuretic peptide, high sensitive TroponineT) and 
multiple mechanisms (albumin, vitamin D).
Results In both groups, 36 women were included. Women with recurrent miscarriage 
had a significantly higher median HsCRP (1.49mg/L) compared to women with no 
miscarriage (1.01mg/L, p=0.03) and a significantly lower mean albumin (46.0 vs 47.6g/L, 
p=0.004) and vitamin D (55.6 vs 75.4nmol/L, p=0.007), respectively. Differences remained 
after adjustments for classic cardiovascular risk factors (BMI, smoking, diabetes mellitus, 
and hypertension).
Conclusions Our findings suggest a proinflammatory state in women with a history of 
recurrent miscarriage, which suggests a less optimal health, compared to women with no 
miscarriage. More research (observational and intervention) is warranted to investigate 
the association with vitamin D.
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Cardiovascular disease is the leading cause of morbidity and mortality in women in the 
western world[1]. There is increasing evidence that women with adverse pregnancy 
outcome are at increased risk of future cardiovascular disease, most well established for 
preeclampsia[2, 3]. Recent epidemiological research suggests that also women with a 
history of recurrent miscarriage have an increased risk of cardiovascular disease later 
in life[4-6]. Recurrent miscarriage is commonly defined as three or more consecutive 
pregnancy losses before 22 weeks of gestation[7]. It is a very heterogeneous condition 
and affects 0.5-3% of all fertile couples[8]. Several hypotheses are possible for the 
association between recurrent miscarriage and cardiovascular disease: shared risk 
factors and underlying pathology may lead to both diseases or alternatively, miscarriage 
could trigger a mechanism or cascade (second hit) that in turn leads to cardiovascular 
disease. Possibly via interactions with well-known risk factors. Two small studies are 
published concerning classical cardiovascular risk factors in women with a history of 
recurrent miscarriage with inconsistent results[9, 10]. An altered cardiovascular risk 
profile in women with recurrent miscarriage was found in the first study[9], although in the 
second study no difference in cardiovascular function and risk factors was described[10]. 
In addition to classic cardiovascular risk factors, there is a wide variety of novel 
biomarkers strongly associated with future cardiovascular disease in general [11, 12]. 
For example, high-sensitivity C-reactive protein (HsCRP), an inflammatory biomarker 
and lipoprotein(a) (Lp(a)), a lipid related biomarker. The most recent European guideline 
for the prevention of cardiovascular disease states that biomarkers may be useful in 
specific subgroups[12]. Knowledge about these markers might contribute to a better 
understanding of the association between miscarriage and future cardiovascular disease.
Therefore, we conducted a follow-up study to determine novel cardiovascular bio-






Women who visited the recurrent miscarriage clinic at Leiden University Medical Centre 
between 2000 and 2010 and had their third consecutive miscarriage before the age of 
31 years were invited to participate in this follow-up study. Recurrent miscarriage was 
defined as ≥ 3 consecutive miscarriages before 22 weeks of gestation. Women with 
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 primary miscarriage (without birth ≥ 22 weeks of gestation before miscarriage) and 
secondary miscarriage (with a birth ≥ 22 weeks of gestation before miscarriage) were 
included. All women had a routine recurrent miscarriage work-up to identify possible 
causes for the recurrent miscarriage: a standardized history of the couple was performed, 
karyotyping of the couple (this was offered routinely before 2005 to all couples, after 2005 
this was only offered in presence of low maternal age and/or positive family history for 
recurrent miscarriage[13], presence of uterus anomalies by ultrasound or hysteroscopy 
and presence of acquired and heritable thrombophilia was assessed. Acquired 
thrombophilia: Antiphospholipid syndrome was defined as the presence of elevated 
anticardiolipin antibodies or lupus anticoagulant in repeated samples taken 3 months 
apart and at least 10 weeks after a delivery [14], after revision of the classification criteria 
an elevated level of anti-β2 glycoprotein-I was added to the work-up [15]. Homocysteine 
levels were determined to exclude hyperhomocysteinemia. Heritable thrombophilia 
was defined by the presence of a factor V Leiden mutation, factor II (prothrombin) gene 
mutation, protein C or S deficiency or antithrombin deficiency. Enrolment took place 
between 2012 and 2014.The time interval between the diagnosis recurrent miscarriage 
and the time of follow-up had to be at least 2 years. 
Unexposed matched group
For the reference group women with one or more uncomplicated pregnancy(ies) and no 
miscarriages were enrolled. In the Netherlands, it is common practice that independent 
primary care midwives are taking care of low-risk women (with no medical or obstetrical 
history) during pregnancy and child birth. The zip code of each woman with recurrent 
miscarriage was used to contact the nearest midwifery practice to take the impact 
of  socio-economic status into account. Women with the same zip code, the same age 
(difference in birthdate maximal 1 year) and of which the time of first delivery was close 
to the time of the third miscarriage of the matched exposed woman (maximal 6 months 
before or 6 months after) were asked to participate.  
In both groups pregnant and lactating women (within the last 3 months) were  excluded. 
Procedures and definitions
After enrolment all women were asked to fill out a web based questionnaire and were 
invited for risk factor screening including venous blood samples. The questionnaire 
included general information, medical history, family history of cardiovascular disease, 
use of medication, intoxications and obstetric history. Information about medical 
history, use of medication, intoxications and pregnancy outcome was cross checked 
in obstetrical records to overcome recall bias. Pregnancy outcome in at least one 
continuing pregnancy was recorded. Gestational diabetes was defined as a glucose 
intolerance resulting in hyperglycemia with onset during pregnancy[16]. Preeclampsia 
was defined as systolic blood pressure above 140 mmHg and/or diastolic pressure 
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above 90 mmHg combined with proteinuria [17], pregnancy induced hypertension as 
systolic blood pressure above 140 mmHg and/or diastolic pressure above 90 mmHg or 
higher measured on two occasions(after 20 weeks’ gestation)[18], preterm birth as a 
delivery between 24 and 37 weeks gestation, intra-uterine growth restriction as birth 
weight below the 10th percentile for gestational age and sex according to the Perinatal 
Registry of the Netherlands birth weight percentiles [19]. Recurrent miscarriage was 
defined as idiopathic when the work-up for causes of recurrent miscarriage showed no 
abnormalities.
Cardiovascular risk factor assessment
Assessment of cardiovascular risk factors was performed by trained research nurses 
or physicians at the Leiden University Medical Centre or at the participants’ home. 
Urine was collected for assessment of microalbuminuria immediately after waking 
up. Venous blood samples were collected after an overnight fast. A panel of novel 
cardiovascular biomarkers was tested in this study. Biomarkers were classified into; 
inflammation (HsCRP, Lipoprotein-associated phospholipase A2 (Lp-PLA2)), thrombosis 
(homocysteine, folate, anti-Cardiolipin antibodies (aCL) and anti-ß-2-Glycoprotein 
antibodies (aβ2GPI)) IgG and/or IgM, lipid metabolism (Lp(a)), renal function (creatinine, 
microalbuminuria),  myocardial damage (N-terminal pro-brain natriuretic peptide(NT-
proBNP), high sensitive Troponine T (hsTroponineT) and multiple mechanisms (albumin, 
25-OH-Vitamin D). We describe these biomarkers with their possible association with 
cardiovascular disease in short in table 1.
The blood samples were centrifuged after coagulation, separated and serum was frozen 
at -80°C within 2 hours. Routine chemistry analyses were performed on a Roche Modular 
P800 chemistry analyzer using reagents of Roche Diagnostics (Mannheim, Germany). 
Analytical variation of all analytes was well below 5%. Homocysteine was analyzed on an 
Immulite 2000 Xpi immunoanalyzer of Siemens Healthcare Diagnostics (Tarry town, NY, 
USA). Analytical variation varied between 5% and 8%. NT-proBNP, Folate, hsTroponinT,25-
OH-Vitamin D and Lp(a) were analyzed on a Roche Modular E170 Immunoanalyzer. 
Analytic variation varied between 3% and 6%. Immunological analyses were performed 
on an Immunocap 250 immunoanalyzer (Thermo Fisher Scientific, Waltham, MA, USA). 
Analytical variation was up to 5% for aCL and 10% for aβ2GPI antibodies. Lp-PLA2 was 
measured using an ELISA (Diadexus, San Francisco, CA, USA). All analyses were performed 
by technicians blinded for obstetrical history.
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Table 1. Novel cardiovascular biomarkers, possible associations and mechanisms
Biomarker Possible  
association with
Mechanisms
HsCRP Inflammation Acute phase protein with hepatic origin [21]
Lp-PLA2 Inflammation Vascular-specific inflammatory biomarker. (Atherosclerotic plaques 
in blood vessels) [36]
Homocysteine Thrombosis Endothelial cell damage, reduction in the flexibility of vessels, and 
alters the process of haemostasis. Hyperhomocysteinemia can also 
arise from nutritional deficiencies of folate, vitamin B6, and vitamin 
B12. [33]
Folate Thrombosis Lowering serum homocysteine.[37]
aCL Thrombosis Antiphospholipid antibody: changes in the coagulation cascade, 
inhibition of protein C, antithrombin and annexin, platelet activation 
and complement, increased expression of endothelial adhesion mol-
ecules. [38] aCL seem to represent the group of autoantibodies with 
the highest correlation and possible risk outcome with CVD. [39]
aβ2GPI Thrombosis Antiphospholipid antibody: changes in the coagulation cascade, 
inhibition of protein C, antithrombin and annexin, platelet activation 
and complement, increased expression of endothelial adhesion mol-
ecules, [38]. Locally, using cellular models aβ2GPI antibodies seems 
to have a prominent pathogenic role. [39]
Lp(a) Lipid metabolism The physiological function of Lp(a) is unclear, pathogenic role in 
atherosclerosis and thrombosis formation. [40]
Creatinine Renal function May be surrogate marker for generalized vascular damage as well as 
renal dysfunction. Renal dysfunction may enhance intermediate risk 
factors such as hypertension, hyperhomocysteinemia and abnor-
malities of thrombogenic factors. [41]
Microalbuminuria Renal function May be a marker of widespread vascular abnormalities, including 
those of the glomerular capillary wall. Renal dysfunction. [41]
NT-proBNP Myocardial damage NT-proBNP is synthesized in response to ventricular stretch and 
ischemic injury [42]




Negative acute-phase protein. Interacts with free fatty acids, and 
inhibits their promoting effects on platelet aggregation and throm-
bosis. May act as an indirect and sacrificial antioxidant and inhibits 
peroxidase, free radical generation. Inhibitor of endothelial apopto-
sis.[24]
Vitamin D Multiple mecha-
nisms
Modulation of inflammatory processes. Favourably influence cardi-
ovascular health including downregulation of the renin–angiotensin 
system, enhancement in insulin secretion and insulin sensitivity, and 
protection against angiogenesis. [26]
HsCRP: high-sensitivity C-reactive protein. Lp-PLA2: Lipoprotein-associated phospholipase A2, aCL: anti-Cardiolipin, 
aβ2GPI: anti-ß-2-Glycoprotein, Lp(a ):Lipoprotein (a), NT-proBNP : N-terminal pro-brain natriuretic peptide, hsTroponineT: 
high sensitive Troponine T
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Matched data were analyzed using SPSS software version 22.0 (Statistical Package for 
Social Science; SPSS, Chicago, Illinois, USA). Comparisons of normal distributed data 
were performed using paired T- test. Comparisons of categorical data were performed 
using the McNemar’s test. Skewed variables were log transformed, differences on the 
logarithmic scale were calculated and then back transformed to the original scale. This 
results in estimates of the ratio of the (geometric) mean in the recurrent miscarriage 
group over the mean in the no miscarriage group. For all tests, a p-value < 0.05 is indicated 
statistical significant. Multivariate analyses were performed using unianova test, to 
adjust for the following potential confounders (classical cardiovascular risk factors): 
Model 1: BMI; Model 2: BMI and smoking; and Model 3 BMI, smoking, diabetes mellitus 
and hypertension. The calculations were repeated in a subgroup analysis including 
women with idiopathic recurrent miscarriage. 
Ethics
Approval from the medical ethics committee of Leiden University Medical Centre (P04-
020; October 3, 2012) was obtained and all participants gave informed consent. The 
study was registered with the Dutch trial registry NTR3408. This study is part of the REMI 
(REcurrent MIscarriage) studies, studies which investigate consequences and causes of 
recurrent miscarriage.
Results
A flowchart of the inclusion of the participants is shown in Figure 1. Of the 76 included 
women (38 women with recurrent miscarriage and 38 women with at least one 
uncomplicated pregnancy and no miscarriage) 4 women were excluded from analysis, 
because they did not meet the inclusion criteria for this study as described in Figure 1, 
leaving 36 matched pairs. 
Women with recurrent miscarriage were slightly younger at follow-up and had a signi-
ficantly higher gravidity and lower parity than those in the no miscarriage group (Table 2). 
Women with recurrent miscarriage were more often smokers during pregnancy (p=0.05). 
On all other variables groups were comparable. 
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Matched to women without miscarriage
Invited n= 148
Excluded from analysis 
• Recurrent miscarriage: n=2 (1 lactating, 1 non consecutive miscarriage)
• No miscarriage: n=2 (1 history of miscarriage, 1 matched to excluded woman) 






Declined to participate due to emotional reasons 
n= 17
Did not meet inclusion criteria 








Did not meet inclusion criteria (pregnant/lactating 
during study period) 
n= 10
Figure 1. Flow chart Selection of participants







Maternal age at index pregnancya 26.36 (2.65) 26.47 (2.69) 0.70
Maternal ageb 34.50 (3.59) 33.28 (3.51) <0.001 
Caucasian (%) 32 (88.9) 30 (83.3) 0.63
University level education (%) 16 (44.4) 8 (22.2) 0.08
BMIb 23.78 (3.49) 25.89 (7.08) 0.09
Smoking during pregnancyd (%) 5 (13.9) 14 (38.9) 0.05
Smokingb,c (%) 5 (13.9) 10 (27.8) 0.23
Diabetes mellitusb,c (%) 0 (0) 4 (11.1) 0.04
Antihypertensive medication useb,c (%) 0 (0) 3 (8.3) 0.08
Gravidity 2.28 (0.62) 7.11 (2.07) <0.001
Parity 2.25 (0.60) 1.64 (0.83) 0.001
Primary miscarriages (%) -- 27 (75.0) --
At least one continuing pregnancyc (%) 37 (100) 35 (97.2) 0.31
Gestational diabetesd (%) 0 (0) 0 (0) --
Preeclampsia/Pregnancy induced hypertensionc,d (%) 0 (0) 3 (8.3) 0.08
Preterm birthd (%) 1 (2.8) 4 (11.1) 0.38
Intra uterine growth restrictiond (%) 4 (11.1) 4 (11.1) 1.00
BMI body mass index
Data are presented as mean (SD)
a Age at first pregnancy for unexposed women, age at third consecutive miscarriage for exposed women
b At time of follow-up
c Chi-squared test. Mc Nemars test not possible (at least one variable in each 2-way table is a constant)
d In at least one pregnancy
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In 78% of the women with recurrent miscarriage (n=28) no abnormalities were found. 
 Parental chromosomal abnormality was found in one case, antiphospholipid syndrome in 
one case, hyperhomocysteinemia in three cases and heritable thrombophilia was found 
in three cases. 
Novel cardiovascular biomarkers were presented in Table 3. Women with recurrent 
miscarriage had a significantly higher HsCRP compared to women with no miscarriage. 
Significantly lower values of homocysteine, albumin and vitamin D were found in women 
with recurrent miscarriage compared to women with no miscarriage. These significantly 
differences remained in the multivariate analyses adjusting for BMI, smoking, diabetes 
mellitus and hypertension (using three different models), except for albumin adjusted for 
all four classic cardiovascular risk factors (model 3). A significant lower value of creatinine 
was found in multivariate analysis, model 2 and 3, in women with recurrent miscarriage 
compared to women with no miscarriage.  
The results for the subgroup analysis including women with idiopathic recurrent mis-
carriage (table 4) are consistent with the results of the total group. Not all differences 
were statistically significant. 
Discussion
Main findings
Increased levels of HsCRP and decreased levels of albumin and vitamin D were found in 
women with a history of recurrent miscarriage compared to women with no miscarriage, 
also after adjustments for classic cardiovascular risk factors (BMI, smoking, diabetes 
mellitus and hypertension). These cardiovascular biomarkers are involved in mechanisms 
regarding inflammation. 
Interpretation
Our findings indicate a proinflammatory state in women with a history of recurrent 
miscarriage, which cannot be explained by confounders as BMI, smoking, diabetes 
mellitus and hypertension. Inflammation plays an important pathogenic role in all stages 
of atherosclerosis [20]. HsCRP can detect low grade inflammation and adds prognostic 
information on cardiovascular risk comparable to blood pressure or cholesterol [21]. 
Values <1, 1 to 3, and >3 mg/l indicate lower, average, or higher relative cardiovascular 
risk, respectively [21]. Therefore, we can conclude that we found a clinically relevant 
elevation in the recurrent miscarriage group (unadjusted mean difference HsCRP mg/L 
1.95, 95%CI 1.17; 3.31). Lower values of albumin were found in women with recurrent 
miscarriage. Albumin is inversely associated with cardiovascular disease [22, 23] and 
several potential biological mechanisms might explain this (Table 1). The most obvious 
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during the inflammatory process [24, 25]. Vitamin D (concentrations of 20 to 60 nmol/L) 
is also inversely associated with cardiovascular disease risk [26]. Vitamin D is involved in 
many processes of potential relevance to cardiovascular disease (Table 1). A deficiency 
could lead to increased inflammation, endothelial dysfunction, elevated blood pres-
sure, decreased insulin sensitivity and secretion, arterial stiffness and degradation 
of atherosclerotic plaque[27]. Vitamin D is produced by the action of UVB light on the 
skin. Skin pigmentation may reduce capacity to synthesize vitamin D and due to a lower 
exposure in winter months there are seasonal variations. To a lesser extent, it is also 
provided in the diet from foods, mostly of animal origin[27]. We found a significantly lower 
vitamin D concentration in women with recurrent miscarriage, suggesting a decreased 
intake of vitamin D precursors, whether a decreased exposure to sunlight plays a role is 
uncertain. As the percentage of Caucasian women was comparable in both groups, we 
don’t expect an impact of ethnicity on our findings. We assessed vitamin D levels only 
at follow-up. In addition, it is possible that women with recurrent miscarriage already 
have decreased values of vitamin D during pregnancy. Only one study assessed vitamin D 
levels and  immunological implications, such as presence of autoantibodies and cytokine 
production, in women with recurrent miscarriage (N=133) and found that 47.4% of these 
had a vitamin D deficiency (<30 ng/ml) [28]. Over the last decade, the role of vitamin D in 
human reproduction has been increasingly considered as important. Adverse outcomes 
linked to vitamin D insufficiency in pregnancy includes pre-eclampsia, gestational 
diabetes, small-for-gestational age and preterm birth [29-31]. Many potential underlying 
mechanisms of vitamin D in regulating each of the outcomes are hypothesized, including 
that vitamin D could act as an immune regulator during implantation [32]. Our findings 
call for more (observational and intervention) studies to investigate the association 
between vitamin D and recurrent miscarriage.
Surprisingly, in contrast with the previous described findings, we found that women 
with recurrent miscarriage had lower levels of homocysteine compared to women with 
no miscarriage. Hyperhomocysteinemia is associated with recurrent miscarriage and 
with cardiovascular disease [33, 34]. Our findings could be a confounding effect of the 
folate and vitamin B supplementation in the recurrent miscarriage group. Homocysteine 
evaluation is part of the routine work-up in women with recurrent miscarriage. In case of 
elevated levels, women are advised to use folate and vitamin B supplementation. Women 
might continue this after their pregnancies and/or at least in between pregnancies. All 
women are advised to use periconceptional folate supplementation. As women with 
recurrent miscarriage have a higher gravidity this could also have influenced our results.
We found comparable results in the sub analysis including women with idiopathic 
recurrent miscarriage (although not all significant, probably due to a loss of power). 
 Indicating that our results are independent of a supposed cause for the recurrent mis-
carriage, such as thrombophilia.
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To our knowledge, this is the first study which examined novel cardiovascular biomarkers 
after recurrent miscarriage. Strengths of our study include a unique well-defined cohort. 
As recurrent miscarriage is a highly heterogenic condition we strived to more homogeneity 
and therefore included only women who had their third consecutive miscarriage before 
the age of 31. A younger age at diagnosis reduces the change of miscarriages due to fetal 
abnormalities and makes a maternal cause of recurrent miscarriage more plausible [35]. 
All women had a routine work-up at baseline to identify possible causes for the recurrent 
miscarriage and therefore we could perform a subgroup analysis including women with 
idiopathic recurrent miscarriage (Table 3). Because of the matching on zip code, age and time 
of pregnancy we took several confounding factors into account. Our study has also some 
limitations. Because women with recurrent miscarriage were included in the study before 
the matched controls were invited to participate, there was a small difference between the 
age at time of the follow-up measurements. We don’t expect that this will influence the 
results. Almost 50% of the eligible women did not respond on the invitation and 17 women 
declined to participate (due to emotional reasons) in this follow-up study (Figure 1), which 
could possible introduce selection bias. Given the high percentage of women who had at 
least one continuing pregnancy in the recurrent miscarriage group (97.3%), it is likely that 
women without live births (women with possibly the most unfavorable profile) more often 
declined or did not respond. Therefore, our findings in women with recurrent miscarriage 
could even be an underestimate. Selection bias is also possible in the unexposed group; 
probably women with a higher education were more likely to participate. Another limitation 
is the relatively small group of patients, especially in our subgroup analysis. Therefore, this 
study may partly be underpowered and we should be cautious drawing conclusions. There 
is a wide range of novel cardiovascular biomarkers which makes it impossible to study all 
of them. Based on the most recent literature we have selected biomarkers which have the 
potential to link recurrent miscarriage and cardiovascular disease [11, 12]. Unfortunately, 
we did not take the accurate blood sample (sodium citrate tube) for the examination of 
potential interesting biomarkers fibrinogen and lupus anticoagulant. 
Perspectives
Our findings suggest a proinflammatory state in women with a history of recurrent 
miscarriage compared to women with no miscarriage. This suggests an overall poorer 
health in women with a history of recurrent miscarriage, which could partly explain their 
increased risk for cardiovascular disease later in life. No differences were found in more 
specific biomarkers, for example regarding lipid metabolism and myocardial damage. 
Routine screening of novel cardiovascular biomarkers on patient level seems with the 
current insight not warranted, although screening for vitamin D status seems plausible. 
Women with a history of recurrent miscarriage should be given healthy lifestyle advises, 
such as abstention of smoking, improving dietary habits and sufficient exposure to 
sunlight.
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No increased prevalence of family history 
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Objectives To assess if a family history of cardiovascular disease is more prevalent in 
women with recurrent miscarriage. Women with a history of recurrent miscarriage have 
an increased risk of future cardiovascular disease. This association indicates shared 
common risk factors, including genetics. 
Methods A matched case control study was performed. Women who visited the recurrent 
miscarriage clinic at Leiden University Medical Centre (between 2000-2014) and had their 
third consecutive miscarriage ≤ 35 years were included. Controls were women with at 
least one uncomplicated pregnancy and no miscarriage, matched on zip code, age and 
date of pregnancy. All women filled out a questionnaire. Family history of premature 
myocardial infarction and/or stroke was defined as having a first-degree relative with 
myocardial infarction and/or stroke < 60 years. Family history of cardiovascular disease 
as having a first-degree relative with myocardial infarction, stroke, hypertension or 
thrombosis, irrespective of age at event. Odds ratios (OR) were calculated.
Results 103 women with recurrent miscarriage were matched to 143 controls. The 
prevalence of family history of premature myocardial infarction and/or stroke (OR 0.66 (95% 
CI 0.31-1.41)) and the prevalence of family history of cardiovascular disease (OR 1.15 (95% 
CI 0.60-2.21)) was not increased in women with recurrent miscarriage compared to women 
with no miscarriage. A family history of hypertension seems more prevalent in women with 
recurrent miscarriage, although not significant (multivariate analysis: OR 1.71 (0.94-3.11)). 
Conclusions for practice No increased prevalence of family history of cardiovascular 
disease was found in women who experienced recurrent miscarriage.
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Cardiovascular disease(CVD) is the leading cause of death among women in the world 
(World Health Organization 2013). Women are disproportionally affected by CVD 
compared to men, it is diagnosed less often and they are less likely to receive appropriate 
preventive care (Weiss, 2009). It is important to identify women at risk as early as possible 
so that they can benefit from preventive measures (Daviglus et al. 2006). 
In the most recent American Heart Association guidelines for the prevention of CVD in 
women, pregnancy complications as preeclampsia, gestational diabetes and pregnancy-
induced hypertension are indicated as a major risk factor for CVD (Mosca et al. 2011). 
Recurrent miscarriage is not mentioned in this guideline. There is increasing evidence 
that (recurrent) miscarriage is a risk factor for CVD as well (Ranthe et al. 2013; Oliver-
Williams et al. 2013, Wagner et al. 2015). Miscarriage is defined as the spontaneous loss 
of pregnancy before 22 weeks’ gestation. Three or more consecutive miscarriages are 
defined as recurrent miscarriage and affects 0.5 to 3% of couples trying to conceive 
(Stirrat 1990, Jivraj et al. 2001). Recurrent miscarriage is a heterogeneous condition and 
has many possible etiologic factors: genetic disorders, uterine anomalies, endocrine 
factors, maternal autoimmune disorders, metabolic disorders, maternal thrombophilia, 
obesity and toxic factors (de la Rochebrochard et al. 2002), although the percentage of 
cases without an identifiable cause is about 50% (Porter et al. 2005; Yang et al. 2006). 
We hypothesize that the association between miscarriages and cardiovascular disease 
indicates shared common acquired risk factors, such as smoking and antiphospholipid 
syndrome, and shared heritable (genetic) risk factors. 
A Scottish retrospective cohort study found an increased incidence of ischemic heart 
disease in the parents of women who experienced multiple miscarriages before their 
first birth, which supports the hypothesis of shared genetic factors (Smith et al. 2011). A 
family history of (premature) CVD is an independent predictor of myocardial infarction 
and CVD (Weijmans et al. 2015).
We conducted a matched case-control study to investigate whether a family history of 
premature CVD was more common in women who experienced recurrent miscarriage 




Women who visited the recurrent miscarriage outpatient clinic at Leiden University 
Medical Centre between 2000 and 2014 and had their third consecutive miscarriage 
≤ 35 years of age were invited to participate in this matched case control study. Recurrent 
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miscarriage was defined as ≥ 3 consecutive miscarriages before 22 weeks of gestation. All 
women had a routine recurrent miscarriage work-up to identify possible causes for the 
recurrent miscarriage: a standardized history of the couple was performed, karyotyping 
of the couple, presence of uterus anomalies by ultrasound or hysteroscopy and presence 
of acquired and heritable thrombophilia. Acquired thrombophilia: Antiphospholipid 
syndrome was defined as the presence of IgG anticardiolipin antibodies or lupus anti-
coagulant in repeated samples taken 3 months apart and at least 10 weeks after a 
delivery (Visser et al. 2011), after revision of the classification criteria the presence of β2 
glycoprotein-I was added to the work-up (Miyakis et al. 2006). Hyperhomocysteinemia 
was evaluated. Heritable thrombophilia was defined by the presence of a factor V Leiden 
mutation, factor II (prothrombin) gene mutation, protein C or S deficiency or antithrombin 
deficiency. 
Controls
Women with one or more uncomplicated pregnancy(ies) and no miscarriage were enrolled. 
In the Netherlands it is common practice that independent community midwives are 
taking care of low-risk women (with no medical or obstetrical history) during pregnancy 
and child birth. The zip code of each woman with recurrent miscarriage was used to 
contact the nearest midwifery practice to take the impact of socio-economic status into 
account. Women, matched on zip code, age (maximal 1 year younger or 1 year older) and 
time of delivery (first delivery at the time of the third miscarriage of the matched exposed 
woman; maximal 6 months before or 6 months after) were asked to participate. 
Enrolment took place between 2012 and 2014. 
Procedures and definitions
After enrolment all women were asked to fill out a web based questionnaire. The 
questionnaire included general information, medical history, use of medication, intoxi-
cations, obstetric history and family history including cardiovascular disease. The 
questionnaire was made using ProMISe, an Internet based application for the design, 
maintenance and use of data management projects according to the security conditions 
demand by good clinical practice (2016). Information about medical history, use of 
medication, intoxications and pregnancy outcome was cross checked in obstetrical 
records to overcome recall bias. Maternal age was defined as age at third consecutive 
miscarriage for women with recurrent miscarriage or age at first pregnancy for women 
with no miscarriage. Height and weight was self-reported. Body mass index (BMI) was 
calculated as weight/length2. Smoking during pregnancy was self-reported and was found 
positive if a woman smoked during at least one pregnancy. Primary recurrent miscarriage 
was defined as three consecutive miscarriages without a prior live birth. Secondary 
recurrent miscarriage was defined as three consecutive miscarriages with a prior live birth. 
Ethnicity was based on country of birth of the women. Education was defined as whether 
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or not university level (college and university education together). Presence of a history 
of thrombosis, hypertension, diabetes mellitus and hypercholesterolemia was based on 
the questionnaire, including questions about use of medication. Hypertension at time of 
questionnaire was found positive if a woman used antihypertensive treatment at that time.
Family history was based on the questionnaire which included the following questions: 
Do you have any relatives with myocardial infarction, stroke, thrombosis and/or 
hypertension? How many brothers and sisters do you have? How many first-degree 
relatives had the previous mentioned disease and how many first-degree relatives had 
the disease before the age of 60? 
Family history of premature myocardial infarction(MI) and/or stroke was defined as 
having at least one first-degree relative with MI and/or stroke before the age of 60. This 
cut off point of age was used in analyses from the Framingham cohort (Murabito et 
al. 2004). Family history of cardiovascular disease was defined as having at least one 
first-degree relative with MI, stroke, hypertension or thrombosis, irrespective of age at 
event.
Statistics - Sample size 
Assumed were the following predictions:
Combination 1: (65%): Cases and controls both don’t have family history of CVD.
Combination 2: (17%): Cases have family history of CVD, controls don’t have.
Combination 3: (5%): Cases don’t have family history of CVD, controls have. 
Combination 4 (13%): Cases and controls both have family history for CVD.
The calculation was based on the assumption that we would find a family history of 
premature CVD in 30% of the women with recurrent miscarriage (cases) and in 18% of 
the women with no miscarriage (controls). This assumption is based on the Epic-Norfolk 
study, in which 27% of all healthy participants had a first-degree relative with “outcome” 
coronary heart disease (Sivapalaratnam et al. 2010). A sample size of 150 women (75 
exposed, 75 non-exposed) was sufficient, we took a 10% drop-out in consideration (sided 
alpha .05. power 80%) We planned to include women in 1:1 ratio, i.e. one women who had 
recurrent miscarriage compared to at least 1 woman with no miscarriage. PASS, Power 
Analysis and Sample Size Software (NCSS Statistical Software) was consulted.
Data were analyzed using SPSS software 20.0 (Statistical Package for Social Science; 
SPSS, Chicago, Illinois, USA). Comparisons of baseline characteristics between cases and 
controls were performed using independent T-test, Mann-Whitney test, X2 or Fisher exact 
test as appropriate. Comparison of family history between cases and matched controls 
was performed by a conditional matched logistic regression analysis using a stratified 
Cox regression. Odds ratios (OR) were calculated with 95% confidence intervals (CI). For 
all tests, a p-value ≤ 0.05 indicated statistical significants. A multivariate analysis was 
performed including BMI, university level education and smoking during pregnancy as 
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covariates. A sub analysis was performed, repeating the previous mentioned analyses, in 
women with primary recurrent miscarriage and their matched controls.
Ethics
Approval from the medical ethics committee of Leiden University Medical Centre (P04-
020; October 3 2012) was obtained and all participants gave informed consent. This study 
is part of the REMI (REcurrent MIscarriages) studies, studies which investigate conse-
quences and causes of recurrent miscarriages.
Results 
A flowchart of the inclusion of the participants is shown in Figure 1. For some cases two 
or three controls agreed to participate. 11 women (five cases, six controls) were excluded 
from further analysis because they did not meet the matching criteria (maternal age). 
103 women with recurrent miscarriage were included and 143 women with no miscarriage.
Eligible women with recurrent 
miscarriage n=278






Analyzed:      Cases 
n=103












Figure 1. Flow chart of participants
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Demographics of the women are presented in the baseline table (Table 1). Mean maternal 
age at time of questionnaire differed between women with recurrent miscarriage and 
women with no miscarriage: 34.76 and 35.92 years, respectively (p=0.03). Women with 
recurrent miscarriage were more often smokers during pregnancy (19.4%) compared to 
women with no miscarriage (7.0%) (p=<0.001) and had more often hypertension at time 
of questionnaire (3.9% vs 0%, p=0.03). The number of siblings was comparable between 
both groups. 








Maternal age at index pregnancy  mean (SD) 29.60 (3.48) 29.28 (3.23) 0.46
Maternal age at questionnaire  mean (SD) 34.76 (4.02) 35.92 (4.04) 0.03
Caucasian (%) 94 (92.2) 
Missing: 1
137 (95.9) 0.27





University level education (%) 48 (46.6) 83 (58.0) 0.08
Smoking during pregnancy (%) 20 (19.4) 10 (7.0) < 0.001
Smoking at time of questionnaire (%) 17 (16.5) 18 (12.6) 0.38
Gravidity median (min/max) 6 (3/15)  2 (1/4) < 0.001
Parity median (min/max) 1(0/4) 2 (1/4) < 0.001
Primary miscarriage (%) 67 (65) -- n/a
At least one continuing pregnancy (%) 85 (82.5) 143 (100.0) < 0.001
Thrombosis (%)* 0 (0.0) 1 (0.7) 1.00
Hypertension (%)* 4 (3.9) 0 (0.0) 0.03
Diabetes Mellitus (1 and 2) (%)* 4 (3.9) 0 (0.0) 
Missing: 1
0.03
Hypercholesterolemia (%)* 0 (0.0) 1 (0.7) 1.00
Number of siblings mean (SD) 1.90 (1.47) 1.80 (1.15)
Missing: 1
0.52
BMI: body mass index
*at time of questionnaire
Table 2. Analyses of recurrent miscarriage
The existence of Recurrent  miscarriage  
N=103
Abnormal parental karyotyping (%) 1 (1.0) Missing: 4
Uterus anomaly (%) 0 (0.0)            
Anti-phospholipid syndrome (%) 4 (3.9) Missing: 1
Hyperhomocysteinemia (%) 7 (6.8)            
Heritable thrombophilia (%) 7 (6.8)          
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Analyses of recurrent miscarriage are described in table 2. In 81.6 % of the women 
(N=84) no identifiable cause was found. Seven cases were diagnosed with heritable 
thrombophilia: factor II (prothrombin) gene mutation (N=3), factor V Leiden (N=5) One 
case had two clotting defects.
No increase was found in prevalence of a family history of premature MI and/or stroke 
in women with a history of recurrent miscarriage (15.6%) compared to women with no 
miscarriage (19.1%) (multivariate analyses: OR 0.65 (95%CI 0.30-1.42)) (Table 3). Eight 
women with recurrent miscarriage and nine women with no miscarriage did not fill in this 
part of the questionnaire, indicated as “missing” in the table. No increase was found in 
prevalence of a family history of any cardiovascular disease, MI, stroke or thrombosis in 
women with a history of recurrent miscarriage compared to women with no miscarriage. 
Adjusting for acquired risk factors as BMI, smoking during pregnancy and university level 
did not change the estimator of interest. Women with recurrent miscarriage had more 
often a family history of hypertension (54.3%), compared to women with no miscarriage 
(44.9%), although not significant (multivariate analyses: OR 1.71 (95%CI 0.94-3.11)).
Table 3. Family history of cardiovascular disease in women with recurrent miscarriage

















0.66 (0.31-1.41) 0.65 (0.30-1.42) 0.28




1.15 (0.60-2.21) 1.31 (0.66-2.61) 0.44




0.90 (0.44-1.83) 0.90 (0.43-1.90) 0.78




0.51 (0.14- 1.97) 0.56 (0.14-2.28) 0.42
Thrombosis (%) 10 (9.7) 12 (8.4) 1.07 (0.45- 2.50) 0.86 (0.35-2.15) 0.75




1.46 (0.84- 2.56) 1.71 (0.94-3.11) 0.08
MI: myocardial infarction.
CI: confidence interval
*Adjusted for BMI, university level education and smoking during pregnancy
** p-value refers to the multivariate analysis.
Comparable results were found in the subgroup analysis, including 67 women with pri-
mary recurrent miscarriage (Table 4). 
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Table 4. Family history of cardiovascular disease in women with primary recurrent miscarriage


















0.77 (0.33-1.81) 0.63 (0.25-1.59) 0.33




1.26 (0.58-2.76) 1.31 (0.58-2.97) 0.52




0.75 (0.33-1.71) 0.69 (0.29-1.67) 0.46




0.73 (0.13-4.13) 0.65 (0.11-3.78) 0.65
Thrombosis (%) 6 (9.0) 9 (9.6) 0.79 (0.28-2.25) 0.63 (0.19-2.07) 0.45




2.00 (0.97-4.13) 2.11 (0.95-4.72) 0.07
MI: myocardial infarction.
CI: confidence interval
*Adjusted for BMI, university level education and smoking during pregnancy
** p-value refers to the multivariate analysis.
Discussion
Main findings
In this matched case-control study the prevalence of family history of (premature) 
cardiovascular disease in a first-degree relative did not differ between women with recur-
rent miscarriage and women with no miscarriage. Therefore, our data does not confirm 
the assumption that a link exists between familiar cardiovascular disease and recurrent 
miscarriage when measured by proxy family history. 
Strengths and limitations
A strength of the study is that all women visited the recurrent miscarriage outpatient 
clinic in the past and had a confirmed diagnosis of recurrent miscarriage and therefore 
eliminating recall bias. We included only women who were ≤ 35 years of age at time of 
their third consecutive miscarriage to create a more homogeneous group. A younger 
age at diagnosis makes a maternal cause of recurrent miscarriages more plausible and 
reduces the chance of miscarriages due to fetal abnormalities (Franssen et al. 2005). We 
matched the women with recurrent miscarriage (cases) to women with no miscarriage 
(controls) on zip code (trying to avoid differences in socioeconomic status), age and 
time of pregnancy to make the groups as comparable as possible. Because we already 
matched for these factors they were not included as confounders in the multivariate 
analysis. Another strength of the study is the availability of patient characteristics such as 
BMI, smoking and education level. Information was crosschecked in obstetrical records 
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thereby eliminating recall bias. Previous mentioned characteristics are shared acquired 
risk factors between recurrent miscarriage and cardiovascular disease with a possible 
familial aggregation and therefore they could be a confounder for the genetic link between 
the two diseases. Adjusting for BMI, smoking during pregnancy and university level did 
not change the estimator of interest. It was remarkable that significantly more women in 
the recurrent miscarriage group were smoking during pregnancy compared to women 
with no miscarriage. Since we used the definition smoking in at least one pregnancy, 
exposure to the covariate was not equal in both groups (the number of pregnancies was 
higher in the recurrent miscarriage group). On the other hand, it is not very likely that 
women start smoking during their second or next following pregnancy, especially not 
when they experienced multiple miscarriages and received life style advises. Information 
about current health status was also available, women with recurrent miscarriage had 
more often hypertension at time of questionnaire. It is interesting to see this reflected in 
family history of hypertension as well, which seems more often present in women with 
recurrent miscarriage: OR 1.71 (95%CI 0.94-3.11), although not significant.
Several limitations of our study should be acknowledged. Selection bias may have been 
introduced. Possibly women with recurrent miscarriage and no live birth (the ‘worst’ 
cases) were more likely to decline to participate due to emotional reasons. A high 
percentage of 82.5 of the included women with recurrent miscarriage had at least one 
continuing pregnancy. Family history based on self-report could give recall bias, though 
this approach of data collection about family history of CVD has been proven reliable 
(Murabito et al. 2004; Kee et al. 1993). A reason we did not find an increase in the prevalence 
of a family history of (premature) CVD in women with recurrent miscarriage compared 
to women with no miscarriage, could be due to lack of power. Our power analysis was 
based on the assumption that 30% of the women with recurrent miscarriage would 
have a family history of premature CVD and 18% of the women with no miscarriage. It 
is possible that there is only a small association between a family history of CVD and 
recurrent miscarriage (clinically irrelevant), and due to our relatively small group (N=103) 
we could have missed this association. At time of questionnaire women with recurrent 
miscarriage were significantly younger compared to women with no miscarriage. This 
result was to be expected because women with recurrent miscarriage were included 
in the study before the matched controls were invited to participate. However, the 
difference in age was only 1.2 years and therefore is unlikely to affect the results in 
family history of CVD. We did not ask information about current age of the parents of 
the included women. Some parents will not have reached the age of 60 years at time 
of questionnaire. Because we matched women on zip code, age and time of pregnancy 
we do not expect a difference in parents age between both groups and therefore would 
influence our results. For the composite outcome, any cardiovascular disease the number 
of missing values was quite high. This is because if a part of the questionnaire was not 
filled in (regarding MI/ stroke/ thrombosis/ hypertension/ age/ first-degree relative) 
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and therefore the composite outcome was uncertain ‘any cardiovascular disease’ was 
indicated as missing (Table 3 and 4). 
Comparison of literature
This is not the first study which compared a family history of CVD between women with 
recurrent miscarriage and women with no miscarriage. Mahendru et al found a non-
significant difference of premature CVD in parents of women (planning to conceive) with 
a history of unexplained recurrent miscarriage (48%) versus women with previous normal 
pregnancy (24%), including only 26 women with recurrent miscarriage (Mahendru et al. 
2013). Smith et al, performed a large retrospective cohort study and found an increased 
incidence of ischemic heart disease in the parents of women who experienced three 
or more miscarriages prior before their first birth (N=224); hazard ratio 1.56 (95%CI 
1.14-2.15) (Smith et al. 2011). It is difficult to compare our research with the article by 
Smith et al because of the different approach; Smith used International Classification 
of Disease (ICD) codes for family history of CVD in parents compared to self-reports on 
family history in our study. On the other hand, the incidence of miscarriage was based on 
self-report in the article by Smith et al in contrast to our study. The included women in 
Smith’s article were very young at time of their recurrent miscarriage: 23 years (median, 
interquartile range 20-25) at time of first birth, compared to 29.6 years (mean, SD 3.48) 
at third consecutive miscarriage in our study. Because Smith investigated only women 
with primary recurrent miscarriage we repeated our analyses for women with primary 
recurrent miscarriage (Table 4). We found the same results: no increased prevalence of 
family history of CVD in women with a history of primary recurrent miscarriage. 
A recently published large Danish cohort study found an association between non-
consecutive miscarriages in women and risk of atherosclerotic disease in their first-degree 
relatives (Ranthe et al. 2016). The greater the number of daughters with miscarriages or the 
greater the combined number of miscarriages among daughters, the greater the parental 
risk of ischaemic outcomes. Persons with ≥3 miscarriages among their daughters had 
a 15% increased rate of an ischaemic outcome, compared with persons with the same 
number of children whose daughters had never miscarried. Information about potential 
confounding factors such as smoking and BMI were not available in this study.
Data from the routine recurrent miscarriage work-up to identify possible causes was 
described in Table 2. Seven percent of the women in the recurrent miscarriage group 
were diagnosed with a heritable form of thrombophilia. Heritable forms of thrombophilia, 
such as a polymorphism in factor V Leiden or prothrombin G20210A gene are associated 
with recurrent miscarriage and a modest association with coronary disease is described 
(Kovalevsky et al. 2004; Ye et al. 2006). A stronger association exists between heritable 
thrombophilia and venous thromboembolism. The prevalence of thrombophilia in 
women with recurrent miscarriage in current study (6,8%) was lower than what was 
expected from the literature. Heritable thrombophilia is present in about 15% of the 
PSM 20180328 Proefschrift Wagner.indd   77 14-05-18   10:18
CHAPTER  5
78
Western population (Greer 2000). Data about thrombophilia was not available for the 
controls in this study. The fact that we did not find an increased prevalence of a family 
history of thrombosis in women with recurrent miscarriage compared to women with no 
miscarriage is in line with the literature (Smith et al. 2011). Therefore, we do not think that 
the low prevalence of thrombophilia in our study group can be an explanation for the fact 
that we did not find an increased prevalence of family history of CVD.
Conclusions
No increase was found in prevalence of family history of (premature) cardiovascular 
disease in women who experienced recurrent miscarriage compared to women with no 
miscarriage what contradicts a shared common genetic pathophysiological pathway 
linking cardiovascular disease and recurrent miscarriage. A possible association was 
found between family history of hypertension and recurrent miscarriage, which urge 
more investigation.
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Background The underlying cause of recurrent miscarriage remains often unexplained. 
A multifactorial etiology, including uterine anomalies, endocrine and metabolic factors, 
maternal autoimmune disorders, thrombophilia, toxic factors and genetics is assumed. 
Currently it is still unclear which specific genes are involved. The aim of this study was 
to investigate systematically which genetic variants are reproducibly associated with 
recurrent miscarriage.
Methods A systematic review and meta-analysis was performed. PubMed, Embase and 
Web of Science were searched (till 7 October 2014) for case-control studies that assessed 
the association between genetic variants and recurrent miscarriage (defined as two or 
more unexplained miscarriages). The control groups consisted of women with at least 
one successful pregnancy and no miscarriages. Genetic variants significantly associated 
with recurrent miscarriages in at least two independent studies were considered as 
reproduced variants and were included. The association between genes and recurrent 
miscarriages was assessed at the allele level and a pooled odds ratio was estimated in a 
random-effects model. A subgroup analysis was performed for the association between 
genetic variants and three or more consecutive miscarriages. I2 statistics was reported. 
Egger test was used to check funnel plot asymmetry.
Results The literature search yielded 4050 articles; a total of 241 studies were included. 
We identified 25 reproduced genetic variants, of which 16 remained significantly 
associated with recurrent miscarriage in a random-effects meta-analysis. These variants 
were in the following genes: F2, FV, FXIIIa, HLA-G, IL10, IL18, MTHFR (two variants), NOS3, 
PAI1 , STAT3, TNFA (two variants) and VEGFA (three variants). Odds ratios for these 16 
variants ranged from 1.21 to 2.64. Eight variants were significantly associated with three 
or more consecutive miscarriages, in the following genes: FV, IFNG, MTHFR, NOS3, TNFA 
(two variants) and VEGFA (two variants).
Conclusions This meta-analysis found 16 genetic variants associated with recurrent 
miscarriage. Major involved pathways seem to be: coagulation and fibrinolysis, immuno-
logy and inflammation and angiogenesis. Unravelling mechanisms by which these 
genetic variants affect the risk of recurrent miscarriage can reveal potential targets in the 
search for treatment. This meta-analysis also suggests that recurrent miscarriage and 
cardiovascular disease share genetic risk factors. 
Keywords: genetic variants, recurrent miscarriage, risk-factors, cardiovascular disease
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Spontaneous miscarriage is the most common complication of pregnancy. About 15% 
of clinically recognized pregnancies end in a miscarriage (Rai and Regan, 2006;Wilcox, 
Weinberg et al., 1988). The definition of recurrent miscarriage varies between two and 
three and consecutive versus non-consecutive miscarriages (Kolte, Bernardi et al., 2015). 
Generally, the definition of three or more consecutive miscarriages prior to the 22nd week 
of gestation is used (Stirrat, 1990) which affects 0.5-3% of all fertile couples (Jivraj, Anstie 
et al., 2001). In more than 50% of the cases, the underlying cause remains unexplained 
after diagnostic tests (Porter and Scott, 2005). Etiologic factors which are assumed to be 
involved in the pathogenesis of recurrent miscarriage include genetic disorders, uterine 
anomalies, endocrine factors, maternal autoimmune disorders, metabolic disorders, 
maternal thrombophilia, obesity and toxic factors, such as smoking and alcohol con-
sumption (Branch, Gibson et al., 2010). Research suggests a multifactorial etiology 
with a role for genetics (Christiansen, Steffensen et al., 2008;Kolte, Nielsen et al., 2011). 
An increase in the risk of spontaneous miscarriage was seen in family of women with 
recurrent miscarriage compared to normal control subjects (Christiansen, Mathiesen 
et al., 1990;Kolte, Nielsen et al., 2011;Miskovic, Culic et al., 2012;Nybo Andersen, 
Wohlfahrt et al., 2000). In addition, a case-control study showed that women with two 
or more unexplained recurrent miscarriages more often had a family history of recurrent 
miscarriage compared to healthy control subjects, RR 3.2 (95%CI 1.3-8.1) (Parazzini, 
Bocciolone et al., 1991). However, it is still unclear what specific genes are involved 
and what individual variants contribute to the development of recurrent miscarriages. 
Polymorphisms have been investigated in almost 90 different genes (Rull, Nagirnaja et 
al., 2012).
The aim of this study was to give a systematic overview of the genetic variants associated 
with recurrent miscarriage. A meta-analysis was performed to assess the pooled effect of 
the genetic variants that are repeatedly investigated and that are significantly associated 
with recurrent miscarriage in at least two of the performed studies. 
Methods
Literature search
The databases PubMed, Embase and Web of Science were searched in collaboration 
with a trained librarian (last updated 7 October 2014). Terms used in the search strategy 
were ‘Recurrent Miscarriage, ‘Habitual Abortion’, ‘Pregnancy Loss’, ‘Polymorphisms, or 
‘Genes’.  All relevant keyword variants were used, and database specific adaptation of 
the key terms was performed. In addition, names of specific genes and polymorphisms 
which are known to be related to preeclampsia (Buurma, Turner et al., 2013) were added 
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to the search strategy. The only limitation used in the search was language; studies had to 
be published in English or Dutch. References of related systematic reviews were checked 
for additional articles. 
Eligibility criteria
We searched for case-control studies comparing genetic variants between women with 
recurrent miscarriage and controls. Inclusion criteria were: 1. Recurrent miscarriage 
defined as two or more unexplained miscarriages (irrespective whether consecutive or not) 
in first and/or second trimester; 2. The control group consisted of women who had at least 
one successful pregnancy and no miscarriages. If a subset of subjects in a study suited the 
inclusion criteria, only the subset was included. In case of overlapping study populations 
only the study with the most extensive data was included, to avoid duplication.
All titles and abstracts were reviewed by two researchers (M.W. and A.V. and a subset by 
M.W. and A.B.), who independently assessed if the study compared at least one genetic 
variant between women with and without recurrent miscarriage. Genetic variant studies 
were screened for whether they met the inclusion criteria and whether the investigated 
genetic variant showed a significant association (P<0.05 was defined as significant) at 
the allelic and/or genotypic level with recurrent miscarriage. When a genetic variant 
was found to be significantly associated with recurrent miscarriage in at least two 
studies, that variant was considered a reproduced genetic variant. Finally, only studies 
that investigated any of these reproduced genetic variants were included in the meta-
analysis.
Data extraction
Studies that met the inclusion criteria were entered into separate databases by two 
researchers (M.W. and A.V.) independently. These two databases were compared, 
differences were discussed until consensus was reached and allele frequencies were 
extracted. In case of missing data, at least two attempts were made to contact the 
corresponding author. When neither the published report nor the corresponding author 
provided sufficient data to calculate an odds ratio at the allele level or give assurance 
that the study met the inclusion criteria, the study was excluded. 
Statistical analyses
Pooled odds ratio’s (OR) with 95% confidence intervals (CI) were calculated at the allele 
level for the association between reproduced genetic variants and recurrent miscarriage. 
Data were pooled using a random-effects-model to take into account between-study 
heterogeneity. I2 was reported, which reflects the percentage of total variation across 
studies due to heterogeneity rather than due to change (Higgins, Thompson et al., 2003). 
Funnel plots were generated for all reproduced genetic variants. Egger test (Egger, Davey 
et al., 1997) was used to check funnel plot asymmetry (test for small study effect) which 
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may reflect publication bias. This test was only used when 10 or more studies were included 
to investigate a genetic variant, because otherwise test power is too low to distinguish 
chance from real asymmetry (Sterne, Sutton et al., 2011). If funnel plot asymmetry 
existed and between study heterogeneity was evident a comparison between a random-
effects-model and a fixed-effects-model was made. A subgroup analysis was performed 
for studies which included women with three or more consecutive miscarriages, applying 
the previously described analyses. All analyses were performed using STATA (StataCorp. 
2011. Stata Statistical Software, Release 10, College Station, TX, USA: StataC).
Results
The initial literature search yielded 4050 articles. Finally 129 articles, comprising 
241 studies, were included in this meta-analysis (Figure 1). Altogether, 25 reproduced 
genetic variants in 18 genes were described. Included articles were published between 
1997 and 2014. The number of studies per genetic variant ranged from 2 to 38, the 
number of cases per study ranged from 5 to 1000. A significant association for 16 of the 
25 reproduced genetic variants and recurrent miscarriage was found in a random-effects 
meta-analysis. These variants were in the following genes: F2, FV, FXIIIa, HLA-G, IL10, 
IL18, MTHFR (two variants), NOS3, PAI1 , STAT3, TNFA (two variants) and VEGFA (three 
variants) (Figure 2A-B). Odds ratio’s ranged from 1.21 to 2.64, no significant protective 
effects were found (Table 1). 
A subgroup analysis was performed for studies which included women with three or more 
consecutive miscarriages; 19 reproduced genetic variants could be included. A significant 
association between 8 variants and three or more consecutive miscarriages was found in 
the random-effects meta-analysis in the following genes: FV, IFNG, MTHFR, NOS3, TNFA 
(two variants) and VEGFA (two variants) (Table 2) (Figure 2C-D). The references of the 
included studies per variant are described in Table 3. Characteristics and references of all 
included studies, forest and funnel plots for all individual genetic variants are provided 
in the supplementary data.
Genetic variants involved in the renin-angiotensin system
Eleven studies investigating the angiotensin converting enzyme (ACE) insertion/deletion 
(I/D) polymorphism (rs1799752) were included in this analysis, resulting in a pooled OR of 
1.20 (95% CI 0.95-1.53). In the subgroup analysis of women with three or more consecutive 
miscarriages, 4 studies were included, resulting in a pooled OR of 0.85 (95% CI 0.72-1.02). 
Genetic variants involved in lipid metabolism
Five studies were included in the apolipoprotein E (APOE) (rs429358) analysis. E3 versus 
E4 allele (minor allele) was included in the meta-analysis resulting in a pooled OR of 
3.09(95% CI 0.93-10.24). 
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Genetic variants involved in coagulation and fibrinolysis
Seven reproduced genetic variants in five genes concerning coagulation and fibrinolysis 
were included in the meta-analysis, six variants remained significantly associated 
with recurrent miscarriage following meta-analysis. The variant factor 2 (F2) G20210A 
(rs1799963), also known as prothrombin mutation, was investigated in 26 studies resulting 
in an OR of 1.94 (95%CI 1.23-3.06). A subgroup analysis was performed for studies 
defining cases as three or more consecutive miscarriages for F2 G20210A resulting in an 
OR of 1.62 (95%CI 0.82-3.19), including 14 studies. Factor V Leiden (FVL) (rs6025) was the 
most frequently investigated polymorphism regarding recurrent miscarriages. A total of 
38 studies were included, resulting in an OR of 1.88 (95%CI 1.47-2.40). For the subgroup 
three or more consecutive miscarriages 21 studies were included with a pooled OR of 1.79 
(95%CI 1.32-2.42) The variant factor XIIIa (FXIIIa) Val34Leu (rs5985) was investigated in 8 
studies and was associated with recurrent miscarriage; pooled OR of 1.58 (95%CI 1.04-
2.41). Three studies were included in the subgroup analysis for three or more consecutive 
miscarriages, resulting in an OR of 1.36 (95%CI 0.43- 4.28).
Two variants in the methylenetetrahydrofolate reductase (MTHFR) gene were included. 
The MTHFR A1298C polymorphism (rs1801131) was investigated in 14 studies resulting 
in an OR 1.34 (95%CI 1.05-1.72). The subgroup analysis for three or more consecutive 
miscarriages resulted in an OR of 1.13 (95%CI 0.91-1.40), including 7 studies. The MTHFR 
C677T variant (rs1801133) was investigated in 32 studies and was associated with recurrent 
miscarriage with an OR of 1.28 (95%CI 1.12-1.47). The subgroup analysis for three or more 
consecutive miscarriages showed a comparable result. The variant plasminogen activator 
inhibitor-1 (PAI1) -675 4G/5G (rs1799889) was investigated in 14 studies and was associated 
with recurrent miscarriage with a pooled OR of 1.29 (95%CI 1.05-1.57). The variant protein 
Z (PZ) intron F G79A (rs3024718) was not associated with recurrent miscarriage after meta-
analysis, including 4 studies, with a pooled OR of 0.88 (95%CI 0.38-2.04). 
Genetic variants involved in inflammation and immunology
Eleven reproduced variants in seven genes involved in inflammation and immunology 
were included, five remained significantly associated with recurrent miscarriage after 
meta-analysis. The only reproduced genetic variant concerning human leukocyte 
antigen (HLA) comprised HLA-G. Eleven studies investigated the HLA-G 14bp I/D variant 
(rs1704). A pooled OR of 1.21 (95%CI 1.01-1.45) was found in the meta-analysis. Interferon-
gamma (IFNG) 874A/T (rs2430561), reported in 5 studies, was not associated with 
recurrent miscarriage after meta-analysis with an OR 1.12 (95%CI 0.82-1.54). However, 
in the subgroup analysis for three or more consecutive miscarriages an association was 
found; pooled OR 1.39 (95% CI 1.14- 1.70). The variant Interleukin (IL)1B -511C/T (rs16944) 
was investigated in 4 studies resulting in an OR of 1.17 (95%CI 0.79- 1.73). Four studies 
investigated the variant IL6 -174G/C (rs1800795) resulting in an OR of 1.74 (95%CI 0.96-
3.15). 
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Three variants concerning IL10 were included. The variant  IL10 -592C/A (rs1800872) was 
investigated in 7 studies, a pooled OR of 0.84 (95%CI 0.63-1.12) was found. Similar results 
were found in the subgroup analysis regarding three or more consecutive miscarriages, 
including 4 studies. IL10 -819C/T (rs1800871) was investigated in 4 studies resulting in a 
pooled OR of 1.22 (95%CI 0.93-1.60). Similar results were found in the subgroup analysis 
regarding three or more consecutive miscarriages, including 3 studies. IL10 -1082A/G 
(rs1800896) was investigated in 6 studies and was associated with recurrent miscarriage 
with an OR of 1.25 (95%CI 1.02-1.54). In the subgroup analysis, three or more consecutive 
miscarriages; a pooled OR of 1.23 (95% CI 0.86-1.76) was found including 3 studies. The 
variant IL18 -656C/A (rs1946519) was investigated in only 2 studies and was associated 
with recurrent miscarriage with an OR of 1.92 (95%CI 1.61-2.30). Three variants in the 
tumour necrosis factor –alpha(TNFA) gene were included. Five studies concerned the 
-238G/A variant (rs361525);  a pooled OR of 1.37 (95%CI 0.88-2.14) was found. However, a 
significant association was found for the subgroup with three consecutive miscarriages 
(including 3 studies); pooled OR 1.52 (95%CI 1.21-1.92). TNFA -308G/A (rs1800629) was 
investigated in 7 studies, a pooled OR of 1.46 (95% CI 1.17-1.84) was found. A similar 
result was found in the subgroup analysis for three consecutive miscarriages, including 
4 studies. The TNFA -1031C/T (rs1799964) variant was investigated in 2 studies and 
associated with recurrent miscarriage, pooled OR 2.64 (95%CI 1.90-3.66).
Genetic variants involved in oxidative stress
The variant NOS3 Glu298Asp (rs1799983) was investigated in 8 studies resulting in a 
pooled OR of 1.53 (95% CI 1.16-2.01). Seven of these studies included women with three 
consecutive miscarriage, pooled OR 1.65 (95%CI 1.25-2.17)
Genetic variants involved in oncogenesis
The variant signal transducer and activator of transcription 3 (STAT3) rs1053004 was 
investigated in only 2 studies and remained associated with recurrent miscarriage after 
meta-analysis with a pooled OR of 1.51 (95%CI 1.30-1.75).
Genetic variants involved in angiogenesis
Three reproduced variants in the vascular endothelial growth factor A(VEGFA) were 
included and all remained associated after meta-analysis. VEGFA -583T/C (rs3025020) was 
investigated in 3 studies and was associated with recurrent miscarriage with a pooled OR 
of 1.75 (95%CI 1.50-2.03). All the available studies included women with three or more 
consecutive miscarriages. VEGFA 936C/T (rs3025039) was reported in 9 studies resulting 
in an OR of 1.35 (95%CI 1.09-1.68). A similar result was found in the subgroup analysis 
for three or more consecutive miscarriages, including 5 studies. The VEGFA -1154G/A 
(rs1570360) variant was reported in 10 studies resulting in an OR of 1.24 (95%CI 1.02-1.50). 




In this meta-analysis 16 genetic variants were associated with recurrent miscarriage. 
Meta-analysis of several individual genetic variants has been performed previously in 
relation to recurrent miscarriage. However, this is the first meta-analysis which gives 
a complete overview for all genetic variants which were reproducibly significantly 
associated with recurrent miscarriage. These more robust data could lead to improved 
understanding of the pathogenesis of recurrent miscarriage and could help to find the 
right direction for future treatment options. 
Strengths/Limitations
This meta-analysis included only reproduced genetic variants, defined as variants that 
were at least twice independently significantly associated with recurrent miscarriage. 
This method was described before (Buurma, Turner et al., 2013;Mooyaart, Valk et al., 
2011) and aims to minimize the number of false-positive results. However, it is possible 
that variants which were only described in studies with small sample size and lack of 
power were missed using this method. Publication bias is a concern in all meta-analyses. 
Overestimation of effect is possible due to the fact that studies with a non-significant 
effect are less likely to be published. For this reason Egger tests were performed, which 
showed no evidence of funnel plot asymmetry. Of note, we only performed this test for 
analyses including 10 or more studies as recommended by Sterne et al (Sterne, Sutton et 
al., 2011). 
Criteria for study inclusion and exclusion are critical parts of a meta-analysis and can affect 
results. Recurrent miscarriage is a very heterogenic condition and as described in the 
introduction the definition of recurrent miscarriage varies in the literature between two 
and three and consecutive versus non-consecutive miscarriages (Kolte, Bernardi et al., 
2015). To reduce the clinical heterogeneity we performed a subgroup analysis for studies 
which included women with three or more consecutive miscarriages. To further reduce 
this heterogeneity we included only studies that comprised women with pregnancy loss 
before the third trimester and the miscarriages had to be unexplained. However, bias 
is still possible due to the variations in examinations performed to make the diagnosis 
‘unexplained recurrent miscarriage’. All control women had to be parous women (with no 
miscarriage), to be sure that all women had been at risk to miscarry. Despite our efforts, 
statistical heterogeneity was evident for several investigated variants (Table 1 and 2).  
Comparisons with literature
Genetic variants in the following genes were associated with recurrent miscarriage in 
this meta-analysis: F2, FV, FXIIIa, HLA-G, IL10, IL18, MTHFR (two variants), NOS3, PAI1 , 
STAT3, TNFA (two variants) and VEGFA (three variants). Three main groups or pathways 
can be distinguished; variants concerning coagulation and fibrinolysis (F2  G20210A, 
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FVL, FXIIIa Val34Leu, MTHFR A1298C, MTHFR C677T, PAI1 -675 4G/5G), variants concerning 
immunology and inflammation (HLA-G 14bp I/D, IL10 -1082A/G, IL18 -656C/A, TNFA -308G/
A, TNFA -1031C/T) and variants involved in angiogenesis (VEGFA -583T/C, VEGFA 936C/T, 
VEGFA -1154G/A).  
Six genetic variants involved in coagulation and fibrinolysis remained associated with 
recurrent miscarriage. Inherited thrombophilia is an important topic of research on 
women with recurrent miscarriage. The major heritable forms of thrombophilia are 
F2 G20210A and FVL polymorphisms. Women with inherited thrombophilia have been 
shown to be at increased risk not only of thromboembolism, but also of complications 
of pregnancy including preeclampsia and fetal loss (Walker, 2000). MTHFR A1298C and 
MTHFR C677T polymorphism remained associated with recurrent miscarriage after 
meta-analysis. Both polymorphisms reduce the activity of the MTHFR enzyme, causing 
elevated concentration of homocysteine. Increased homocysteine concentration is 
associated with neural tube defects and has led to the hypothesis that high concentrations 
of homo cysteine might be embryotoxic (Zetterberg, 2004). Hyperhomocysteinemia is 
related to recurrent miscarriage (Steegers-Theunissen, Boers et al., 1992;Wouters, Boers 
et al., 1993). PAI1 regulates fibrinolysis, the 4G deletion allele is associated with high 
PAI1 plasma levels (Burzotta, Di et al., 1998). An association between the PAI1 -675 4G 
deletion and recurrent miscarriage was found in our meta-analysis with an OR of 1.29, 
and a 95%CI of 1.05-1.57. The meta-analysis published in 2013 by Su et al (Su, Lin et al., 
2013) did not find a significant association between PAI1 and recurrent miscarriage: OR 
1.44 (95%CI 0.97-2.14). This is probably due to the number of included studies: we were 
able to include 14 studies, compared to 11 studies in the meta-analysis performed by 
Su et al. 
It is assumed that HLA-G plays an important role in the maternal-fetal interface (Kovats, 
Main et al., 1990). HLA-G modulates cytokine secretion to induce immunotolerance, 
regulates trophoblast invasion for implantation and contributes to vascular remodelling 
of spiral arteries for pregnancy maintenance (Roussev and Coulam, 2007). Lower 
circulating levels of soluble(s) HLA-G during the first trimester were found in women 
with recurrent pregnancy loss versus healthy pregnant controls (Jassem, Shani et al., 
2012). We found a pooled OR of 1.21 (95%CI 1.01-1.45) between HLA-G 14bp and recurrent 
miscarriage, although significant heterogeneity was evident across studies (I2=57.0%). No 
significant association was found in our subgroup analysis for three or more consecutive 
miscarriages, likely because of the small number of included studies (4 studies). This 
result is comparable with the very recently published meta-analysis by Meuleman et al 
(Meuleman, Lashley et al., 2015). 
A significant association between IFNG 874A/T and recurrent miscarriage was only found 
in our meta-analysis including three or more consecutive miscarriages. IFNG is a pro-
inflammatory cytokine, produced by type 1 T-helper cells which activate macrophages 
and are responsible for cell-mediated immunity and phagocyte-dependent protective 
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responses (Romagnani, 1999). Significantly higher levels of IFNG were found in women 
with recurrent miscarriage compared to women with a normal pregnancy (Raghupathy, 
Makhseed et al., 1999;Wilson, Jenkins et al., 2004). A meta-analysis performed in 2008 
(Bombell and McGuire, 2008) showed a comparable result (OR 1.29), although they did 
not find a significant association. Our association likely turned out to be significant 
because we were able to include the large study performed by Parveen et al (Parveen, 
Shukla et al., 2012) (which found an association: OR 1.49 (1.13-1.95)).
One of the three included polymorphisms in the IL10 gene remained significantly 
associated with recurrent miscarriage; IL10 -1082A/G (OR 1.25 (95%CI 1.02-1.54)). IL10 
is known to selectively suppress Th1-mediated cellular responses by inhibiting the 
production of inflammatory cytokines (IFNG and TNFA). It has been proposed that a 
decrease in production of IL10 is associated with recurrent miscarriage and increased 
production is associated with normal pregnancy (Hill, Polgar et al., 1995;Kamali-
Sarvestani, Zolghadri et al., 2005;Makhseed, Raghupathy et al., 2000). However this is 
still controversial; a study found higher IL10 levels at miscarriage than during normal 
pregnancy (Vassiliadis, Ranella et al., 1998). Our results suggest that women with 
recurrent miscarriage may have a genetic predisposition to secrete higher levels of IL10. 
Further research is needed to clarify the role of IL10 in recurrent miscarriages.
A closely related pro-inflammatory cytokine is IL18, also known as IFNG inducing factor 
(Al-Khateeb, Sater et al., 2011;Boraschi and Dinarello, 2006). We found a significant 
association between IL18 -656C/A with an OR of 1.92, however only two studies were 
included indicating the need for more research. 
Also produced by type 1 T-helper cells is the cytokine TNFA (El-Far, El-Sayed et al., 
2009;Liu, Wang et al., 2010). The TNFA -308G/A variant remained significantly associated 
with recurrent miscarriages; pooled OR 1.46 (1.17-1.84), including seven studies. This is 
in contrast with the meta-analysis performed in 2009 by Medica et al (Medica, Ostojic 
et al., 2009), which did not find a significant association. Since the publication of the 
latter meta-analysis, new large studies were published in women with three or more 
consecutive miscarriages that did find an association between the variant and recurrent 
miscarriage (Alkhuriji, Alhimaidi et al., 2013;Gupta, Prakash et al., 2012). We were able 
to include those. The -1031C/T variant also remained significantly associated with 
recurrent miscarriage in our meta-analysis. The variant was investigated in only 2 studies 
resulting in an OR of 2.64 (95%CI 1.90-3.66). The polymorphisms described above in pro-
inflammatory cytokines (in the genes IFNG, IL18 and TNFA) are in line with the hypothesis 
of a change in the maternal T-helper cell response; in women with recurrent miscarriage 
towards a persisting Th1- type (Hill, Polgar et al., 1995).  
STAT3 belongs to a family of signal transducers and activators of transcription (STAT1-
STAT6) of intracellular signalling proteins and plays a role in unrestrained growth of human 
tumours (Bromberg and Darnell, Jr., 2000). Two studies regarding the rs1053004 variant 
could be included in the meta-analysis and the polymorphism remained significantly 
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associated with recurrent miscarriage. Further investigation is needed to clarify the 
possible mechanisms of the association between the influence of STAT3 on recurrent 
miscarriage (Garcia, Tirado-Gonzalez et al., 2007). It is hypothesized that altered STAT3 
activity leads to a local inflammatory state through recruitment of inflammatory cells 
and up-regulation of proinflammatory cytokines at the placental membrane, leading to 
accelerated miscarriage (Messoudi, Al-Sulaiti et al., 2013). VEGFA is an endothelial cell 
specific protein that acts as a mediator of angiogenesis and vasculogenesis (Almawi, 
Saldanha et al., 2013). VEGFA is essential in establishing a vascular network during 
early embryo development (Byrne, Bouchier-Hayes et al., 2005). All three included 
polymorphisms (VEGFA -583T/C, 936C/T and -1154G/A) remained significantly associated 
with recurrent miscarriage after meta-analysis suggesting an important role in the 
pathogenesis of recurrent miscarriage.
The use of genetic information is expected to play a major role in future personalized 
medicine (Chan and Ginsburg, 2011). Personalized medicine is a medical model including 
each person’s unique clinical, genetic, genomic, and environmental information to 
better classify disease, facilitate the development of new targeted therapies and to more 
accurately determine disease predisposition which will be helpful in disease prevention.
Cardiovascular disease 
Recent epidemiological studies suggest a relationship between recurrent miscarriage and 
a risk for cardiovascular disease later in life (Oliver-Williams, Heydon et al., 2013;Ranthe, 
Figure 1. Selection of articles 
PSM 20180328 Proefschrift Wagner.indd   91 14-05-18   10:18
CHAPTER  6
92
Andersen et al., 2013). Smith et al found an association between recurrent miscarriage 
and a family history of ischemic heart disease (Smith, Wood et al., 2011), suggesting a 
shared genetic predisposition between the two diseases. It is noteworthy to mention 
that several of the variants that were associated with recurrent miscarriage in this 
meta-analysis are also identified as risk factors for developing cardiovascular disease. 
For example F2 G20210A, FVL and PAI1 -675 4G/5G polymorphism were associated with 
coronary disease in a large meta-analysis (Ye, Liu et al., 2006). In another meta-analysis, 
NOS3 Glu298Asp was found to be significantly associated with ischemic heart disease 
(Casas, Bautista et al., 2004). F2 G20210A, FVL, FXIIIa Val34Leu, MTHFR A1298C, MTHFR 
Figure 2. Odds ratio’s with 95% confidence intervals for variants that were reproducibly 
associated with recurrent miscarriage
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A. All reproduced genetic variants that were significantly associated with recurrent miscarriage after meta-analysis
B. All reproduced genetic variants that were not significantly associated with recurrent miscarriage after meta-analysis
C. Subgroup analysis: All reproduced genetic variants that were significantly associated with three or more consecutive 
miscarriages after meta-analysis
D. Subgroup analysis: All reproduced genetic variants that were not significantly associated with three or more 
consecutive miscarriages after meta-analysis
C677T, NOS3 Glu298/Asp and PAI1 -675  4G/5G were associated with ischemic stroke in 
another meta-analysis (Casas, Hingorani et al., 2004;Kang, Wu et al., 2014). 
In summary our study found 16 genetic variants that are associated with recurrent 
miscarriage. This meta-analysis gives a comprehensive overview of the involved pathways; 
coagulation and fibrinolysis, immunology and inflammation and angiogenesis. Further 
studies are needed to investigate the mechanisms of how these genetic variants affect 
the risk of developing recurrent miscarriages. Additionally, this meta-analysis suggests 
that recurrent miscarriage and cardiovascular disease share genetic risk factors. 
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ACE I/D rs1799752 D 11 1928 1170 1.20 (0.95, 1.53) 76.8 0.52
APOE rs429358 E4 5 969 532 3.09 (0.93,10.24) 84.3 --
F2 G20210A rs1799963 A 26 3989 3424 1.94 (1.23,3.06) 49.0 0.96
FVL rs6025 A 38 6025 5246 1.88 (1.47,2.40) 47.2 0.10
FXIIIa Val34Leu rs5985 T 8 836 568 1.58 (1.04,2.41) 71.3 --
HLA-G 14bp I/D rs1704 I 11 1449 1362 1.21 (1.01, 1.45) 57.0 0.36
IFNG 874A/T rs2430561 T 5 596 620 1.12 (0.82, 1.54) 67.6 --
IL1B -511C/T rs16944 C 4 808 527 1.17 (0.79, 1.73) 81.7 --
IL6 -174G/C rs1800795 C 4 616 715 1.74 (0.96, 3.15) 87.1 0.34
IL10 -592C/A rs1800872 A 7 879 1062 0.84 (0.63, 1.12) 73.2 --
IL10 -819C/T rs1800871 T 4 720 841 1.22 (0.93, 1.60) 67.8 --
IL10 -1082A/G rs1800896 G 6 1193 1144 1.25 (1.02, 1.54) 52.6 --
IL18 -656C/A rs1946519 A 2 517 524 1.92 (1.61, 2.30) 0.0 --
MTHFR A1298C rs1801131 C 14 2289 1758 1.34 (1.05, 1.72) 79.3 0.67
MTHFR C677T rs1801133 T 32 4146 4573 1.28 (1.12, 1.47) 63.4 0.44
NOS3 Glu298Asp rs1799983 T 8 1574 1352 1.53 (1.16, 2.01) 72.0 --
PAI1 -675 4G/5G rs1799889 4G 14 2759 2091 1.29 (1.05, 1.57) 78.8 0.56
PZ intron F G79A rs3024718 A 4 420 433 0.88 (0.38, 2.04) 87.2 --
STAT3 rs1053004 C 2 670 751 1.51 (1.30, 1.75) 0.0 --
TNFA -238G/A rs361525 A 5 1058 1201 1.37 (0.88, 2.14) 64.3 --
TNFA -308G/A rs1800629 A 7 1276 1463 1.46 (1.17, 1.84) 28.5 --
TNFA -1031C/T rs1799964 C 2 561 484 2.64 (1.90, 3.66) 23.8 --
VEGFA -583T/C rs3025020 T 3 696 785 1.75 (1.50, 2.03) 0.0 --
VEGFA 936C/T rs3025039 T 9 1509 1640 1.35 (1.09, 1.68) 50.6 --
VEGFA -1154G/A rs1570360 A 10 1879 1972 1.24 (1.02, 1.50) 66.1 0.41
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ACE I/D D 4 544 593 0.85 (0.72, 1.02) 0.0 --
F2 G20210A A 14 2314 1911 1.62 (0.82, 3.19) 51.1 0.25
FVL A 21 3518 3156 1.79 (1.32, 2.42) 34.2 0.10
FXIIIa Val34Leu T 3 272 268 1.36 (0.43, 4.28) 90.8 --
HLA-G 14bp I/D I 4 700 405 1.06 (0.88, 1.28) 5.6 --
IFNG 874A/T T 3 372 485 1.39 (1.14, 1.70) 0.0 --
IL6 -174G/C C 3 474 537 1.67 (0.78, 3.58) 90.7 --
IL10 -592C/A A 4 482 601 0.82 (0.54, 1.23) 77.7 --
IL10 -819C/T T 3 424 536 1.21 (0.79, 1.85) 78.5 --
IL10 -1082A/G G 3 412 534 1.23 (0.86, 1.76) 68.0 --
MTHFR A1298C C 7 1019 1106 1.13 (0.91, 1.40) 54.8 --
MTHFR C677T T 19 1991 2944 1.31 (1.10, 1.55) 60.0 0.31
NOS3 Glu298Asp T 7 1429 1217 1.65 (1.25, 2.17) 67.3 --
PAI1 -675 4G/5G 4G 7 1042 1377 1.31 (0.95, 1.82) 84.3 --
TNFA -238G/A A 3 569 813 1.52 (1.21, 1.92) 0.0 --
TNFA -308G/A A 4 737 1025 1.52 (1.10, 2.10) 53.5 --
VEGFA -583T/C T 3 696 785 1.75 (1.50, 2.03) 0.0 --
VEGFA 936C/T T 5 827 901 1.38 (1.00, 1.90) 62.2 --
VEGFA -1154G/A A 5 1114 1110 1.20 (0.91, 1.57) 71.3 --
Table 3. References of the included articles, per genetic variant
Variant
ACE I/D (Al Sallout and Sharif, 2010;Bagheri, Abdi, I et al., 2010;Buchholz, Lohse et al., 
2003;Choi, Kwon et al., 2011;Dossenbach-Glaninger, van et al., 2008b;Fatini, Gen-
sini et al., 2000;Kim, Choi et al., 2014;Ozdemir, Yenicesu et al., 2012;Poursadegh, 




(Al Sallout and Sharif, 2010;Bagheri, Abdi, I et al., 2010;Choi, Kwon et al., 
2011;Kim, Choi et al., 2014)
APOE (Agarwal, Parveen et al., 2010;Asgari, Akbari et al., 2013;Korkmazer, Ustunyurt et 
al., 2013;Ozdemir, Yenicesu et al., 2012;Poursadegh, Farajzadeh et al., 2014)
F2 G20210A (Abu-Asab, Ayesh et al., 2011;Altintas, Pasa et al., 2007;Bagheri, Rad et al., 
2011a;Buchholz, Lohse et al., 2003;Carp, Salomon et al., 2002;Dossenbach-Gla-
ninger, van et al., 2003;Dutra, Fraga et al., 2014;Finan, Tamim et al., 2002;Guer-
ra-Shinohara, Bertinato et al., 2012;Hohlagschwandtner, Unfried et al., 
2003;Ivanov, Komsa-Penkova et al., 2009;Karata, Aydin et al., 2012;Lino, Traina 
et al., 2014;Mitic, Kovac et al., 2010;Mohamed, El Moaty et al., 2010;Mougiou, 
Androutsopoulos et al., 2008;Mtiraoui, Borgi et al., 2004;Parand, Zolghadri et 
al., 2013;Parveen, Shukla et al., 2013;Pihusch, Buchholz et al., 2001;Poursadegh, 
Chaparzadeh et al., 2013;Serrano, Lima et al., 2011;Sotiriadis, Vartholomatos et 
al., 2007;Sottilotta, Oriana et al., 2006;Yenicesu, Cetin et al., 2010;Yildiz, Yavuzcan 
et al., 2012






(Altintas, Pasa et al., 2007;Bagheri, Rad et al., 2011a;Guerra-Shinohara, Berti-
nato et al., 2012;Hohlagschwandtner, Unfried et al., 2003;Karata, Aydin et al., 
2012;Lino, Traina et al., 2014;Mitic, Kovac et al., 2010;Mohamed, El Moaty et al., 
2010;Mougiou, Androutsopoulos et al., 2008;Mtiraoui, Borgi et al., 2004;Parand, 
Zolghadri et al., 2013;Parveen, Shukla et al., 2013;Serrano, Lima et al., 2011;Yildiz, 
Yavuzcan et al., 2012)
FVL (Abu-Asab, Ayesh et al., 2011;Altintas, Pasa et al., 2007;Bagheri, Rad et al., 
2011a;Biswas, Choudhry et al., 2008;Buchholz, Lohse et al., 2003;Carp, Salo-
mon et al., 2002;Dizon-Townson, Kinney et al., 1997;Dossenbach-Glaninger, 
van et al., 2003;Dutra, Fraga et al., 2014;Eroglu, Yeniel et al., 2006;Finan, Tamim 
et al., 2002;Guerra-Shinohara, Bertinato et al., 2012;Hashimoto, Shizusawa et 
al., 1999;Hohlagschwandtner, Unfried et al., 2003;Ivanov, Komsa-Penkova et 
al., 2009;Karata, Aydin et al., 2012;Kaur, Puri et al., 2013;Kobashi, Kato et al., 
2005;Lino, Traina et al., 2014;Mahjoub, Mtiraoui et al., 2005;Mitic, Kovac et al., 
2010;Mohamed, El Moaty et al., 2010;Mougiou, Androutsopoulos et al., 2008;Mti-
raoui, Borgi et al., 2004;Mukhopadhyay, Saraswathy et al., 2009;Ozdemir, 
Yenicesu et al., 2012;Parand, Zolghadri et al., 2013;Parveen, Shukla et al., 
2013;Pihusch, Buchholz et al., 2001;Poursadegh, Chaparzadeh et al., 2013;Rai, 
Shlebak et al., 2001;Serrano, Lima et al., 2011;Sotiriadis, Vartholomatos et al., 
2007;Sottilotta, Oriana et al., 2006;Yenicesu, Cetin et al., 2010;Yildiz, Yavuzcan et 
al., 2012;Younis, 2000;Yusoff, Abdullah et al., 2002)
Subgroup 
analysis
(Altintas, Pasa et al., 2007;Bagheri, Rad et al., 2011a;Dizon-Townson, Kinney et al., 
1997;Eroglu, Yeniel et al., 2006;Guerra-Shinohara, Bertinato et al., 2012;Hashi-
moto, Shizusawa et al., 1999;Hohlagschwandtner, Unfried et al., 2003;Karata, 
Aydin et al., 2012;Kaur, Puri et al., 2013;Kobashi, Kato et al., 2005;Lino, Traina 
et al., 2014;Mahjoub, Mtiraoui et al., 2005;Mitic, Kovac et al., 2010;Mohamed, El 
Moaty et al., 2010;Mougiou, Androutsopoulos et al., 2008;Mtiraoui, Borgi et al., 
2004;Parand, Zolghadri et al., 2013;Parveen, Shukla et al., 2013;Rai, Shlebak et 
al., 2001;Serrano, Lima et al., 2011;Yildiz, Yavuzcan et al., 2012).
FXIIIa Val34Leu (Bagheri, Rad et al., 2011b;Dossenbach-Glaninger, van et al., 2003;Elmahgoub, 
Afify et al., 2014;Jeddi-Tehrani, Torabi et al., 2010;Lino, Traina et al., 2014;Lopez, 




(Bagheri, Rad et al., 2011b;Elmahgoub, Afify et al., 2014;Lino, Traina et al., 
2014;Lopez, Vivenes et al., 2006)
HLA-G 14bp I/D (Afkhami, Shekari et al., 2014;Aruna, Sirisha et al., 2011;Berger, Hogge et al., 
2010;Christiansen, Kolte et al., 2012;Shankarkumar, Shankarkumar et al., 
2011;Suryanarayana, Rao et al., 2008;Tripathi, Abbas et al., 2004;Vargas, Sarturi 
et al., 2011;Xue, Yang et al., 2007;Yan, Lin et al., 2006;Zhu, Huo et al., 2010)
Subgroup 
analysis
(Christiansen, Kolte et al., 2012;Suryanarayana, Rao et al., 2008;Tripathi, Abbas et 
al., 2004;Vargas, Sarturi et al., 2011).
IFNG 874A/T (Bompeixe, Carvalho Santos et al., 2012;Kamali-Sarvestani, Zolghadri et al., 
2005;Parveen, Shukla et al., 2012;Prigoshin, Tambutti et al., 2004;Zastavna, Sos-
nina et al., 2014)
Subgroup 
analysis
(Kamali-Sarvestani, Zolghadri et al., 2005;Parveen, Shukla et al., 2012;Prigoshin, 
Tambutti et al., 2004)
IL1B -511C/T (Hefler, Tempfer et al., 2002;Kim, Lee et al., 2014;Ma, Xu et al., 2012;Wang, Yunis et 
al., 2002)
IL6 -174G/C (Demirturk, Ates et al., 2014;Parveen, Shukla et al., 2012;Unfried, Bocskor et al., 
2003;von, Bompeixe et al., 2005)
Subgroup 
analysis
(Demirturk, Ates et al., 2014;Parveen, Shukla et al., 2012;Unfried, Bocskor et al., 
2003)
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IL10 -592C/A (Alkhuriji, Alhimaidi et al., 2013;Bahadori, Zarei et al., 2014;Kamali-Sarvestani, 
Zolghadri et al., 2005;Kaur and Kaur, 2011;Parveen, Shukla et al., 2012;Qaddou-
rah, Magdoud et al., 2014;Zastavna, Sosnina et al., 2014)
Subgroup 
analysis
(Alkhuriji, Alhimaidi et al., 2013;Bahadori, Zarei et al., 2014;Kamali-Sarvestani, 
Zolghadri et al., 2005;Parveen, Shukla et al., 2012)
IL10 -819C/T (Bahadori, Zarei et al., 2014;Kamali-Sarvestani, Zolghadri et al., 2005;Parveen, 
Shukla et al., 2012;Qaddourah, Magdoud et al., 2014)
Subgroup 
analysis
(Bahadori, Zarei et al., 2014;Kamali-Sarvestani, Zolghadri et al., 2005;Parveen, 
Shukla et al., 2012)
IL10 -1082A/G (Bahadori, Zarei et al., 2014;Kamali-Sarvestani, Zolghadri et al., 2005;Kim, Lee et 
al., 2014;Parveen, Shukla et al., 2012;Qaddourah, Magdoud et al., 2014;Zastavna, 
Sosnina et al., 2014)
Subgroup 
analysis
(Bahadori, Zarei et al., 2014;Kamali-Sarvestani, Zolghadri et al., 2005;Parveen, 
Shukla et al., 2012)
IL18 -656C/A (Al-Khateeb, Sater et al., 2011;Messaoudi, Dandana et al., 2012)
MTHFR A1298C (Bae, Choi et al., 2009;Dossenbach-Glaninger, van et al., 2003;Hohlagschwandt-
ner, Unfried et al., 2003;Jeddi-Tehrani, Torabi et al., 2011;Lino, Traina et al., 
2014;Mtiraoui, Zammiti et al., 2006;Nair, Khanna et al., 2012;Ozdemir, Yenicesu et 
al., 2012;Parveen, Tuteja et al., 2013;Poursadegh, Chaparzadeh et al., 2012;Sere-
mak-Mrozikiewicz, Drews et al., 2010;Sotiriadis, Vartholomatos et al., 2007;Yenic-
esu, Cetin et al., 2010;Yousefian, Kardi et al., 2014)
Subgroup 
analysis
(Bae, Choi et al., 2009;Hohlagschwandtner, Unfried et al., 2003;Lino, Traina et al., 
2014;Mtiraoui, Zammiti et al., 2006;Parveen, Tuteja et al., 2013;Seremak-Mrozik-
iewicz, Drews et al., 2010;Yousefian, Kardi et al., 2014)
MTHFR C677T (Abu-Asab, Ayesh et al., 2011;Bae, Choi et al., 2009;Biswas, Choudhry et 
al., 2008;Buchholz, Lohse et al., 2003;Creus, Deulofeu et al., 2012;Dossen-
bach-Glaninger, van et al., 2003;Dutra, Fraga et al., 2014;Eroglu, Yeniel et 
al., 2006;Hohlagschwandtner, Unfried et al., 2003;Jeddi-Tehrani, Torabi et 
al., 2011;Karata, Aydin et al., 2012;Kaur, Puri et al., 2013;Kobashi, Kato et al., 
2005;Lino, Traina et al., 2014;Mitic, Kovac et al., 2010;Mohamed, El Moaty et 
al., 2010;Mtiraoui, Zammiti et al., 2006;Nair, Khanna et al., 2012;Ozdemir, 
Yenicesu et al., 2012;Park, Han et al., 2011;Parveen, Tuteja et al., 2013;Pihusch, 
Buchholz et al., 2001;Poursadegh, Chaparzadeh et al., 2012;Puri, Kaur et al., 
2013;Seremak-Mrozikiewicz, Drews et al., 2010;Sotiriadis, Vartholomatos et 
al., 2007;Unfried, Griesmacher et al., 2002;Vettriselvi, Vijayalakshmi et al., 




(Bae, Choi et al., 2009;Creus, Deulofeu et al., 2012;Eroglu, Yeniel et al., 
2006;Hohlagschwandtner, Unfried et al., 2003;Karata, Aydin et al., 2012;Kaur, 
Puri et al., 2013;Kobashi, Kato et al., 2005;Lino, Traina et al., 2014;Mitic, Kovac 
et al., 2010;Mohamed, El Moaty et al., 2010;Mtiraoui, Zammiti et al., 2006;Nair, 
Khanna et al., 2012;Parveen, Tuteja et al., 2013;Poursadegh, Chaparzadeh et al., 
2012;Puri, Kaur et al., 2013;Seremak-Mrozikiewicz, Drews et al., 2010;Unfried, 
Griesmacher et al., 2002;Yildiz, Yavuzcan et al., 2012;Yousefian, Kardi et al., 2014)
NOS3 Glu298Asp (Almawi, Guarino et al., 2013;Dutra, Fraga et al., 2014;Hefler, Tempfer et al., 
2002;Karvela, Papadopoulou et al., 2008;Luo, Li et al., 2013;Parveen, Faridi et al., 
2011;Shin, Lee et al., 2010;Suryanarayana, Rao et al., 2006)
Subgroup 
analysis
(Almawi, Guarino et al., 2013;Hefler, Tempfer et al., 2002;Karvela, Papadopou-
lou et al., 2008;Luo, Li et al., 2013;Parveen, Faridi et al., 2011;Shin, Lee et al., 
2010;Suryanarayana, Rao et al., 2006)




PAI1 -675 4G/5G (Al Sallout and Sharif, 2010;Buchholz, Lohse et al., 2003;Dossenbach-Gla-
ninger, van et al., 2003;Elmahgoub, Afify et al., 2014;Jeddi-Tehrani, Torabi et al., 
2011;Jeon, Kim et al., 2013;Kim, Choi et al., 2014;Lino, Traina et al., 2014;Mag-
doud, Herbepin et al., 2013;Ozdemir, Yenicesu et al., 2012;Parveen, Tuteja et 
al., 2013;Poursadegh, Chaparzadeh et al., 2013;Subrt, Ulcova-Gallova et al., 
2013;Yenicesu, Cetin et al., 2010)
Subgroup 
analysis
(Al Sallout and Sharif, 2010;Elmahgoub, Afify et al., 2014;Kim, Choi et al., 
2014;Lino, Traina et al., 2014;Magdoud, Herbepin et al., 2013;Parveen, Tuteja et 
al., 2013;Subrt, Ulcova-Gallova et al., 2013)
PZ intron F G79A (Al-Shaikh, Sater et al., 2013;Dossenbach-Glaninger, van et al., 2008a;El-Hamid 
and El-Khayat, 2011;Topalidou, Effraimidou et al., 2009)
STAT3 (Finan, Mustafa et al., 2010;Messoudi, Al-Sulaiti et al., 2013)
TNFA -238G/A (Alkhuriji, Alhimaidi et al., 2013;Finan, Al-Irhayim et al., 2010;Gupta, Prakash et 
al., 2012;Lee, Jeon et al., 2013;Liu, Wang et al., 2010)
Subgroup 
analysis
(Alkhuriji, Alhimaidi et al., 2013;Finan, Al-Irhayim et al., 2010;Gupta, Prakash et 
al., 2012)
TNFA -308G/A (Alkhuriji, Alhimaidi et al., 2013;Finan, Al-Irhayim et al., 2010;Gupta, Prakash et 
al., 2012;Kaur and Kaur, 2011;Lee, Jeon et al., 2013;Liu, Wang et al., 2010;Pie-
trowski, Bettendorf et al., 2004)
Subgroup 
analysis
(Alkhuriji, Alhimaidi et al., 2013;Finan, Al-Irhayim et al., 2010;Gupta, Prakash et 
al., 2012;Pietrowski, Bettendorf et al., 2004)
TNFA -1031C/T (Finan, Al-Irhayim et al., 2010;Lee, Jeon et al., 2013)




(Al-Khateeb, Mustafa et al., 2011;Almawi, Saldanha et al., 2013;Li, Donghong et 
al., 2013)
VEGFA 936C/T (Aggarwal, Parveen et al., 2011;Almawi, Saldanha et al., 2013;Eller, Branch et al., 
2011;Lee, Hong et al., 2010;Li, Donghong et al., 2013;Magdoud, Dendana et al., 
2012;Papazoglou, Galazios et al., 2005;Samli, Demir et al., 2012;Traina, Daher et 
al., 2011)
(Aggarwal, Parveen et al., 2011;Almawi, Saldanha et al., 2013;Li, Donghong et 
al., 2013;Magdoud, Dendana et al., 2012;Papazoglou, Galazios et al., 2005;Traina, 
Daher et al., 2011)
VEGFA -1154G/A (Aggarwal, Parveen et al., 2011;Almawi, Saldanha et al., 2013;Eller, Branch et 
al., 2011;Lee, Hong et al., 2010;Li, Donghong et al., 2013;Magdoud, Dendana et 
al., 2012;Papazoglou, Galazios et al., 2005;Samli, Demir et al., 2012;Su, Lin et al., 
2011;Xing, Yan et al., 2011)
Subgroup 
analysis
(Aggarwal, Parveen et al., 2011;Almawi, Saldanha et al., 2013;Li, Donghong et al., 
2013;Magdoud, Dendana et al., 2012;Papazoglou, Galazios et al., 2005;Xing, Yan 
et al., 2011)
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Introduction The cause of recurrent pregnancy loss remains often unknown. Possibly, 
pathophysiological pathways are shared with other pregnancy complications. 
Material and methods All women with secondary recurrent pregnancy loss (SRPL) 
visiting Leiden University Medical Centre (January 2000-2015) were included in this 
retrospective cohort to assess whether women with SRPL have a more complicated first 
pregnancy compared to control women. SRPL was defined as ≥ 3 consecutive pregnancy 
losses before 22 weeks’ gestation, with a previous birth. The control group consisted of 
all Dutch nullipara delivering a singleton (January 2000-2015). Information was obtained 
from the Dutch Perinatal Registry. Outcomes were preeclampsia, preterm birth, post-
term birth, intrauterine growth restriction, breach position, induction of labor, Caesarean 
section, congenital abnormalities, perinatal death and severe hemorrhage in the first 
ongoing pregnancy. Subgroup analyses were performed for women with idiopathic SRPL 
and for women ≤ 35 years.
Results 172 women with SRPL and 1.196.178 control women were included. Women with 
SRPL were older and had a higher BMI; 29.7 years versus 28.8 years and 25.1 versus 24.1, 
respectively. Women with SRPL more often had a post-term birth (OR 1.86 95%CI (1.10-
3.17)) and more perinatal deaths occurred in women with SRPL compared to the control 
group (OR 5.03 95%CI (2.48-10.2)). Similar results were found in both subgroup analyses.
Conclusions The first ongoing pregnancy of women with (idiopathic) SRPL is more often 
complicated by post-term birth and perinatal death. Revealing possible links between 
SRPL and these pregnancy complications might lead to a better understanding of 
underlying pathophysiology. 
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Recurrent pregnancy loss is commonly defined as three or more consecutive pregnancy 
losses before 22 weeks of gestation(1) and affects 0.5-3% of all fertile couples(2) and 
includes intrauterine pregnancy demise confirmed by ultrasound or histology and non- 
visualized pregnancy losses(3). Recurrent pregnancy loss is a heterogeneous condition 
and has many possible etiologic factors: genetic disorders, uterine anomalies, endocrine 
factors, maternal autoimmune disorders, metabolic disorders, maternal thrombophilia, 
obesity and toxic factors, although the percentage of cases without an identifiable 
cause is about 50%(4, 5). Some of these etiologic factors like autoimmune disorders 
and thrombophilia might cause a dysregulation of placental vasculature, which can 
lead to multiple pregnancy complications like miscarriage, pre-eclampsia, fetal growth 
restriction and fetal death(6). 
Approximately 40% of the women with recurrent pregnancy loss have a previous ongoing 
pregnancy and are diagnosed with secondary recurrent pregnancy loss(SRPL)(2). Few 
studies described pregnancy outcome prior to recurrent pregnancy loss with different 
results. One study described that most women did not have obstetric complications(7), a 
higher rate of fetal death was found in some studies(5, 8) and higher rates of preeclampsia(8, 
9), low birth weight, hemorrhage and preterm delivery(8) were described. Knowledge of 
obstetric details regarding the pregnancy prior to the consecutive pregnancy losses may 
contribute to our understanding of the pathophysiology of recurrent pregnancy loss.
This study was performed to assess whether women with SRPL have a more complicated 
first pregnancy compared to control women. 
Material and methods
Study design
All women with SRPL visiting the recurrent miscarriage clinic at Leiden University Medical 
Centre, between January 2000 and January 2015 were identified in this retrospective 
cohort design. SRPL was defined as having ≥ 3 consecutive pregnancy losses before 
22 weeks of gestation (including intrauterine pregnancy demise confirmed by ultrasound 
and non-visualized spontaneous pregnancy losses), with a previous birth ≥ 22 weeks of 
gestation. Women with a previous multiple pregnancy were excluded from the study. 
Information was obtained from medical records.
The control group consisted of all Dutch nullipara delivering a singleton ≥ 22 weeks 
of gestation between January 2000 and January 2015. Data were obtained from the 
Perinatal Registry of the Netherlands(Perined), a nationwide database that covers 
around 96% of all maternal, obstetric and neonatal outcomes in the Netherlands(10). 




The following maternal characteristics were identified at visiting the recurrent 
miscarriage clinic: number of consecutive pregnancy losses, parity before recurrent 
pregnancy loss, presence of late pregnancy loss; defined as having at least one 
miscarriage after 13 weeks of gestation. All women had a routine recurrent pregnancy 
loss work-up to identify possible causes for the recurrent pregnancy loss: a standardized 
history of the couple was performed, karyotyping of the couple (this was offered 
routinely before 2005 to all couples, after 2005 this was only offered in presence of low 
maternal age and/or positive family history for recurrent pregnancy loss(11), presence of 
uterus anomalies by ultrasound or hysteroscopy and presence of acquired and heritable 
thrombophilia. Acquired thrombophilia: Antiphospholipid syndrome was defined as 
the presence of anticardiolipin antibodies or lupus anticoagulant in repeated samples 
taken 3 months apart and at least 10 weeks after a delivery(12), after revision of the 
classification criteria the presence of anti-β2 glycoprotein-I was added to the work-
up(13). Hyperhomocysteinemia was evaluated. Heritable thrombophilia was defined 
by the presence of a factor V Leiden mutation, factor II (prothrombin) gene mutation, 
protein C or S deficiency or antithrombin deficiency. Recurrent pregnancy loss was 
defined as idiopathic when the work-up for causes of recurrent pregnancy loss showed 
no abnormalities.  A sub analysis was performed in women with idiopathic SRPL to 
clarify if the prevalence of pregnancy complications in women with SRPL solely could 
be explained by the presence of known causes for recurrent pregnancy loss or that other 
(unknown) links could be an explanation.  
Maternal age was defined as age at first delivery (index pregnancy). Body mass index 
(BMI) was calculated as weight/ length2, at time of visiting the recurrent miscarriage 
clinic. Smoking was self-reported at time of visiting the recurrent miscarriage clinic. 
Clinical data from the first ongoing pregnancy (prior to the recurrent pregnancy loss) was 
obtained. Preeclampsia was defined as systolic blood pressure above 140 mmHg and/
or diastolic pressure above 90 mmHg combined with proteinuria(14), preterm birth as a 
delivery before 37 weeks of gestation, post-term birth as a delivery ≥ 42 weeks of gestation, 
intra-uterine growth restriction (IUGR) as birth weight below the 10th percentile for 
gestational age and sex according to the Perined birth weight percentiles(15). Information 
about fetal position during labor, induction of labor, delivery by Caesarean section, 
presence of congenital abnormalities and gender of neonate were collected. Perinatal 
death was defined as fetal loss after 22 weeks of gestation till 7 days after birth. Severe 
hemorrhage was defined as ≥ 1000 cc blood loss within 24 hours postpartum. 
Statistical analyses
Data were analyzed using SPSS software version 22.0 (Statistical Package for Social 
Science; SPSS, Chicago, Illinois, USA). Comparisons of normal distributed data were 
performed using independent T- test. Comparisons of categorical data were performed 
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using the X2 test. Odds ratios with 95% confidence intervals were calculated for pregnancy 
outcome variables. For all tests, a p-value < 0.05 is indicated statistical significant. Sub 
analyses were performed for women with idiopathic SRPL and for women who were 
≤ 35 years at their first delivery. 
Ethics
Approval from the medical ethics committee of Leiden University Medical Centre 
(C15.028; March 2, 2015) was obtained. 
Results
A total of 175 women with SRPL were identified. Two women with a multiple pregnancy 
before their pregnancy losses were excluded from analysis. 
Analyzes of recurrent pregnancy loss were described in Table 1. 81.5% of the women 
had only one ongoing pregnancy before their pregnancy losses. In 105 women (60.7%) 
recurrent pregnancy loss was defined as idiopathic. 1.196.178 women were included 
in the control group. Women with SRPL were significantly older and had a higher BMI 
compared to the control group, 29.7 (4.8) years versus 28.8 (4.9) years and 25.1 (4.9) 
versus 24.1 (4.4), respectively (Table 2). Information about smoking during pregnancy 
was not available for the control group. 
Comparisons of pregnancy outcome in the first ongoing pregnancy between women 
with SRPL and the control group were described in Table 3. Women with SRPL more 
often had a post-term birth compared to the control group (OR 1.85 95%CI (1.09-3.15)). 
Significantly more perinatal deaths (N=8) occurred in women with SRPL (4.6%) compared 
to the control group (1.0%), OR 5.00 95%CI (2.46-10.2). Causes of perinatal death were: 
three intrauterine fetal demises (two had a severe IUGR, in one case no cause was found), 
one placental abruption, one spontaneous delivery at 23 weeks’ gestation, two cases 
with multiple congenital abnormalities and one severe meconium aspiration.
For all other pregnancy outcomes (preeclampsia, preterm birth, IUGR, breach position, 
induction of labor, caesarean section, congenital abnormalities, gender and severe 
hemorrhage) no statistically significant differences were found between both groups. 
In the subgroup analysis including only women with idiopathic SRPL (N=105), comparable 
results were found (Table 3); more often post-term birth in women with idiopathic SRPL 
(although not significant: OR 1.83 95%CI (0.92-3.62)) and more perinatal deaths OR 7.37 
95%CI (3.42-15.9) compared to the control group. 
The results of the subgroup analysis including only women who were ≤ 35 years at time of 
first ongoing pregnancy were similar to the results of the total group (Table 4). 




In this study women with SRPL had higher rates of post-term birth and perinatal death 
in their first ongoing pregnancy prior to recurrent pregnancy loss compared to all Dutch 
nullipara.
A strength of the study is that all women followed a well-documented protocol to identify 
possible causes for recurrent pregnancy loss as described in Table 1. Therefore, we could 
perform subgroup analyses including only women with idiopathic SRPL (Table 3) and 
women ≤ 35 years (Table 4), which in both cases, revealed comparable results to the total 
group. Therefore, in this study differences in pregnancy outcome cannot be explained 
by the presence of known causes (such as abnormal karyotyping or acquired/heritable 
thrombophilia) for recurrent pregnancy loss or a higher age. 
Limitations of the study should be acknowledged. For some analyzes our study could be 
underpowered. For example, for the outcome preterm birth we found a non-significant 
difference with an OR of 1.2 in the main analysis including 173 women with SRPL. 
Performing a power analysis learns that, with this number of included women, we could 
detect an OR of 1.8 (incidence in population 7.8%, using a 2-sided test with 80% power at 5% 
significance). Therefore, we cannot exclude any possible small differences in pregnancy 
outcome between SRPL and the control group. Bias could have been introduced because 
we included only women with SRPL visiting the recurrent miscarriage clinic at Leiden 
University Medical Centre, which is a tertiary referral center. It is possible that women 
with adverse pregnancy outcome before their recurrent pregnancy loss were more likely 
to be referred to this center than women who had a first uncomplicated pregnancy. 
 
Four heterogenous studies with respect to study design and outcome examined 
pregnancy outcome prior to SRPL before (5, 7-9), with diverse results. In comparison with 
the other studies we included a relatively large group (Weintraub (matched case-control 
study, N=58)) (9) and Ooi (cohort study N=85) (7), although not the largest; Nielsen 
(cohort study) included 358 women with SRPL (8). The study by Yang et al included 675 
women, however there was no control group (5). To our knowledge this is the first study 
investigating the outcome post-term birth. We found that women with SRPL deliver 
more often post-term in their first pregnancy compared to the control group. In the 
Netherlands women who reach a gestational age of 41 weeks can choose between two 
treatment options; induction at or beyond 41 weeks versus expectant management until 
42 weeks (only in obstetrical low risk women without contra-indications for expectant 
management). A possible link between SRPL and post-term birth may be a prostaglandin 
deficiency. Data from animal studies demonstrate that the primary impulse for the 
initiation of labor arises from the fetal hypothalamo-pituitary-adrenal (HPA) axis. The HPA 
axis stimulates steroid synthesis and prostaglandin production and therefore cervical 
dilation and start of myometrial contractions(16, 17). Relative prostaglandin deficiency 
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has been suggested to exist in several pregnancy complications; preeclampsia, IUGR 
and in early pregnancies of women with a history of recurrent pregnancy losses(18). 
Prostaglandin production increases during full-term labor. No data was found on 
prostaglandin production in post-term pregnancies(18). In spontaneous preterm labor, 
inflammation is suggested to be the main underlying mechanism. Several factors have 
been supposed to start this process; infection, uteroplacental ischemia, and hormonal 
abnormalities (progesterone or corticotropin-releasing hormone related)(17). In contrast 
to our results, a study describes a higher risk of preterm birth in women with SRPL(8). If 
the hypothesis of a relative prostaglandin deficiency is correct, SRPL women with post-
term birth will be the ones who did not have an activation of the HPA axis due to other 
pregnancy complications that causes inflammation and therefore preterm labor. 
Remarkable more perinatal deaths occurred in women with SRPL. Our result is in line 
with the findings by Field et al; women with recurrent miscarriage were more than 
twice as likely to have previous perinatal deaths compared to women without recurrent 
miscarriage(19). Yang et al reported a history of perinatal death in 7.8% of women 
attending a recurrent miscarriage clinic (N=675) (no control group)(5). In both studies, 
no further details are described. Causes of perinatal death varied from intrauterine 
fetal demise, IUGR, placental abruption, preterm birth to congenital abnormalities. 
Independently, preterm birth, IUGR and congenital abnormalities were not elevated 
in women with SRPL compared to the control group. Although, we could have missed 
a small difference in outcome between both groups due to a lack of power. Also in the 
subgroup analyses, including women with idiopathic SRPL and women ≤ 35 years, we 
found significantly higher values of perinatal death. It is not possible to identify one 
common cause or pathway to link recurrent pregnancy loss to the observed pregnancy 
complications. Our findings support the hypothesis that dysregulation of placental 
vasculature could be an underlying pathophysiologic mechanism linking pregnancy 
complications such as miscarriage, IUGR and death(6). Preeclampsia is also mentioned 
in this hypothesis; however we did not find an increased risk of preeclampsia in the first 
ongoing pregnancy for women with SRPL, in contrast to the (larger) studies of Weintraub 
and Nielsen(8, 9). Shared maternal risk factors for recurrent pregnancy loss and still birth, 
the single major determinant of perinatal death, are; maternal age ≥ 40 years, smoking, 
obesity and diabetes mellitus(20). An association between increasing maternal BMI and 
post-term birth has also been described(21), although the mechanisms are not fully 
understood. Mechanical and hormonal interactions between mother, fetus and placenta 
are involved in the onset of labor. Women with obesity have increased inflammation, 
circulating leptin concentrations, insulin resistance, lipolysis and dyslipidemia. It has 
been hypothesized that these metabolic abnormalities influence the onset of labor and 
uterine contractility(22), possibly via previous mentioned HPA axis(23). In our study 
women with SRPL had a significantly higher BMI compared to all Dutch women, 25.1(4.9) 
versus 24.1(4.4) p<0.01, respectively, so this could have affected the pregnancy outcome. 
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Since BMI was not available in the Perinatal Registry we used data on BMI from the 
Statistics Netherlands(CBS). As only aggregated data was available, it was not possible to 
perform a subgroup analysis for women with elevated BMI.  9.4% of the women with SRPL 
reported to smoke at time of visiting the recurrent miscarriage clinic. Smoking was not 
adequately monitored in the Perinatal Registry for the years 2000-2015. However, a large 
Dutch study identified approximately 13% of women smoked during their pregnancy 
in 2001, this prevalence dropped to 6.3% in 2010(24). We cannot specify the impact of 
smoking behavior on the pregnancy outcome as it is unknown how many of the SRPL 
women were smoking during their first pregnancy. Possibly women stopped smoking 
after their adverse pregnancy outcome. 
In conclusion, the first ongoing pregnancy of women with (idiopathic) SRPL is more often 
complicated by post-term birth and perinatal death. More research (epidemiological and 
basic, including larger groups) is needed to reveal possible links between SRPL and these 
pregnancy complications as this might lead to a better understanding of the underlying 
pathophysiology.
Table 1. Analyzes of women with secondary recurrent pregnancy loss
Secondary recurrent pregnancy loss
N=173
Number of consecutive pregnancy loss median (min-max) 4.00 (3-18)
 3 (%) 78 (45.1)
 4 (%) 54 (31.2)
 >4 (%) 41 (23.7)
Parity before recurrent pregnancy loss median (min-max) 1.00 (1-3)
 1 (%) 141 (81.5)
 2 (%) 27 (15.6)
 >2 (%) 5 (2.9)
Late miscarriage (%) 24 (13.9)
Abnormal parental karyotyping (%) 2 (1.2)             Missing 21
Uterus anomaly (%) 3 (1.7)
Anti-phospholipid syndrome (%) 10 (5.8)           Missing 3
Hyperhomocysteinemia (%) 12 (6.9)           Missing 7
Heritable thrombophilia (%) 27 (15.6)         Missing 3
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Maternal agea Mean (SD)
29.7 (4.8) 29.1 (4.7) 28.8 (4.9) 0.02b
0.53c
 Missing (%) 15 (8.7) 8 (7.7) -
BMI Mean (SD)
25.1 (4.9) 25.4 (5.2) 24.1 (4.4)d <0.01b
<0.01c
 Missing (%) 26 (15.1) 17 (16.2) n/a
Smoking (%) 16 (9.2) 8 (7.6)
n/a
n/a
 Missing (%) 1 (0.6) -
BMI: body mass index, n/a: not available
a at first delivery
b comparison between secondary recurrent pregnancy loss and control group
c comparison between idiopathic recurrent pregnancy loss and control group
d women 20-45 years between 2000-2015 (Statistics Netherlands/ National Institute for Public Health and the Environment 
2017)
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Preeclampsia (%) 5 (2.9) 4 (3.8) 42770 (3.7)
OR(95%CI) 0.79 (0.32-1.92) 1.05 (0.38-2.84) 1
Missing (%) 1 (0.6) - 25145 (2.1)
Preterm birth (%) 16 (9.2) 12 (11.4) 92589 (7.8)
OR(95%CI) 1.20 (0.72-2.01) 1.52 (0.83-2.78) 1
Missing (%) - - 11866 (1.0)
Post-term birth (%) 15 (8.7) 9 (8.6) 57745 (4.8)
OR(95%CI) 1.85 (1.09-3.15) 1.83 (0.92-3.62) 1
Missing (%) - - 11866 (1.0)
Intra uterine growth restriction (%) 16 (9.6) 9 (8.8) 107751 (9.1)
OR(95%CI) 1.06 (0.64-1.79) 0.97 (0.49-1.92) 1
Missing (%) 7 (4.1) 3 (2.9) 11780 (1.0)
Breach (%) 11 (6.4) 7 (6.7) 70362 (6.0)
OR(95%CI) 1.07 (0.58-1.96) 1.12 (0.52-2.41) 1
Missing (%) - - 21705 (1.8)
Induction of labor (%) 21 (15.2) 16 (19.3) 205683 (17.3)
OR(95%CI) 0.86 (0.54-1.37) 1.15 (0.66-1.98) 1
Missing (%) 35 (20.2) 22 (21.0) 4570 (0.4)
Caesarean section (%) 25 (14.5) 17 (16.2) 207638 (17.4)
OR(95%CI) 0.80 (0.53-1.23) 0.92 (0.55-1.54) 1
Missing (%) - - 2741 (0.2)
Congenital abnormalities (%) 6 (3.5) 4 (3.8) 34040 (2.8)
OR(95%CI) 1.23 (0.54-2.77) 1.35 (0.50-3.67) 1
Missing (%) - - -
Neonate gender -male (%) 90 (52.3) 55 (52.4) 614781 (51.4)
OR(95%CI) 1.01 (0.75-1.37) 1.00 (0.68-1.47) 1
Missing (%) 1 (0.6) - 693 (0.1)
Perinatal death (%) 8 (4.6) 7 (6.7) 11482 (1.0)
OR(95%CI) 5.00 (2.46-10.2) 7.37 (3.42-15.9) 1
Missing (%) - - -
Severe hemorrhage (%) 9 (5.3) 8 (7.8) 67585 (5.8)
OR(95%CI) 0.90 (0.46-1.76) 1.35 (0.66-2.77) 1
Missing (%) 3 (1.7) 2 (1.9) 36009 (3.0)
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Preeclampsia (%) 3 (2.1) 38037 (3.5)
OR(95%CI) 0.59 (0.19-1.84) 1
Missing (%) 1 (0.7) 22455 (2.1)
Preterm birth (%) 15 (10.5) 84025 (7.8)
OR(95%CI) 1.39 (0.82-2.38) 1
Missing (%) - 10305 (0.9)
Post-term birth (%) 13 (9.1) 51676 (4.8)
OR(95%CI) 1.99 (1.13-3.53) 1
Missing (%) - 10305 (0.9)
Intra uterine growth restriction (%) 14 (9.8) 96788 (8.9)
OR(95%CI) 1.16 (0.67 -2.02) 1
Missing (%) 6 (4.2) 10211 (0.9)
Breach (%) 10 (7.0) 62964 (5.9)
OR(95%CI) 1.21 (0.64 – 2.30) 1
Missing (%) - 19077 (1.7)
Induction of labor (%) 14 (12.7) 184184 (16.9)
OR(95%CI) 0.68 (0.39-1.19) 1
Missing (%) 28 (19.6) 4043 (0.4)
Caesarean section (%) 21 (14.7) 179684 (16.5)
OR(95%CI) 0.87 (0.55-1.39) 1
Missing (%) - 2562 (0.2)
Congenital abnormalities (%) 5 (3.5) 30646 (2.8)
OR(95%CI) 1.26 (0.52-3.07) 1
Missing (%) - -
Neonate gender -male (%) 75 (52.4) 562246 (51.4)
OR(95%CI) 1.06 (0.76-1.47) 1
Missing (%) 1 (0.7) 631 (0.1)
Perinatal death (%) 8 (5.6) 10156 (0.9)
OR(95%CI) 6.33 (3.10-12.9) 1
Missing (%) - -
Severe hemorrhage (%) 7 (4.9) 60189 (5.7)
OR(95%CI) 0.87 (0.41-1.86) 1
Missing (%) 3 (2.1) 31797 (2.9)
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In this thesis, several studies are presented examining the association between recurrent 
miscarriage and cardiovascular disease. Main aim of this thesis was to assess whether 
miscarriages are independently associated with an increased risk of cardiovascular 
disease later in life. And, if this was true, to identify cardiovascular risk factors and predict 
long term cardiovascular disease risk in women with a history of recurrent miscarriage. 
We found an increased risk of ischemic heart disease in women with a history of two 
(multivariate analysis HR 1.82) and three or more miscarriages (HR 3.18), irrespective 
whether consecutive or not (chapter 2). Women with a history of recurrent miscarriage 
have significantly higher 10- and 30-year cardiovascular risk scores compared to women 
with a history of no miscarriage. These results indicate an opportunity for the early 
identification of women prone to cardiovascular disease later in life. Women with a history 
of two or more miscarriages must be made aware of their increased cardiovascular risk 
and appropriate risk factor modifications will have to be offered, for example life style 
advises; weight management and smoking control. 
In this chapter, I give an interpretation of the findings of the studies described in the 
previous chapters and propose remaining questions. Suggestions for clinical imple-
mentation and future research will be discussed.
(Recurrent) miscarriage; a new cardiovascular risk factor 
Studies regarding novel cardiovascular risk factors, including pregnancy complications 
such as (recurrent) miscarriage are hampered by the nature of the events in question. 
The events during pregnancy and the development of cardiovascular disease are often 
separated by decades and observational studies are the best used method to increase our 
understanding of these novel risk factors. We performed a large cohort study (including 
60105 women with a median follow-up of 17 years) and demonstrated an association 
between miscarriage and ischemic heart disease (chapter 2), independent of classical 
cardiovascular disease risk factors (maternal age, BMI, social class and smoking). The 
association between both events was already clinically relevant from 2 miscarriages 
onwards (multivariate analysis HR 1.82 (95%CI 1.30 to 2.54)). The risk for cardiovascular 
disease increases with increasing number of miscarriages and was, surprisingly, 
independent of the consecutive nature of the miscarriages. Our research is in line with a 
large Danish cohort study of 1 million women, which found a dose-dependent association 
between miscarriage and future risk of ischemic heart disease and other atherosclerotic 
endpoints [1]. Overall, at present, several studies have established that (recurrent) 
miscarriage is associated with ischemic heart disease in the future and possibly other 
cardiovascular outcomes ([1-4] chapter 2). 
There are two challenges, which I will discuss in the next paragraphs. Firstly, trying to 
understand the underlying mechanisms for the association between recurrent mis-
carriage and cardiovascular disease. This might also contribute to our knowledge of 
the aetiology of recurrent miscarriage, of which the cause often remains unknown. And 




secondly, how to incorporate (recurrent) miscarriage as a new risk factor in the algorithm 
for future cardiovascular disease, especially since novel risk factors for cardiovascular 
disease are rising.
Mechanisms possible involved in the association between recurrent miscarriage and 
cardiovascular disease
Many underlying mechanisms for the association between recurrent miscarriage and 
cardiovascular disease are hypothesized. The following mechanisms will be discussed; 
endothelial dysfunction, shared classic cardiovascular risk factors, antiphospholipid 
syndrome and immunologic disbalance, genetics and novel cardiovascular biomarkers. 
Finally, the relation between recurrent miscarriage, other pregnancy complications and 
cardiovascular disease will be discussed. 
Endothelial dysfunction
A unifying mechanism between recurrent miscarriage and cardiovascular disease could 
be the presence of endothelial dysfunction. Endothelial cells form the inner surface of 
blood vessels and have many important regulatory functions in the cardiovascular system 
such as vasoconstriction and dilatation. Healthy endothelium also has anti-thrombotic 
(through prostacyclin’s), anti-inflammatory (through developmental endothelial locus-1) 
and anti-proliferative (through nitric oxide and prostaglandin I2) functions [5] [6]. 
Figure 1. Endothelial dysfunction and Cardiovascular disease. Based on [11]
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In normal pregnancies, maternal uterine arteries are remodelled to create a high-flow, 
low-resistance uteroplacental vascular system that provides adequate blood flow needed 
for fetal growth[7]. Placentation starts in the first trimester of pregnancy. The needed 
invasion of extra villous trophoblasts into the uterine spiral arteries could be impaired 
by endothelial dysfunction. Dysregulation of the placental vasculature is thought to be 
the pathophysiologic mechanism leading to multiple pregnancy complications such 
as miscarriage, preeclampsia, intrauterine growth restriction, and perinatal death[8]. 
Further, endothelial dysfunction is the initial step in the pathogenesis of atherosclerosis. 
[9, 10] leading to cardiovascular disease events (Figure 1). 
In conclusion endothelial dysfunction is a plausible explanation for the association 
between miscarriage and cardiovascular disease. It is likely that the endothelium is 
already damaged before the miscarriages, caused by diverse maternal predisposing 
factors. Possibly the pregnancy itself leads to endothelium damage (second hit), or it 
is a combination of both.  Underlying maternal factors associated with endothelial dys-
function will be discussed in more detail. 
Classic cardiovascular risk factors
Classic cardiovascular risk factors include age, obesity, hypertension, smoking, 
dyslipidaemia, and diabetes. Cardiovascular disease risk factors adversely affect a diverse 
range of endothelial homeostatic functions (under influence of environmental and genetic 
factors) resulting in endothelial dysfunction (Figure 1) which can lead to both recurrent 
miscarriage and cardiovascular disease. A remarkable higher prevalence of pre-existing 
hypertension and pre-existing diseases of circulatory system was found in women with 
miscarriages (dose-dependent) (chapter 2). All women with pre-existing morbidity related 
to cardiovascular disease (hypertension, type one diabetes mellitus, kidney disease and 
any disease of circulatory system) were excluded from main analysis. The association 
between miscarriages and future cardiovascular disease was independent of classical 
cardiovascular risk factors such as age, BMI, social class and smoking.
In chapter 3 we determined classical cardiovascular risk factors and calculated cardio-
vascular disease risk in women after recurrent miscarriage (mean follow-up 7.5 years) and 
found an increased (extrapolated) 10 and 30-year cardiovascular disease risk compared 
to women with no miscarriage, calculated by Framingham risk scores. We are not able to 
answer the question on causal effect as we were only able to look at cardiovascular risk 
factors in women after they experienced recurrent miscarriage. 
The high number of women who smoked in the recurrent miscarriage group was remark-
able. Women with recurrent miscarriage were more often smokers during at least one 
pregnancy (38.9%) compared to women with no miscarriage (13.9%), p=0.05. Active 
smoking is a known risk factor for recurrent miscarriage; a meta-analysis describes an 
increased risk of miscarriage (risk ratio 1.23, 95% CI 1.16-1.30) [12]. It is hypothesized that 
the vasoconstrictive and anti-metabolic properties of some components of cigarette 




smoke (nicotine, carbon monoxide, cyanide) could lead to placental insufficiency and 
embryonic and fetal growth restriction and demise, other studies suggest that smoking 
results in an increase of mature oocytes leading to miscarriages [13]. Smoking was still 
more common in women with a history of recurrent miscarriage at time of follow-up 
(chapter 3) although not significant. Also, other values of classical cardiovascular risk 
factors were higher in women with recurrent miscarriage compared to no miscarriage, 
although only significant for systolic blood pressure. A lack of power is likely when 
investigating the individual risk factors as our preliminary sample size analysis was 
based on the Framingham risk score. It would be interesting to investigate the individual 
risk factors in a larger study group, and perform multivariate analyses as well, to answer 
the question which risk factors are contributing the most to the elevated cardiovascular 
risk score in women with a history of recurrent miscarriage. 
In conclusion, women with recurrent miscarriage seem to have a higher prevalence of 
classical cardiovascular risk factors before, and after their miscarriages. However, this 
is not the overall explanation for the association between miscarriages and future 
cardiovascular disease, as the association was found to be independent of classical 
cardiovascular risk factors such as age, BMI, social class and smoking (chapter 2).
Antiphospholipid syndrome and immunology
Acquired thrombophilia (antiphospholipid syndrome) is clearly related to recurrent 
miscarriage as well as cardiovascular disease. Antiphospholipid syndrome is an 
autoimmune disorder characterized by the occurrence of venous and arterial thrombosis 
and pregnancy complications (such as recurrent miscarriage and early preeclampsia), in 
the presence of antiphospholipid antibodies. Women with antiphospholipid syndrome 
are at increased risk for accelerated atherosclerosis and cardiovascular disease events 
[14]. The exact mechanisms by which the antibodies cause these morbidity is not fully 
understood. It is suggested that endothelial cells play a central role and represent 
the common pathway between autoimmunity and inflammation in the pathogenesis 
of antiphospholipid syndrome. Circulating antibodies and underlying endothelial 
dysfunction are a necessary ‘first hit’ for the development of thrombosis, pregnancy 
complications and cardiovascular disease, an inflammatory ‘second hit’ by up-regulation 
of β2-glycoprotein (an apolipoprotein, member of the complement control family, 
considered to be a natural inhibitor of coagulation) receptors is needed to precipitate the 
thrombotic event [14]. These inflammatory factors may include infection, immunological 
and other non-immunological procoagulant factors, such as oestrogen-containing 
contraceptive pills, surgery and immobility [15]. 
Acquired thrombophilia is included in the work-up of recurrent miscarriage to iden-
tify any causes. Together with: a standardized history of the couple, evaluation of 
hyperhomocysteinemia, heritable thrombophilia, karyotyping of the couple and 
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checking the presence of uterus anomalies by ultrasound or hysteroscopy. If no 
abnormalities are found; a woman is diagnosed with idiopathic recurrent miscarriage. 
In contrast to the large cohort study described in chapter 2, information about causes 
of recurrent miscarriage was available in our follow-up study in cardiovascular disease 
risk (chapter 3). We performed a subgroup analysis including women with idiopathic 
recurrent miscarriage which showed comparable results to the results of the total 
group. The calculated risk scores were even slightly higher in women with idiopathic 
recurrent miscarriage. Therefore, in our study, the increased cardiovascular disease 
risk scores in women with recurrent miscarriage cannot be explained by the presence 
of antiphospholipid syndrome. Recently, the first case control study regarding the 
association between pregnancy loss and premature arterial thrombosis, which adjusted 
for both classic cardiovascular risk factors and the presence of antiphospholipid 
antibodies, was published [16]. An increased risk of arterial thrombosis, independent of the 
presence of antiphospholipid syndrome, was found in women with ≥ 3 pregnancy losses 
(miscarriage and stillbirth together), OR 1.95, (95%CI 0.92–4.14). However, it cannot be 
excluded that other immunological factors will play a role. The maternal immune system 
plays an important role in the success of pregnancy, optimal regulation is essential to 
tolerate the allogeneic foetus. As in more than 50% of the cases the cause of recurrent 
miscarriage remains unknown, it is thought that maladaptation of the maternal immune 
system could explain part of its pathophysiology. Research shows that in specific cases 
immunotherapy might benefit pregnancy outcome, although there is no clear evidence 
yet [17]. On the other hand the activation of the immune system plays a significant role in 
the pathogenesis of atherosclerosis and other cardiovascular diseases[18]. This possible 
link between recurrent miscarriage and cardiovascular disease has not been further 
elaborated in this thesis, but it is an interesting starting point for future research. Vitamin 
D, that could act as an immune regulator during implantation will be discussed later in 
this chapter (subheading: novel cardiovascular biomarkers). 
Genetic link
A shared genetic background could be a link between recurrent miscarriage and 
cardiovascular disease. Both diseases have a familial aggregation[19, 20]. The degree of 
endothelial damage (leading to both conditions) may be in part, related to intrinsic and 
environmental factors such as genetic polymorphisms (Figure 1 [11]).  We were not able 
to confirm this hypothesis in our matched case-control study concerning family history 
of premature cardiovascular disease in chapter 5; no increased prevalence was found in 
women with recurrent miscarriage. In chapter 6 our findings do suggest shared genetic 
risk factors between recurrent miscarriage and cardiovascular disease. Several of the 16 
genetic variants which remained significantly associated with recurrent miscarriage after 
meta-analysis, are also identified as risk factors for cardiovascular disease.
A higher prevalence of family history of ischemic heart disease and other atherosclerotic 




disease (not premature) in women with recurrent miscarriage was found in two other, 
large cohort, studies [21, 22]. Limitations of our study are the relatively small number of 
included women with recurrent miscarriage (N=103) and the lack of information about 
the age of their parents. Some parents will not have reached the age of 60 years at time 
of questionnaire and are still at risk to develop premature myocardial infarction and/or 
stroke. In the same study (chapter 5) we find that women with recurrent miscarriage had 
more often hypertension at time of questionnaire. It was interesting to see this reflected 
in family history of hypertension as well, which seems more often present in women with 
recurrent miscarriage: OR 1.71 (95%CI 0.94-3.11). Based on our results we cannot rule out 
a shared genetic background between both conditions, and we conclude that the design 
of our research probably is not the best to investigate our hypothesis.
In chapter 6 genetic variants associated with recurrent miscarriage are described of 
which several, are also identified as risk factors for cardiovascular disease. Most of them 
are involved in pathways concerning coagulation and fibrinolysis; factor II (prothrombin), 
factor V Leiden, FXIIIa Val34Leu, MTHFR A1298C, MTHFR C677T and PAI1 -675 4G/5G 
polymorphism [23-25], and NOS3 Glu298Asp polymorphism [26] is involved in oxidative 
stress and plays a crucial role in regulating endothelial function [27]. 
Heritable thrombophilia (defined by the presence of a factor II (prothrombin) gene 
mutation, factor V Leiden mutation, protein C or S deficiency or antithrombin deficiency) 
has been an important topic of research in women with recurrent miscarriage for years. 
It is included in the work-up to identify possible causes of recurrent miscarriage. A strong 
association exists between heritable thrombophilia and venous thrombosis[28]. Several 
meta-analyses have reported an increased risk of recurrent miscarriage in women with 
heritable thrombophilia; however, heterogeneity between studies is significant and the 
definition of recurrent miscarriage limits firm conclusions[29, 30]. Overall, heritable 
thrombophilia appears to be only a weak contributor to recurrent miscarriage (and 
therefore as well to the association between recurrent miscarriage and cardiovascular 
disease). In line with this is, at first; the lack of association between a family history of 
venous thrombosis and recurrent miscarriage (chapter 5) [21]. And second, the result of 
a meta-analysis of randomized controlled trials (including eight trials and 483 patients); 
no increased live birth rate was found with the use of low-molecular-weight heparin in 
women with recurrent miscarriage and heritable thrombophilia[31]. Suggesting no benefit 
of low-molecular-weight heparin in preventing recurrent miscarriage in women with 
inherited thrombophilia. Perhaps, the ongoing study; the Alife2 study, which is evaluating 
the efficacy of low-molecular-weight heparin on pregnancy outcome, in women (aged 18-
42) with heritable thrombophilia and a history of two or more miscarriage and/or intra-
uterine fetal death, adds information to this discussion in the future. 
MTHFR A1298C and MTHFR C677T polymorphisms reduce the activity of the MTHFR 
enzyme, causing elevated concentration of homocysteine. Hyperhomocysteinemia is 
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related to recurrent miscarriage [32] and increases risk of cardiovascular disease. Despite 
this, we found lower values of homocysteine in women with a history of recurrent 
miscarriage compared to women with no miscarriage, which could be a confounding 
effect of the folate and vitamin B supplementation in the recurrent miscarriage group as 
described in chapter 4. 
Meanwhile many new studies have been conducted regarding the association between 
genetic polymorphisms and recurrent miscarriage. Therefore, it could be helpful to 
repeat meta-analysis with newly added studies to find possible new involved pathways 
in the aetiology of recurrent miscarriage and their relationship with future cardiovascular 
disease. And moreover, genetic and more in depth genetic studies such as epigenetics in 
families with a heavy burden of both miscarriage and cardiovascular disease could help 
to identify a likely (possibly immunological) link between the two conditions, which could 
potentially lead to a better understanding of the underlying pathology and possibly new 
treatment options. 
Novel cardiovascular biomarkers
In chapter 4 we focused on non- classical cardiovascular risk factors, the so called novel 
cardiovascular biomarkers, in women with recurrent miscarriage as knowledge about 
these markers might contribute to a better understanding of the association between 
recurrent miscarriage and cardiovascular disease. We found that women with recurrent 
miscarriage had significantly higher values of HsCRP and lower values of albumin 
and vitamin D compared to women with no miscarriage at time of follow-up. These 
cardiovascular biomarkers are involved in mechanisms regarding inflammation; indicating 
a proinflammatory state in women with recurrent miscarriage and will adversely affect a 
diverse range of endothelial homeostatic functions (Figure 1). No differences were found 
in more specific cardiovascular biomarkers, for example regarding renal function and 
myocardial damage. 
Especially the decreased concentration of vitamin D is interesting. Vitamin D is inversely 
associated with cardiovascular disease risk [33] via several mechanisms; increased 
inflammation, endothelial dysfunction, elevated blood pressure, decreased insulin 
sensitivity and secretion, arterial stiffness and degradation of atherosclerotic plaque 
[34]. Over the last decade, the role of vitamin D in human reproduction has been increa-
singly considered as important. Adverse outcomes linked to vitamin D insufficiency 
in pregnancy includes pre-eclampsia, gestational diabetes, small-for-gestational 
age and preterm birth [35-37]. Many potential underlying mechanisms of vitamin D in 
regulating each of the outcomes are hypothesized, including that vitamin D could act 
as an immune regulator during implantation [38]. Research showed that trophoblasts 
produce and response to vitamin D in early pregnancy [39, 40]. Furthermore, it has been 
established that vitamin D influences local anti-inflammatory responses (via inhibition 
of TNF-alpha-induced inflammatory cytokines) and induces decidualization for success-




ful pregnancy[41-43]. We assessed vitamin D levels only at follow-up. In addition, it is 
possible that women with recurrent miscarriage already have decreased values of 
vitamin D during and/or before pregnancy. Only one study assessed vitamin D levels and 
immunological implications, such as presence of several autoantibodies and cytokine 
production, in women with recurrent miscarriage and found that a high proportion of 
women had a vitamin D deficiency (<30 ng/ml) with immunological implications [44]. 
With this knowledge, supplementation of vitamin D might be a potential treatment in 
women with recurrent miscarriage. At first, there is need for more observational studies 
to investigate the association between vitamin D and recurrent miscarriage (adjusting 
for ethnicity and seasonal variations). And secondly, if an association is established, 
intervention studies (randomized controlled trials) are needed to evaluate the effect of 
vitamin D supplementation on pregnancy outcome in women with recurrent miscarriage. 
Next to a possible treatment option in women with recurrent miscarriage, vitamin D 
might be useful in cardiovascular risk estimation. Vitamin D deficiency is a strong risk 
marker for cardiovascular disease[45]. In the prevention of cardiovascular disease, no 
significant and consistent protective effect of vitamin D supplementation was found in 
randomized controlled trials.
Recurrent miscarriage, other pregnancy complications and cardiovascular disease
In chapter 7 we investigated whether women with secondary recurrent miscarriage had 
a more complicated first pregnancy compared to all Dutch nullipara. Approximately 
40% of the women with recurrent miscarriage have a previous ongoing pregnancy and 
are as a consequence diagnosed with secondary recurrent miscarriage [46]. We found 
that women with secondary recurrent miscarriage had higher rates of post-term birth 
and perinatal death in their first ongoing pregnancy preceding recurrent miscarriage. 
Causes of perinatal death varied from intrauterine fetal demise, intrauterine growth 
restriction, placental abruption, preterm birth to congenital abnormalities. The higher 
rate of perinatal death supports the hypothesis that placental vasculopathy is an 
underlying pathophysiologic mechanism linking an array of pregnancy complications 
[8, 47]. Preeclampsia is also mentioned in this hypothesis; however, we did not find an 
increased risk of preeclampsia in the first ongoing pregnancy for women with secondary 
recurrent miscarriage, in contrast to the (larger) studies of Weintraub and Nielsen[48, 
49]. Shared maternal risk factors for recurrent miscarriage and still birth, the single 
major determinant of perinatal death, are; maternal age ≥ 40 years, smoking, obesity and 
diabetes mellitus [50]. An association between increasing maternal BMI and post-term 
birth has also been described [51], although the mechanisms are not fully understood. 
These common risk factors are also (classical) risk factors for developing cardiovascular 
disease[52], contributing to endothelial dysfunction and linking recurrent miscarriage to 
cardiovascular disease.
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In sum, (recurrent) miscarriage and cardiovascular disease are both diseases with a 
multifactorial aetiology. Previous mentioned mechanisms are involved in the association 
between both diseases. Although none of them gives a clear explanation on its own, and 
the contribution of the described mechanisms seems present but not substantial. It is 
supposed that a unifying mechanism between recurrent miscarriage and cardiovascular 
disease is the presence of endothelial dysfunction. Described mechanisms of shared 
classic cardiovascular risk factors, antiphospholipid syndrome, genetic polymorphisms 
and novel cardiovascular biomarkers involved in inflammation all contribute to this 
phenomenon. Genetic and immunologic etiology need further elucidation. 
It remains unknown if women with recurrent miscarriage have an increased cardiovascular 
disease risk due to pre-existing common risk factors, due to the complicated preg-
nancies that leads to permanent (endothelial) damage, or, perhaps the most likely; 
a combination of these two (second hit) as illustrated in figure 2. For preeclampsia, in 
which the association with cardiovascular disease is well investigated, this discussion is 
still ongoing.  
Figure 2. Incorporate (recurrent) miscarriage as a new risk factor in the algorithm for future 
cardiovascular disease




Definition of recurrent miscarriage
The variation in the definition of recurrent miscarriage, between two and three and 
consecutive versus non-consecutive miscarriages [53, 54] complicates the incorporation 
of recurrent miscarriage as a new risk factor for cardiovascular disease. Also, there 
is disagreement on gestational age at time of miscarriage; early or late, and whether 
detection of fetal heart activity by ultrasound is obliged or biochemical pregnancies 
are included as well. Generally, in the international literature, recurrent miscarriage is 
defined as three or more consecutive pregnancy losses before 22 weeks of gestation[55]. 
For this reason, we have chosen this definition setting up our research protocols. In the 
Netherlands, a woman is diagnosed with recurrent miscarriage after two pregnancy 
losses before 20 weeks of gestation, irrespective whether consecutive or not [53].  
As this lack of consensus makes it difficult to compare study results between different 
centres, the ESHRE special interest group early pregnancy, published a consensus 
statement in 2015, during the writing of this thesis[54]. They recommend the term 
recurrent pregnancy loss be used to describe repeated pregnancy demise, and the 
term recurrent miscarriage be used when all pregnancy losses have been confirmed as 
intrauterine miscarriages, by ultrasound or histology.  For this reason, we changed the 
term recurrent miscarriage into recurrent pregnancy loss in chapter 7, according to the 
comments of the reviewers, as we included also non-visualized miscarriages. In future 
research we recommend using this terminology as well [54]. In this thesis, we kept to our 
predefined definition and terminology of recurrent miscarriage. 
Probably we should make a distinction between the most useful definition of recurrent 
miscarriage regarding aetiology and subsequent pregnancy prognosis on the one hand, 
and the most useful definition to point out a woman at future risk for cardiovascular 
disease on the other hand. In this thesis, we focus on the last mentioned. The results 
in chapter 2 showed that women who have experienced two or more miscarriages, 
irrespective of whether consecutive or not, have an increased risk of ischemic heart 
disease. In subgroup analysis, the risk for ischemic heart disease was lower in women 
with consecutive miscarriages compared to women with two or more non-consecutive 
miscarriages. This suggests that the number of events (two or more) is more important 
than the consecutive nature of events. 
Current guidelines
Given the world-wide health problem of cardiovascular disease in women, and its 
economic implications there is a strong rationale for the prevention of cardiovascular 
disease in women. More gender specific analyses have been published making it possible 
to do more definitive recommendations [52], Wilson and Jonner set up ten criteria to 
determine the suitability for establishing screening programs including for example; the 
condition should be an important health problem, there should be an accepted treatment 
recognized for the disease and diagnosis and treatment should be cost-effective [56]. 
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In recent years, pregnancy complications are incorporated in guidelines as novel risk 
factors for cardiovascular disease in women. The 2011 guidelines for the prevention 
of cardiovascular disease of The American Heart Association indicate a history of 
gestational diabetes or hypertensive complications of pregnancy as a major risk factor 
for developing cardiovascular disease and advises monitoring and control of risk factors 
in these women postpartum [52]. In 2014, the first Dutch guideline on cardiovascular risk 
management after reproductive and pregnancy-related disorders was published [57]. 
This guideline states no increased risk for ischemic heart disease in women with recurrent 
miscarriage, RR1.99 (95%CI 0.94,4.19). However, only 3 cohort studies were included 
(up to 2012) and several studies were published afterwards, including a meta-analysis 
which found a significant increased risk (chapter 2) [1-4]. Optimization of modifiable 
cardiovascular risk factors, by giving lifestyle advices, is recommended to reduce the risk 
of future cardiovascular disease for all reproductive and pregnancy-related disorders 
mentioned in this guideline. Follow-up is only recommended for women with a history 
of preeclampsia, (relative risk CVD; 2.15 (95%CI 1.76–2.61). This includes that at the age 
of 50 years, women are offered a full cardiovascular risk profile performed according 
to the Dutch guideline for cardiovascular risk management. The most recent European 
Guidelines on cardiovascular disease prevention (2016) states that there is no data to 
suggest that recurrent pregnancy loss is associated with an increased cardiovascular 
disease risk [58]. They recommend that periodic screening (not further specified) for 
hypertension and diabetes mellitus should be considered in women with gestational 
diabetes and hypertensive complications of pregnancy.
Recently published data, including this thesis, suggest it is time to update these 
mentioned guidelines. As the hazard ratio for ischemic heart disease in women with two 
or more miscarriages is comparable with the hazard ratio for cardiovascular disease in 
women with hypertensive disorders of pregnancy [59] an equal approach for women 
with two or more miscarriages seems justified and I recommend to add a history of two 
or more miscarriage to the risk factors for cardiovascular disease.
Future perspectives 
The important and growing field of the utilization of big data analysis in healthcare is very 
interesting. In the future, the increased use of statistical machine learning techniques 
will probably help us to interpret all variables involved in the association between 
two heterogeneous conditions such as miscarriage and cardiovascular disease. It may 
be helpful in teasing out subtle information from observational datasets and provide 
reliable interpretations for individualizing care decisions and personalized medicine.
With current knowledge, women with two or more miscarriage should be made aware 
of an increased cardiovascular risk and advised lifestyle advises including discontinuing 
smoking, improving dietary habits, healthy weight and adequate physical exercise 




(reducing endothelial damage) to prevent cardiovascular disease events. Appropriate 
risk factor modifications can lower their risk for future cardiovascular disease. In women 
with a history of preeclampsia estimates showed that lifestyle interventions after this 
pregnancy complication have the potential to decrease cardiovascular risk by 4-13%[60].
Individual cardiovascular risk estimation in women with a history of two or more 
miscarriages should be considered. Evidence on costs and cost-effectiveness of 
cardiovascular screening in women with miscarriages is lacking. To start, a comparable 
approach, such as advised in the Dutch guideline on cardiovascular risk management in 
women with a history of preeclampsia can be applied. At the age of 50 years, performance 
of a full cardiovascular risk profile according to the Dutch guideline for cardiovascular 
risk management could be offered. Although this age limit is up for discussion. Evidence 
is suggesting that screening and prevention should be offered earlier in life to women 
with a complicated pregnancy. For example, the mean age of stroke onset was about 10 
years earlier in women with a history of pregnancy complications (preeclampsia, HELLP 
syndrome and placental abruption), compared to women without such a history [61]. A 
suggested new approach is to start screening for cardiovascular risk factors postpartum 
and repeat it every 10 years. The ideal age of screening should be studied further.
Future research is needed to determine whether women with a history of two or more 
miscarriages will benefit from screening and preventive interventions. A cohort study 
with a long follow-up is suggested to evaluate the results of these life style advises and 
interventions. 
Conclusions
In conclusion, given the consistent reporting of an association between miscarriages 
and later ischemic heart disease (and possibly other cardiovascular disease), it is time 
to update current guidelines and add a history of two or more miscarriages to the risk 
factors for cardiovascular disease.
Future studies should aim to determine how the inclusion of information on miscarriages 
(and other adverse pregnancy events) could improve cardiovascular disease risk evalua-
tion in women. 
Women with recurrent miscarriage must be made aware of their increased risk for 
cardiovascular disease later in life and given lifestyle advises. Individual cardiovascular 
risk estimation in women with a history of recurrent miscarriage must be implemented.  
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Recurrent miscarriage and the subsequent risk of cardiovascular disease
Cardiovascular disease (CVD) is the leading cause of death in women in the Western 
world. There is increasing evidence that women with adverse pregnancy outcomes are 
at increased risk of CVD. A history of preeclampsia, gestational diabetes or pregnancy-
induced hypertension is mentioned as an important factor for cardiovascular disease in 
women in the American Heart Association guideline. The association between recurrent 
miscarriage and CVD is less clear. Recurrent miscarriage is affecting 0.5-3% of the fertile 
couples and is commonly defined as three or more consecutive pregnancy losses before 
22 weeks of gestation. It is a highly heterogeneous condition. Possible etiologic factors 
include genetic disorders, uterine anomalies, endocrine factors, maternal autoimmune 
disorders, metabolic disorders, maternal thrombophilia, obesity and toxic factors such as 
smoking and alcohol consumption. In about 50% of the cases the cause remains unknown. 
Recurrent miscarriage might be a first sign of subsequent CVD in women. Several hypo-
theses are possible for an association between both diseases; shared common risk factors 
such as obesity and smoking, endothelial dysfunction and a genetic predisposition is 
assumed. Early identification of women at increased risk of CVD from their reproductive 
history may enable them to benefit from screening and preventive interventions.
In this thesis we investigated the possible association between recurrent miscarriage 
and future cardiovascular disease. 
Chapter 1 provides an introduction and outline of this thesis.
Chapter 2 reports a large retrospective cohort study with a long follow-up which 
assessed whether consecutive miscarriage is associated with an increased risk of 
cardiovascular disease later in life. Data from the Aberdeen Maternity and Neonatal 
Databank was used. 60105 women were analysed; 9419 with non-, 940 with two, 167 with 
three or more consecutive miscarriages and 49579 women with no miscarriage. Women 
were linked to Scottish Morbidity Records for hospital admissions for cardiovascular 
conditions, cardiac surgery and death registrations. A sensitivity analysis was performed 
dividing the women into those who had one, two or ≥ three miscarriages irrespective 
of these were consecutive or not. In the multivariate analyses (including maternal age, 
BMI, social class and smoking) a significant association was found between ischemic 
heart disease and women with two (HR 1.75 (95%CI 1.22-2.52) or ≥ three (HR 3.18 (95%CI 
1.49-6.80) consecutive miscarriages. Similar patterns of risk were observed in the sensi-
tivity analysis. The risk for ischemic heart disease was even slightly lower in women 
with consecutive miscarriages compared to women with 2 or more non-consecutive 
miscarriages. This suggests that the number of events (2 or more) is more important than 
the consecutive nature of events. We conclude that women with a history of two or more 
miscarriages, irrespective of whether consecutive or not, appear to have an increased 
risk of ischemic heart disease.




Chapter 3 describes a follow-up study which determined cardiovascular risk factors and 
predicted long term cardiovascular disease risk in women with a history of recurrent 
miscarriage. Women who visited the recurrent miscarriage clinic at Leiden University 
Medical Center (between 2000-2010) and had their third consecutive miscarriage before 
the age of 31 years of age were invited to participate (between 2012-2014). The reference 
group consisted of women with at least one uncomplicated pregnancy and no miscarriage, 
matched on zip code, age, and date of pregnancy. All women were invited for risk factor 
screening, including physical examination and blood collection. Main outcome measures 
were the (extrapolated) 10- and 30-year cardiovascular risk scores using the Framingham 
risk score. A sub analysis was performed for women with idiopathic recurrent miscarriage. 
36 women were included in both groups, with a mean follow-up of 7.5 years. Women with 
recurrent miscarriage had a significantly higher extrapolated 10-year cardiovascular risk 
score (mean 6.24%, SD 5.44) compared to women with no miscarriage (mean 3.56%, SD 
1.82, p=0.007) and a significantly higher 30-year cardiovascular risk score (mean 9.86%, 
SD 9.10) compared to women with no miscarriage (mean 6.39%, SD 4.20, p=0.04). Similar 
results were found in women with idiopathic recurrent miscarriage (n=28). Therefore, we 
concluded that women with a history of recurrent miscarriage differ in cardiovascular 
risk profile at young age compared to women with no miscarriage. The findings support 
an opportunity to identify women at risk of cardiovascular disease later in life and a 
possible moment for intervention.
Chapter 4 describes novel cardiovascular biomarkers in women with a history of 
recurrent miscarriage at time of follow-up. The inclusion criteria of the exposed (women 
with recurrent miscarriage) and unexposed (women with no miscarriage) women were 
already described in chapter 3. Biomarkers were assessed, regarding the following 
mechanisms; inflammation (HsCRP, Lp-PLA2), thrombosis (homocysteine, folate, 
anti-Cardiolipin antibodies and anti-ß-2-Glycoprotein antibodies), lipid metabolism 
(Lipoprotein (a)), renal function (creatinine, microalbuminuria), myocardial damage (NT-
proBNP, hscTroponine T), multiple mechanisms (albumin, 25-OH-Vitamin D). Women with 
a history of recurrent miscarriage had a significantly higher HsCRP, and significantly lower 
values of albumin and vitamin D compared to women with no miscarriage which indicates 
a proinflammatory response in women with recurrent miscarriage. Inflammation 
plays an important pathogenic role in all stages of atherosclerosis and therefore in the 
development of cardiovascular disease. No differences were found in more specific 
biomarkers, for example regarding renal function and myocardial damage. Therefore, we 
conclude that routine screening of novel cardiovascular biomarkers on patient level is 
not warranted. Women with a history of recurrent miscarriage should be given healthy 
lifestyle advises. More research is needed regarding the association between recurrent 
miscarriage and vitamin D.
Chapter 5 presents a matched case control study to assess if a family history of 
cardiovascular disease was more prevalent in women with recurrent miscarriage. Is so, 
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this association indicates shared risk factors, including genetics. 103 women who visited 
the recurrent miscarriage clinic at Leiden University Medical Centre (between 2000-
2014) and had their third consecutive miscarriage ≤ 35 years were included. 143 controls 
were included, women with at least one uncomplicated pregnancy and no miscarriage, 
matched on zip code, age and date of pregnancy. All women filled out a questionnaire. 
Family history of premature myocardial infarction and/or stroke was defined as having a 
first-degree relative with myocardial infarction and/or stroke < 60 years. Family history 
of cardiovascular disease as having a first-degree relative with myocardial infarction, 
stroke, hypertension or thrombosis, irrespective of age at event. We did not find an 
increased prevalence in women with recurrent miscarriage compared to women with 
no miscarriage. Therefore, our data does not confirm the assumption that a link exists 
between familiar cardiovascular disease and recurrent miscarriage when measured by 
proxy family history. A family history of hypertension seems more prevalent in women 
with recurrent miscarriage, although not significant (multivariate analysis: OR 1.71 (0.94-
3.11)), which urge more investigation. 
Chapter 6 presents a meta-analysis which describes genetic variants reproducibly 
associated with recurrent miscarriage. The association between genes and recurrent 
miscarriages was assessed at the allele level and a pooled odds ratio was estimated in a 
random-effects model. The literature search yielded 4050 articles; a total of 241 studies 
were included. We identified 25 reproduced genetic variants, of which 16 remained 
significantly associated with recurrent miscarriage in a random-effects meta-analysis. 
Several of these variants are also identified as risk factors for cardiovascular disease; 
F2 G20210A, FVL, FXIIIa Val34Leu, MTHFR A1298C, MTHFR C677T and PAI1 -675 4G/5G 
polymorphism, all involved in coagulation and fibrinolysis, and NOS3 Glu298Asp 
polymorphism, involved in oxidative stress. This meta-analysis suggests that recurrent 
miscarriage and cardiovascular disease share genetic risk factors.
Chapter 7 describes a retrospective cohort study which assessed whether women with 
secondary recurrent pregnancy loss (SRPL) (defined as having ≥ 3 consecutive miscarriages 
before 22 weeks of gestation, with a previous birth ≥ 22 weeks of gestation) (N=172) have 
a more complicated first pregnancy compared to all Dutch nullipara (N=1.196.178). Some 
women experience a complication during pregnancy, for instance pregnancy induced 
hypertension, preeclampsia, intrauterine growth restriction and pre-term delivery, 
events which may increase the risk of CVD later in life. Recurrent miscarriage might 
share pathophysiological pathways with other pregnancy complications. It is unclear 
whether these pregnancy complications are on the causal pathway between miscarriage 
and cardiovascular disease, they are possibly a confounding factor. Outcomes were 
the occurrence of preeclampsia, preterm birth, post-term birth, intrauterine growth 
restriction, breach position, induction of labor, delivery by Caesarean section, congenital 
abnormalities, perinatal death and severe hemorrhage in the first ongoing pregnancy. 
Subgroup analyses were performed for women with idiopathic SRPL and for women ≤ 35 




years at first pregnancy. Women with SRPL more often had a post-term birth (OR 95%CI 
1.86 (1.10-3.17)) and more perinatal deaths occurred in women with SRPL compared to 
the control group (OR 95%CI 5.03 (2.48-10.2)). Similar results were found in both subgroup 
analyses. More research is needed to reveal possible links between SRPL and these 
pregnancy complications as this might lead to a better understanding of the underlying 
pathophysiology.
Chapter 8 provides a general discussion and discusses remaining questions, suggestions 
for clinical implementation and future research. We conclude, that given the consistent 
reporting of an association between miscarriages and later ischemic heart disease 
(and possibly other CVD), it is time to update current guidelines and add a history of 
two miscarriages to the risk factors for CVD. Women with recurrent miscarriage should 
be made aware of their increased risk for cardiovascular disease later in life and given 
healthy lifestyle advises including discontinuing smoking, improving dietary habits, 
healthy weight and adequate physical exercise. Individual cardiovascular risk estimation 
in women with a history of recurrent miscarriage should be considered.
Future research is needed to determine whether women with a history of two or more 
miscarriages will benefit from screening and preventive interventions.
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Het risico op hart- en vaatziekten na herhaalde miskramen
Hart- en vaatziekten (HVZ) zijn doodsoorzaak nummer 1 bij vrouwen in de westerse 
wereld. Er is toenemend bewijs dat vrouwen met gecompliceerde zwangerschappen 
een verhoogd risico hebben op het ontwikkelen van HVZ. In de richtlijn van de American 
Heart Association worden een voorgeschiedenis van preëclampsie, diabetes gravidarum 
en zwangerschapshypertensie genoemd als belangrijke risicofactoren voor HVZ. Of er 
ook een associatie bestaat met herhaalde miskramen is nog niet duidelijk. Herhaalde 
miskramen komen voor bij 0.5-3% van de fertiele koppels en wordt meestal gedefinieerd 
als drie of meer achtereenvolgende miskramen tot een amenorroeduur van 22 weken. 
Het is een erg heterogene aandoening. Mogelijke etiologische factoren zijn genetische 
afwijkingen, uterus anomalieën, endocriene factoren, maternale auto-immuun afwij-
kingen, metabole afwijkingen, maternale trombofilie, obesitas en toxische factoren 
zoals roken en alcohol gebruik. In meer dan 50% van de gevallen blijft de oorzaak 
onbekend. Herhaalde miskramen zouden een eerste teken van HVZ kunnen zijn. Voor 
het bestaan van een associatie tussen herhaalde miskramen en HVZ zijn verschillende 
hypotheses mogelijk; gedeelde risicofactoren zoals obesitas en roken, endotheel 
dysfunctie en een genetische predispositie worden verondersteld. Als we vrouwen 
met een verhoogd risico op HVZ op jonge leeftijd kunnen identificeren aan de hand van 
hun obstetrische voorgeschiedenis kunnen ze wellicht baat hebben bij screening en 
preventieve interventies. In dit proefschrift wordt de relatie tussen herhaalde miskramen 
en toekomstige hart- en vaatziekten onderzocht. 
Hoofdstuk 1 is de algemene introductie van dit proefschrift.
Hoofdstuk 2 beschrijft een grote retrospectieve cohortstudie met een lange follow-up, 
waarin onderzocht wordt of er een verband bestaat tussen achtereenvolgende miskramen 
en een verhoogd risico op HVZ later in het leven. Data van de Aberdeen Maternity and 
Neonatal Databank werden gebruikt. 60105 vrouwen werden geanalyseerd; 9419 met 
geen, 940 met twee, 167 met drie of meer achtereenvolgende miskramen en 49579 
vrouwen zonder miskraam. Vrouwen werden gelinkt aan de ‘Scottish Morbidity Records’ 
aangaande ziekenhuisopnames met betrekking tot cardiovasculaire aandoeningen, 
hartchirurgie en overlijdensregistraties. Een sensitiviteitsanalyse werd verricht door een 
onderverdeling te maken van vrouwen met een voorgeschiedenis van één, twee of ≥ drie 
miskramen, onafhankelijk of deze achtereenvolgend waren of niet. In de multivariate 
analyses (gecorrigeerd voor maternale leeftijd, BMI, sociale klasse en roken) werd een 
significante associatie gevonden tussen ischemische hartziekten en vrouwen met twee 
(HR 1.75 (95%CI 1.22-2.52) en ≥ drie (HR 3.18 (95%CI 1.49-6.80) achtereenvolgende 
miskramen. Vergelijkbare risicopatronen werden gevonden in de sensitiviteitsanalyse. Het 
risico op ischemische hartziekten was zelfs iets lager bij vrouwen met achtereenvolgende 
miskramen in vergelijking met vrouwen met twee of meer niet-achtereenvolgende 




miskramen. Wat suggereert dat het aantal events (twee of meer) belangrijker is dan het 
achtereenvolgende karakter. We concluderen dat vrouwen met een voorgeschiedenis 
van twee of meer miskramen, onafhankelijk van of deze achtereenvolgend waren of niet, 
een verhoogd risico hebben op ischemische hartziekten. 
Hoofdstuk 3 beschrijft een follow-up studie naar risicofactoren op HVZ bij vrouwen met 
een voorgeschiedenis van herhaalde miskramen. Tevens wordt aan de hand van deze 
risicofactoren een voorspelling gedaan op het risico op HVZ op de lange termijn. Vrouwen 
die de herhaalde miskramen poli van het Leids Universitair Medisch Centrum bezochten 
tussen 2000-2010 en een derde achtereenvolgende miskraam hadden doorgemaakt 
voor de leeftijd van 31 jaar werden uitgenodigd om deel te nemen (tussen 2012-2014). De 
referentiegroep bestond uit vrouwen die tenminste één ongecompliceerde zwangerschap 
en geen miskraam hadden doorgemaakt, gematcht op postcode, leeftijd en datum 
van zwangerschap. Alle vrouwen werden uitgenodigd voor een risicofactor screening, 
inclusief fysiek onderzoek en bloedafname. De belangrijkste uitkomstmaten waren de 
(geëxtrapoleerde) 10- en 30 jaar risicoscores op HVZ, gebruikmakend van de Framingham 
risicoscore. Een sub analyse werd verricht naar vrouwen met idiopathische herhaalde 
miskramen (miskramen waarbij geen oorzaak werd gevonden). In beide groepen werden 
36 vrouwen geïncludeerd, met een gemiddelde follow-up van 7.5 jaar. Vrouwen met 
herhaalde miskramen hadden een significant hogere geëxtrapoleerde 10-jaar risicoscore 
op HVZ (gemiddeld 6.24%, SD 5.44) vergeleken met vrouwen zonder miskraam (gemiddeld 
3.56%, SD 1.82, p=0.007) en een significant hogere 30-jaar risicoscore op HVZ (gemiddeld 
9.86%, SD 9.10) vergeleken met vrouwen zonder miskraam (gemiddeld 6.39%, SD 4.20, 
p=0.04). Vergelijkbare resultaten werden gevonden bij vrouwen met idiopathische mis-
kramen (n=28). Daaruit concluderen we dat vrouwen met een voorgeschiedenis van 
herhaalde miskramen al op jonge leeftijd een ongunstiger cardiovasculair risicoprofiel 
hebben in vergelijking met vrouwen zonder miskraam. Deze bevindingen ondersteunen 
de hypothese dat een voorgeschiedenis van herhaalde miskramen een mogelijkheid 
biedt om vrouwen met een verhoogd risico op HVZ te identificeren. 
Hoofdstuk 4 beschrijft nieuwe cardiovasculaire biomarkers bij vrouwen met een 
voorgeschiedenis van herhaalde miskramen ten tijde van follow-up. De inclusiecriteria 
van de vrouwen met en zonder miskramen waren gelijk aan de inclusiecriteria van 
hoofdstuk 3. Er werden biomarkers bepaald met betrekking tot de volgende mecha-
nismes: inflammatie (HsCRP, Lp-PLA2), trombose (homocysteïne, foliumzuur, anti-
Cardiolipine antilichamen en anti-ß-2-Glycoproteine antilichamen), lipide metabolisme 
(Lipoproteïne (a)), nierfunctie (creatinine, microalbuminurie), myocard schade (NT-
proBNP, hscTroponine T) en multipele mechanismes (albumine, 25-OH-Vitamine D). 
Vrouwen met een voorgeschiedenis van herhaalde miskramen hadden een significant 
hoger HsCRP, en significant lagere waardes van albumine en vitamine D vergeleken 
met vrouwen zonder miskraam, wat duidt op een pro inflammatie respons in vrouwen 
met herhaalde miskramen. Inflammatie speelt een belangrijke pathogene rol in alle 
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stadia van atherosclerose en daarmee de ontwikkeling van hart- en vaatziekten. 
In de meer specifieke biomarkers werd geen verschil gevonden, zoals bijvoorbeeld 
nierfunctie en myocard schade. We concluderen dat routine screening van nieuwe 
cardiovasculaire biomarkers voor de individuele patiënt niet gewenst is. Vrouwen met 
een voorgeschiedenis van herhaalde miskramen zouden adviezen ten aanzien van een 
gezonde leefstijl moeten krijgen. Meer onderzoek is nodig om de associatie tussen 
herhaalde miskramen en vitamine D te onderzoeken. 
Hoofdstuk 5 beschrijft een gematchte casecontrole studie om te onderzoeken of HVZ 
vaker voorkomen in families van vrouwen met herhaalde miskramen, wat zou kunnen 
wijzen op gedeelde (genetische) risicofactoren. 103 vrouwen die de herhaalde miskramen 
poli van het Leids Universitair Medisch Centrum (tussen 2000-2014) bezochten en een 
derde achtereenvolgende miskraam hadden ≤ 35 jaar werden geïncludeerd. 143 contro-
les werden geïncludeerd; dit waren vrouwen met tenminste één ongecompliceerde 
zwangerschap en geen miskraam, gematcht op postcode, maternale leeftijd en datum 
van zwangerschap. Alle vrouwen vulden een vragenlijst in. Een familieanamnese van 
een prematuur myocardinfarct en/ of herseninfarct was gedefinieerd als het hebben 
van een 1e-graads familielid met een myocardinfarct en/of herseninfarct < 60 jaar. Een 
familieanamnese van HVZ was gedefinieerd als het hebben van een 1e-graads familielid 
met myocardinfarct, herseninfarct, hypertensie en/of trombose, onafhankelijk van 
de leeftijd ten tijde van het event. Er werd geen verhoogde prevalentie gevonden in 
vrouwen met herhaalde miskramen vergeleken met vrouwen zonder miskraam. Onze 
data bevestigt de hypothese dat er een link bestaat tussen familiaire HVZ en herhaalde 
miskramen niet. Een familieanamnese van hypertensie lijkt wel vaker aanwezig in 
vrouwen met herhaalde miskramen, alhoewel niet significant (multivariate analyse: OR 
1.71 (0.94-3.11)), wat meer onderzoek behoeft. 
Hoofdstuk 6 beschrijft een meta-analyse naar genetische varianten geassocieerd met 
herhaalde miskramen. De associatie tussen de genen en herhaalde miskramen werd 
onderzocht op allel niveau en een samengevoegd odds ratio (OR) werd berekend in 
een random effects model. Het literatuuronderzoek bestond uit 4050 artikelen, een 
totaal van 241 studies werd geïncludeerd. Er konden 25 genetische varianten worden 
geïdentificeerd die ten minste twee keer geassocieerd waren met herhaalde miskramen, 
waarvan 16 significant geassocieerd bleven met herhaalde miskramen na de random 
effects meta-analyse. Verschillende van deze varianten zijn ook geïdentificeerd als risico-
factoren op HVZ; F2 G20210A, FVL, FXIIIa Val34Leu, MTHFR A1298C, MTHFR C677T and 
PAI1 -675 4G/5G polymorfisme, allen betrokken bij coagulatie en fibrinolyse, en NOS3 
Glu298Asp polymorfisme, betrokken bij oxidatieve stress. Deze meta-analyse suggereert 
dat herhaalde miskramen en HVZ genetische risicofactoren delen. 
Hoofdstuk 7 beschrijft een retrospectieve cohortstudie naar complicaties in de eerste 
zwangerschap bij vrouwen met secundaire herhaalde miskramen (gedefinieerd als 
≥ 3 achtereenvolgende miskramen met een amenorroeduur van < 22 weken, met een 




voorafgaande zwangerschap met een amenorroeduur ≥ 22 weken) (N=172) verge-
leken met alle Nederlandse nullipara (N=1.196.178). Sommige vrouwen krijgen een 
zwangerschapscomplicatie die het toekomstige risico op HVZ kan verhogen, zoals 
zwangerschapshypertensie, preëclampsie, intra-uteriene groeivertraging en/of 
vroeggeboorte. Mogelijk bestaan er gemeenschappelijke pathofysiologische paden 
tussen herhaalde miskramen en andere zwangerschapscomplicaties. Het is onduidelijk 
of deze complicaties zich bevinden op het causale pad tussen herhaalde miskramen en 
HVZ, of dat ze optreden als confounder. Om deze relatie verder te onderzoeken werden 
de volgende uitkomsten bekeken: het voorkomen van preëclampsie, vroeggeboorte, 
serotiniteit, intra-uteriene groeivertraging, stuitligging, inleiding van de bevalling, 
bevalling door middel van een sectio, congenitale afwijkingen, perinatale sterfte en 
hemorragie postpartum in de eerste doorgaande zwangerschap. Subgroep analyses 
werden verricht bij vrouwen met idiopathische secundaire herhaalde miskramen en bij 
vrouwen die ≤ 35 jaar waren ten tijde van de eerste zwangerschap. Serotiniteit (OR 1.86 
(95%CI 1.10-3.17)) en perinatale sterfte (OR 5.03 (95%CI 2.48-10.2)) kwamen vaker voor bij 
vrouwen met secundaire herhaalde miskramen vergeleken met de controlegroep. Meer 
onderzoek is nodig om mogelijke verbanden tussen secundaire herhaalde miskramen en 
deze zwangerschapscomplicaties te ontdekken, omdat dit tot een beter begrip van de 
onderliggende pathofysiologie kan leiden.
Hoofdstuk 8 bevat een algemene discussie over de bevindingen in dit proefschrift, 
overblijvende vragen worden bediscussieerd en suggesties voor klinische implementatie 
en toekomstig onderzoek worden gegeven. Geconcludeerd wordt dat gegeven de 
consistente bevindingen van een associatie tussen miskramen en ischemische 
hartziekten (en mogelijk ook andere HVZ), het tijd is de huidige richtlijnen te updaten en 
een voorgeschiedenis van twee of meer miskramen als risicofactor op het ontwikkelen 
van HVZ toe te voegen. Vrouwen met herhaalde miskramen zouden geïnformeerd moeten 
worden over het verhoogde risico op het ontwikkelen van HVZ en leefstijladviezen moeten 
krijgen, zoals niet roken, verbeteren van dieetgewoontes, gezond gewicht en voldoende 
beweging. Het bepalen van een individueel cardiovasculair risicoprofiel bij vrouwen 
met een voorgeschiedenis van herhaalde miskramen zou overwogen moeten worden. 
Toekomstig onderzoek is nodig om te bepalen of vrouwen met een voorgeschiedenis van 
twee of meer miskramen baat hebben bij screening en preventieve interventies. 
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